PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33719846-12 2021 Baicalin enhanced the effect of cisplatin on promoting apoptosis, arresting cell on S stage and triggering DNA damage accompanied with the upregulation of Bcl-2-associated X protein (Bax) and downregulation of B-cell lymphoma 2 (Bcl-2) and Cyclin D1 in A549/DPP cells. Cisplatin 32-41 BCL2 apoptosis regulator Homo sapiens 210-227 33721171-11 2021 BB with DOX and CDDP suppressed the proapoptotic Bid gene while overexpressing the anti-apoptotic Bcl-2 gene, separately. Cisplatin 16-20 BCL2 apoptosis regulator Homo sapiens 98-103 33402832-9 2020 Western blot assay revealed that expression of pro-apoptosis protein Bax and C-Caspase 3 increased, but apoptosis-inhibitory protein Bcl-2 expression decreased with 40 mug/mL cis-platinum, 12.5 mug/mL allicin, 25 mug/mL allicin, and 50 mug/mL allicin, while compared to 40 mug/mL cis-platinum, Bax and C-Caspase 3 expression was increased by 50 mug/mL allicin. Cisplatin 175-187 BCL2 apoptosis regulator Homo sapiens 133-138 33569751-11 2021 Our results showed that miRNA-143 overexpression could increase cisplatin-induced apoptosis and increase the sensitivity of CaSki cells to low doses of this chemotherapeutic agent via modulating the expression of apoptosis-related genes including Bcl-2, Bax, and caspase-9. Cisplatin 64-73 BCL2 apoptosis regulator Homo sapiens 247-252 32881195-5 2021 Moreover, the elevation of apoptosis including Bax, Bad, cleaved caspase-3,-9, and decreased protein levels of Bcl-2, Bcl-XL induced by cisplatin were reversed after PD treatment. Cisplatin 136-145 BCL2 apoptosis regulator Homo sapiens 111-116 33396645-6 2020 BCL2L10 is a pro-survival factor in melanoma since its expression reduced the cytotoxic effects of cisplatin, dacarbazine, and ABT-737 (a BCL2, Bcl-xL, and Bcl-w inhibitor). Cisplatin 99-108 BCL2 apoptosis regulator Homo sapiens 0-4 32947166-8 2020 Moreover, the acetazolamide/cisplatin combination could decrease the level of PCNA but increase the level of p53; decrease the ratio of Bcl-2/Bax and increase the expression of caspase-3 compared with the single drug treated group. Cisplatin 28-37 BCL2 apoptosis regulator Homo sapiens 136-141 32374939-7 2020 More importantly, the cisplatin-induced elevated protein levels of Bax, cleaved caspase-3, cleaved caspase-9, and decreased protein level of Bcl-2 were reversed after treatment with Rk1. Cisplatin 22-31 BCL2 apoptosis regulator Homo sapiens 141-146 32579960-7 2020 Since rescue experiments proved that RUNX1 could repress cisplatin-induced apoptosis by up-regulating BCL2 via miR-17~92 cluster, combining RUNX1 inhibitor Ro5-3335 and cisplatin showed synergic effect in triggering OC cell apoptosis. Cisplatin 57-66 BCL2 apoptosis regulator Homo sapiens 102-106 32579960-7 2020 Since rescue experiments proved that RUNX1 could repress cisplatin-induced apoptosis by up-regulating BCL2 via miR-17~92 cluster, combining RUNX1 inhibitor Ro5-3335 and cisplatin showed synergic effect in triggering OC cell apoptosis. Cisplatin 169-178 BCL2 apoptosis regulator Homo sapiens 102-106 32878788-8 2020 Butyl-Pt, pentyl-Pt and cisplatin arrested the cell cycle in the S-phase and induced apoptotic cell death via regulation of expression of B-cell lymphoma 2 (BCL2) and BCL2-associated X (BAX) proteins. Cisplatin 24-33 BCL2 apoptosis regulator Homo sapiens 138-155 32878788-8 2020 Butyl-Pt, pentyl-Pt and cisplatin arrested the cell cycle in the S-phase and induced apoptotic cell death via regulation of expression of B-cell lymphoma 2 (BCL2) and BCL2-associated X (BAX) proteins. Cisplatin 24-33 BCL2 apoptosis regulator Homo sapiens 157-161 32582969-11 2020 Moreover, absence of GPR81 combined with cisplatin exposure increased caspase-3 expression and decreased Bcl-2 levels. Cisplatin 41-50 BCL2 apoptosis regulator Homo sapiens 105-110 32757174-13 2021 In conclusion, KCNQ1OT1 aggravated cisplatin resistance in CRC cells via the miR-497/Bcl-2 axis. Cisplatin 35-44 BCL2 apoptosis regulator Homo sapiens 85-90 32973533-11 2020 DDP and hesperetin also induced significant increases in apoptosis inducing factor (AIF), BCL2 associated X, apoptosis regulator (BAX), cleaved caspase-9, and cleaved caspase-3, and decreased B-cell lymphoma 2 (BCL2), caspase-9, and caspase-3 levels. Cisplatin 0-3 BCL2 apoptosis regulator Homo sapiens 192-209 32973533-11 2020 DDP and hesperetin also induced significant increases in apoptosis inducing factor (AIF), BCL2 associated X, apoptosis regulator (BAX), cleaved caspase-9, and cleaved caspase-3, and decreased B-cell lymphoma 2 (BCL2), caspase-9, and caspase-3 levels. Cisplatin 0-3 BCL2 apoptosis regulator Homo sapiens 90-94 32380907-8 2020 In conclusion, our data suggested that miR-153-5p was a mediator of cisplatin resistance in colorectal cancer by affecting Bcl-2-mediated autophagy, indicating a new therapeutic target for CRC treatment. Cisplatin 68-77 BCL2 apoptosis regulator Homo sapiens 123-128 32044796-8 2020 C61-LNP, as well as C61-LNP + CDDP treatments, caused pro-apoptotic proteomic changes including an increase in cleaved fragments of caspases-3 and -9 consistent with caspase activation as well as an improvement in the anti-apoptotic Bcl2 and Bax levels. Cisplatin 30-34 BCL2 apoptosis regulator Homo sapiens 233-237 31935534-8 2020 Co-treatment of cisplatin and nicotine attenuated the effect of cisplatin on Bcl-2 expression. Cisplatin 16-25 BCL2 apoptosis regulator Homo sapiens 77-82 32124583-11 2020 Our data revealed that silencing of CCAT1 promoted cisplatin-induced apoptosis via modulating the expression of pro- or anti-apoptotic proteins Bax, Bcl-2 and survivin. Cisplatin 51-60 BCL2 apoptosis regulator Homo sapiens 149-154 32653124-7 2020 Furthermore, the mRNA expression of Caspase 3 was down-regulated significantly and the ratio of Bcl-2/Bax was up-regulated significantly in EVs + CDDP group. Cisplatin 146-150 BCL2 apoptosis regulator Homo sapiens 96-101 32253030-0 2020 CircRNACCDC66 regulates cisplatin resistance in gastric cancer via the miR-618/BCL2 axis. Cisplatin 24-33 BCL2 apoptosis regulator Homo sapiens 79-83 32499869-0 2020 Exosome-mediated delivery of miR-30a sensitize cisplatin-resistant variant of oral squamous carcinoma cells via modulating Beclin1 and Bcl2. Cisplatin 47-56 BCL2 apoptosis regulator Homo sapiens 135-139 32499869-9 2020 Exosomes from the cisplatin-resistant cells that have been transfected with miR-30a mimics, when delivered to the naive cisplatin-resistant cells, caused not only the significant enhancements in miR-30a expression but also a concomitant decrease in Beclin1 and Bcl2 expression (autophagic and anti-apoptotic marker). Cisplatin 18-27 BCL2 apoptosis regulator Homo sapiens 261-265 32499869-9 2020 Exosomes from the cisplatin-resistant cells that have been transfected with miR-30a mimics, when delivered to the naive cisplatin-resistant cells, caused not only the significant enhancements in miR-30a expression but also a concomitant decrease in Beclin1 and Bcl2 expression (autophagic and anti-apoptotic marker). Cisplatin 120-129 BCL2 apoptosis regulator Homo sapiens 261-265 32499869-11 2020 Thus, our study highlighted the role of exosomal-mediated miR-30a transfer in regaining sensitivity of the cisplatin-resistant OSCC cells via Beclin1 and Bcl2 regulation and hence suggests at its potential therapeutic role. Cisplatin 107-116 BCL2 apoptosis regulator Homo sapiens 154-158 32210629-10 2020 Annexin V/PI staining and MTT assay results demonstrated that melatonin assisted cisplatin-induced apoptosis accompanied with upregulated caspase-3 and poly ADP-ribose polymerase (PARP) cleavage, as well as Bcl-2 expression. Cisplatin 81-90 BCL2 apoptosis regulator Homo sapiens 207-212 32457911-13 2020 HOTTIP expression confers cisplatin resistance by regulating the miR-216a-5p/BCL-2/Beclin1/autophagy pathway, which provides a novel strategy to overcome resistance to chemotherapy in GC. Cisplatin 26-35 BCL2 apoptosis regulator Homo sapiens 77-82 31935534-8 2020 Co-treatment of cisplatin and nicotine attenuated the effect of cisplatin on Bcl-2 expression. Cisplatin 64-73 BCL2 apoptosis regulator Homo sapiens 77-82 31935534-9 2020 In addition, the effect of nicotine on cell survival under cisplatin treatment was attenuated with the addition of the Bcl-2 inhibitor ABT-737. Cisplatin 59-68 BCL2 apoptosis regulator Homo sapiens 119-124 32010177-8 2019 Suppression of SOCS1-STAT3-Bcl-2 pathway and activation of p53-Pten signaling both contribute to anti-miR-221/222-induced sensitivity to cisplatin in MDA-MB-231 cells. Cisplatin 137-146 BCL2 apoptosis regulator Homo sapiens 27-32 31736281-5 2020 Of these genes, ABCG2, AHNAK2, BCL2, FZD1, and TP73 are associated with published evidence for resistance to 5-fluorouracil and cisplatin. Cisplatin 128-137 BCL2 apoptosis regulator Homo sapiens 31-35 31905343-6 2020 The combined treatment of aspirin and cisplatin suppressed the expression of the anti-apoptotic protein Bcl-2 and the EMT-related proteins, up-regulated the levels of the cleaved PARP and Bax, and blocked the PI3K/AKT and RAF-MEK-ERK signaling pathway. Cisplatin 38-47 BCL2 apoptosis regulator Homo sapiens 104-109 31541355-8 2019 Cisplatin + compound 4 significantly enhanced p53 phosphorylation, induced Bax amount, reduced Bcl2 protein levels, enhanced PARP cleavage and modulated miRNAs expression profile in TNBCs, with a particular overexpression of miR-125a-5p and miR-181a-5p. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 95-99 31807162-12 2019 In addition, combination of radiation and cisplatin had a higher inhibitory effect on Bax protein level and a higher inductive effect on Bcl-2 protein level compared with treatments with radiation and cisplatin alone. Cisplatin 42-51 BCL2 apoptosis regulator Homo sapiens 137-142 31247208-2 2019 Studies show that the Bcl-2 inhibitor ABT737 can significantly improve the effect of cisplatin and induce mitochondrial pathway apoptosis. Cisplatin 85-94 BCL2 apoptosis regulator Homo sapiens 22-27 32021975-9 2020 The cisplatin-induced apoptosis in endometrial cancer cells was inhibited by miR-135a by regulation of BAX and Bcl-2 expression. Cisplatin 4-13 BCL2 apoptosis regulator Homo sapiens 111-116 31609766-5 2019 SIN and cisplatin further decreased the Bcl-2, procaspase-3, and beta-catenin, but increased Bax, cleaved dcaspase 3, MMP9, and MMP2 in combined group than in either alone group. Cisplatin 8-17 BCL2 apoptosis regulator Homo sapiens 40-45 31518663-3 2019 Herein, we first identified the expressions of the anti-apoptotic BCL2 and the prostaglandin-endoperoxide synthase-2 (PTGS2) genes, which were abundant in the gastric carcinoma and associated with poor patient survival, were closely related with the resistance against cisplatin. Cisplatin 269-278 BCL2 apoptosis regulator Homo sapiens 66-70 31462500-8 2019 Conversely, specific inhibitors of BCL-XL, MCL1, or BCL-XL/BCL-2, but not BCL-2 alone, enhanced cell death when combined with cisplatin or paclitaxel. Cisplatin 126-135 BCL2 apoptosis regulator Homo sapiens 59-64 31611969-10 2019 MicroRNA-152 downregulation may induce cisplatin resistance in non-small cell lung cancer cells, whereas microRNA-152 upregulation may improve cisplatin sensitivity among A549/cis cells via downregulation of Bcl-2 and NF-kappaB. Cisplatin 143-152 BCL2 apoptosis regulator Homo sapiens 208-213 31627336-0 2019 The Deubiquitinating Enzyme Inhibitor PR-619 Enhances the Cytotoxicity of Cisplatin via the Suppression of Anti-Apoptotic Bcl-2 Protein: In Vitro and In Vivo Study. Cisplatin 74-83 BCL2 apoptosis regulator Homo sapiens 122-127 31627336-5 2019 Additionally, co-treatment of PR-619 with cisplatin potentiated cisplatin-induced cytotoxicity in UC cells and was accompanied by the concurrent suppression of Bcl-2. Cisplatin 42-51 BCL2 apoptosis regulator Homo sapiens 160-165 31432162-6 2019 Cisplatin also induced Bcl-2-associated X protein expression, and decreased that of Bcl-2 and c-Myc in lung adenocarcinoma cells. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 23-28 31815138-0 2019 Sirt5 Attenuates Cisplatin-Induced Acute Kidney Injury through Regulation of Nrf2/HO-1 and Bcl-2. Cisplatin 17-26 BCL2 apoptosis regulator Homo sapiens 91-96 31815138-12 2019 The levels of Nrf2, HO-1, and Bcl-2 proteins in HK-2 cells were also decreased after CDDP treatment. Cisplatin 85-89 BCL2 apoptosis regulator Homo sapiens 30-35 31815138-13 2019 Moreover, Nrf2 and Bcl-2 siRNA partly abolished the protecting effect of Sirt5 on CDDP-induced apoptosis and cytochrome c release. Cisplatin 82-86 BCL2 apoptosis regulator Homo sapiens 19-24 31815138-15 2019 Together, the results demonstrated that Sirt5 attenuated cisplatin-induced apoptosis and mitochondrial injury in human kidney HK-2 cells, possibly through the regulation of Nrf2/HO-1 and Bcl-2. Cisplatin 57-66 BCL2 apoptosis regulator Homo sapiens 187-192 31518663-4 2019 Further investigations revealed that PTGS2 served as an essential mediator involved in the developing process of the resistance against cisplatin via mediating the inhibition effects of cisplatin on BCL2 expression. Cisplatin 136-145 BCL2 apoptosis regulator Homo sapiens 199-203 31518663-4 2019 Further investigations revealed that PTGS2 served as an essential mediator involved in the developing process of the resistance against cisplatin via mediating the inhibition effects of cisplatin on BCL2 expression. Cisplatin 186-195 BCL2 apoptosis regulator Homo sapiens 199-203 31518663-6 2019 In addition, PTGS2 mediated cisplatin-induced BCL2 expression and subsequent resistance to apoptosis via PGE2/EP4/MAPKs (ERK1/2, P38) axis. Cisplatin 28-37 BCL2 apoptosis regulator Homo sapiens 46-50 31518663-8 2019 Moreover, in the xenograft models, inhibition of PTGS2 by celecoxib significantly augmented the cytotoxic efficacy of cisplatin in the resistant gastric cancer via suppression of PTGS2 and BCL2 expressions regulated by ERK1/2 and P38 signal axis, suggesting PTGS2 might be employed as an adjunctive therapeutic target for reversal of the chemoresistance in a subset of cisplatin resistant gastric cancer. Cisplatin 118-127 BCL2 apoptosis regulator Homo sapiens 189-193 31411791-11 2019 Moreover, SKOV3/DDP cells had a lower miR-1271 level, and enhancing miR-1271 contributed strongly to cisplatin-induced apoptosis through altering the expressions of B-cell lymphoma-2 associated X protein (BAX), cleaved caspase-3 and B-cell lymphoma 2 (Bcl-2). Cisplatin 101-110 BCL2 apoptosis regulator Homo sapiens 233-250 31411791-11 2019 Moreover, SKOV3/DDP cells had a lower miR-1271 level, and enhancing miR-1271 contributed strongly to cisplatin-induced apoptosis through altering the expressions of B-cell lymphoma-2 associated X protein (BAX), cleaved caspase-3 and B-cell lymphoma 2 (Bcl-2). Cisplatin 101-110 BCL2 apoptosis regulator Homo sapiens 252-257 31538075-8 2019 Bcl2 expression was reduced by 69% in the cisplatin+genistein group compared to that in the cisplatin group. Cisplatin 42-51 BCL2 apoptosis regulator Homo sapiens 0-4 31538075-8 2019 Bcl2 expression was reduced by 69% in the cisplatin+genistein group compared to that in the cisplatin group. Cisplatin 92-101 BCL2 apoptosis regulator Homo sapiens 0-4 31276572-2 2019 Cisplatin, most frequently used for HNSCC treatment, activates mitochondria-dependent apoptosis through the BCL-2 family proteins. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 108-113 31239661-11 2019 OA helped CDDP to overcome the resistance by downregulating the expression of proteins like XIAP, Bcl-2 via NF-kappaB pathway. Cisplatin 10-14 BCL2 apoptosis regulator Homo sapiens 98-103 31079851-11 2019 Moreover, apatinib increased cisplatin-induced apoptosis on MDA-MB-231 cells via increasing the level of Bax and active caspase 3 and decreasing the expression of Bcl-2. Cisplatin 29-38 BCL2 apoptosis regulator Homo sapiens 163-168 30875757-2 2019 The goal of this study was to determine whether combining Obatoclax, a BH3 mimetic which inhibits pro-survival Bcl-2 family members, can improve responses to cisplatin chemotherapy, the standard of care treatment for MI-BC. Cisplatin 158-167 BCL2 apoptosis regulator Homo sapiens 111-116 31076571-0 2019 Cancer-associated fibroblasts promote cisplatin resistance in bladder cancer cells by increasing IGF-1/ERbeta/Bcl-2 signalling. Cisplatin 38-47 BCL2 apoptosis regulator Homo sapiens 110-115 31076571-8 2019 The in vivo data also confirmed that CAFs could increase BCa cell resistance to cisplatin by increasing ERbeta/Bcl-2 signalling. Cisplatin 80-89 BCL2 apoptosis regulator Homo sapiens 111-116 31173289-2 2019 PATIENTS AND METHODS: We detected the expressions of SNHG5, apoptosis-specific genes (Bax and Bcl-2) and drug resistance-specific genes (MDR1 and MRP1) in cisplatin-sensitive and cisplatin-resistant GC patients. Cisplatin 155-164 BCL2 apoptosis regulator Homo sapiens 94-99 31010222-9 2019 Cisplatin increased the expression of Bax and reduced the expression of Bcl-2, which activate and inhibit, respectively, the mitochondrial apoptotic pathway in response to oxidative stress. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 72-77 30867764-9 2019 In addition, it was observed that celastrol/cisplatin upregulated the expression of Bcl-associated X protein, cytochrome c, caspase-3 and C/EBP homologous protein, and downregulated the expression of Bcl-2, poly(ADP-ribose) polymerase, 78 kDa glucose-regulated protein and caspase-9, whereas the expression of caspase-8 remained unchanged. Cisplatin 44-53 BCL2 apoptosis regulator Homo sapiens 200-205 30747218-5 2019 Notably, the results also indicated that GA enhanced the anticancer effects of cisplatin in the inhibition of cancer cell proliferation and the induction of cell apoptosis following elevated Bax expression and suppressed Bcl-2 expression. Cisplatin 79-88 BCL2 apoptosis regulator Homo sapiens 221-226 30923410-9 2019 Apoptotic cells, but not necrotic cells, were significantly increased following the combined treatment, and an increase in the Bax/Bcl-2 ratio indicated that the combination of cisplatin and SAHA induced apoptosis through the mitochondrial pathway. Cisplatin 177-186 BCL2 apoptosis regulator Homo sapiens 131-136 30468468-13 2018 Therefore, the expression of AEG-1 and BCL2 was determined in untreated control, cisplatin treated control and miR-136 transfected AGS gastric cancer cells. Cisplatin 81-90 BCL2 apoptosis regulator Homo sapiens 39-43 30210134-0 2019 Gemcitabine, Dexamethasone, and Cisplatin Regimen as an Effective Salvage Therapy for High-grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements. Cisplatin 32-41 BCL2 apoptosis regulator Homo sapiens 126-130 30257981-6 2019 RESULTS: In cisplatin-resistant models, DISARM identified novel candidates including multiple inhibitors of PI3K, MEK, and BCL-2, among other classes, across unrelated malignancies. Cisplatin 12-21 BCL2 apoptosis regulator Homo sapiens 123-128 30386247-7 2018 Altogether, these results suggest that NER and Bcl-2 protein family proteins are potential targets to improve the response to cisplatin treatment. Cisplatin 126-135 BCL2 apoptosis regulator Homo sapiens 47-52 30503360-5 2019 Here, we found that the combination treatment of scutellarin and cisplatin enhanced apoptosis in ovarian cancer cells via increasing the extent of platinum-DNA adducts and the ratio of Bax/Bcl-2. Cisplatin 65-74 BCL2 apoptosis regulator Homo sapiens 189-194 30806186-1 2019 Background: Response to neoadjuvant cisplatin treatment in bladder cancer has been linked to expression of Bcl-2 protein by cancer cells. Cisplatin 36-45 BCL2 apoptosis regulator Homo sapiens 107-112 30806186-2 2019 The objective of this study was to test Bcl-2 as a predictive marker of neoadjuvant cisplatin chemotherapy response in a patient cohort from randomized cystectomy trials. Cisplatin 84-93 BCL2 apoptosis regulator Homo sapiens 40-45 30774376-7 2019 siRNA was used to verify the anti-cisplatin-induced apoptosis effect of Bcl-2. Cisplatin 34-43 BCL2 apoptosis regulator Homo sapiens 72-77 30774376-8 2019 The Bcl-2 inhibitor, ABT-737, was used for improving the sensitivity of MCS to cisplatin. Cisplatin 79-88 BCL2 apoptosis regulator Homo sapiens 4-9 30774376-14 2019 Bcl-2 knockdown by siRNA or blockage by ABT-737 enhanced the cisplatin-induced apoptosis and reduced the 50% inhibitory concentrations of cisplatin for MCS by 58.5% and 88.2%, respectively. Cisplatin 61-70 BCL2 apoptosis regulator Homo sapiens 0-5 30774376-14 2019 Bcl-2 knockdown by siRNA or blockage by ABT-737 enhanced the cisplatin-induced apoptosis and reduced the 50% inhibitory concentrations of cisplatin for MCS by 58.5% and 88.2%, respectively. Cisplatin 138-147 BCL2 apoptosis regulator Homo sapiens 0-5 30774376-15 2019 Conclusion: The upregulated Bcl-2 contributes to cisplatin resistance in our MCS model and targeting it sensitizes the MCS to cisplatin treatment. Cisplatin 49-58 BCL2 apoptosis regulator Homo sapiens 28-33 30774376-15 2019 Conclusion: The upregulated Bcl-2 contributes to cisplatin resistance in our MCS model and targeting it sensitizes the MCS to cisplatin treatment. Cisplatin 126-135 BCL2 apoptosis regulator Homo sapiens 28-33 30614795-0 2019 The ratio of Bcl-2/Bim as a predictor of cisplatin response provides a rational combination of ABT-263 with cisplatin or radiation in small cell lung cancer. Cisplatin 41-50 BCL2 apoptosis regulator Homo sapiens 13-18 30614795-0 2019 The ratio of Bcl-2/Bim as a predictor of cisplatin response provides a rational combination of ABT-263 with cisplatin or radiation in small cell lung cancer. Cisplatin 108-117 BCL2 apoptosis regulator Homo sapiens 13-18 30614795-3 2019 OBJECTIVE: The aim of the study is to investigate the role of Bcl-2 family proteins in predicting SCLC sensitivity to cisplatin treatment, and to identify the potential sensitizer of cisplatin or ratiation treatment in SCLC. Cisplatin 118-127 BCL2 apoptosis regulator Homo sapiens 62-67 30614795-4 2019 METHODS: We collected cisplatin sensitivity data from public available database, and evaluated its possible association with mRNA or protein expression of Bcl-2 family members in SCLC cell lines. Cisplatin 22-31 BCL2 apoptosis regulator Homo sapiens 155-160 30614795-5 2019 RESULTS: The IC50 value of cisplatin was significantly correlated with the ratio of Bcl-2/Bim mRNA expression in 33 SCLC cell lines (P= 0.041) as well as the ratio of Bcl-2/Bim protein expression in 7 SCLC cell lines (P= 0.0252). Cisplatin 27-36 BCL2 apoptosis regulator Homo sapiens 84-89 30614795-7 2019 The synergistic and additive antitumor activity of ABT-263 combined with cisplatin or radiation was associated with the enhanced apoptosis, which may be caused by the disruption of Bcl-2 binding to Bim by ABT-263. Cisplatin 73-82 BCL2 apoptosis regulator Homo sapiens 181-186 30614795-8 2019 CONCLUSIONS: Our study indicates that the ratio of Bcl-2/Bim could be a SCLC response predictor to cisplatin, and ABT-263 addition could be an effective strategy to improve the activity of chemo- or radio-therapy in SCLC. Cisplatin 99-108 BCL2 apoptosis regulator Homo sapiens 51-56 30454003-6 2018 Western blotting and qRT-PCR assay revealed that luteolin increased cisplatin-induced downregulation of Bcl-2 expression. Cisplatin 68-77 BCL2 apoptosis regulator Homo sapiens 104-109 30464531-15 2018 Conclusion: Taken together, our results indicated that TRIM32 is overexpressed in NSCLC and regulates cisplatin resistance, possibly through NF-kappaB and Bcl-2. Cisplatin 102-111 BCL2 apoptosis regulator Homo sapiens 155-160 30096128-9 2018 I-BET151 synergistically enhanced cisplatin chemosensitivity by down-regulation of survivin and Bcl-2. Cisplatin 34-43 BCL2 apoptosis regulator Homo sapiens 96-101 30344696-9 2018 miR-423 inhibited cisplatin-induced apoptosis in endometrial cancer cells by regulation of caspase 3/7 and Bcl-2 expression. Cisplatin 18-27 BCL2 apoptosis regulator Homo sapiens 107-112 30226569-9 2018 Furthermore, the levels of the anti-apoptotic proteins, phosphorylated-protein kinase B and B-cell lymphoma-2 (Bcl-2), were significantly decreased, while the levels of the pro-apoptotic protein Bcl-2-associated X protein were remarkably increased in response to cisplatin treatment. Cisplatin 263-272 BCL2 apoptosis regulator Homo sapiens 195-200 30410558-4 2018 We found that the combined use of A549/DDP cells with SFI and cisplatin enhanced cell cycle arrested in the G2/M phase, which was accompanied by upregulation of p53 and p21 protein expression and induced mitochondrial apoptosis in conjunction with the upregulation of Bax and the downregulation of Bcl-2 protein expression. Cisplatin 62-71 BCL2 apoptosis regulator Homo sapiens 298-303 30468473-5 2018 Western blot was performed to detect protein levels of Prx V, Bcl-2 (B-cell lymphoma 2), BAD ,and caspase-3 in Cisplatin-induced A549 cells. Cisplatin 111-120 BCL2 apoptosis regulator Homo sapiens 62-67 30468473-5 2018 Western blot was performed to detect protein levels of Prx V, Bcl-2 (B-cell lymphoma 2), BAD ,and caspase-3 in Cisplatin-induced A549 cells. Cisplatin 111-120 BCL2 apoptosis regulator Homo sapiens 69-86 30468473-11 2018 With the treatment prolongation of 4 mumol/L Cisplatin in A549 cells, Bcl-2 and caspase-3 were downregulated, while BAD upregulated. Cisplatin 45-54 BCL2 apoptosis regulator Homo sapiens 70-75 30288106-10 2018 Conclusion: Downregulation of S100A9 could significantly increase apoptosis rate, resulting in enhancing sensitivity of SiHa cells to cisplatin, which may be related to Bcl-2, GST-pi, and LRP protein and by altering the AKT/ERK-FOXO1-Nanog signaling pathway. Cisplatin 134-143 BCL2 apoptosis regulator Homo sapiens 169-174 30197679-10 2018 Expression levels of pro-apoptotic protein were upregulated, whereas anti-apoptotic Bcl-2 was downregulated significantly in 143B cells following SAHA/cisplatin treatment. Cisplatin 151-160 BCL2 apoptosis regulator Homo sapiens 84-89 30015875-9 2018 Furthermore, the inhibition of Bcl-2 reduced the OXPHOS and sensitivity of SKOV3/DDP cells to cisplatin in a selective manner. Cisplatin 94-103 BCL2 apoptosis regulator Homo sapiens 31-36 30111297-12 2018 While cisplatin treatment decreased the ratio of Bcl-2 to Bax in normoxic condition, hypoxia conversely increased the ratio in HMM cells treated with cisplatin. Cisplatin 6-15 BCL2 apoptosis regulator Homo sapiens 49-54 30537795-9 2018 The survival rate and Bcl-2/Bax ratio of GIST-T1 cells treated with both Mir-22-3p analogue and cisplatin were significantly decreased, while the apoptosis rate and protein level of caspase-3 were significantly increased (p<0.05). Cisplatin 96-105 BCL2 apoptosis regulator Homo sapiens 22-27 30103745-4 2018 After treatment with 5 mug/mL cisplatin and 0.64 mg/mL SPS, the induction of apoptosis and the protein and mRNA expression of Bax, Bcl-2, COX-2, and cleaved caspase-3 in HN-6 cells were quantified. Cisplatin 30-39 BCL2 apoptosis regulator Homo sapiens 131-136 29760419-0 2018 PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer. Cisplatin 97-106 BCL2 apoptosis regulator Homo sapiens 42-46 29952351-0 2018 Long non-coding RNA Linc00312 modulates the sensitivity of ovarian cancer to cisplatin via the Bcl-2/Caspase-3 signaling pathway. Cisplatin 77-86 BCL2 apoptosis regulator Homo sapiens 95-100 29952351-14 2018 Linc00312 enhanced the sensitivity of SKOV3/DDP cells to cisplatin by promoting cell apoptosis via the Bcl-2/Caspase-3 signaling pathway. Cisplatin 57-66 BCL2 apoptosis regulator Homo sapiens 103-108 30219819-0 2018 MicroRNA-7-5p Promotes Cisplatin Resistance of Cervical Cancer Cells and Modulation of Cellular Energy Homeostasis by Regulating the Expression of the PARP-1 and BCL2 Genes. Cisplatin 23-32 BCL2 apoptosis regulator Homo sapiens 162-166 29679655-8 2018 In fact, NAC allows the anti-apoptotic molecule Bcl-2 to reduce the cell death caused by pro-necrotic concentrations of cisplatin, to a significantly greater extent than in the absence of NAC. Cisplatin 120-129 BCL2 apoptosis regulator Homo sapiens 48-53 30002690-0 2018 miR-181b inhibits chemoresistance in cisplatin-resistant H446 small cell lung cancer cells by targeting Bcl-2. Cisplatin 37-46 BCL2 apoptosis regulator Homo sapiens 104-109 29928364-9 2018 Decreased chemosensitivity to cisplatin may be associated with increased expression of phosphorylated-protein kinase B and cyclin dependent kinase 2 and with decreased expression of p21 and the B cell lymphoma (Bcl)-2 associated X/Bcl-2 ratio. Cisplatin 30-39 BCL2 apoptosis regulator Homo sapiens 194-217 29928364-9 2018 Decreased chemosensitivity to cisplatin may be associated with increased expression of phosphorylated-protein kinase B and cyclin dependent kinase 2 and with decreased expression of p21 and the B cell lymphoma (Bcl)-2 associated X/Bcl-2 ratio. Cisplatin 30-39 BCL2 apoptosis regulator Homo sapiens 231-236 29654165-9 2018 Furthermore, overexpressed NEAT1 reduced the sensitivity of cisplatin (DDP) and inhibited DDP-induced apoptosis and cell cycle arrest via miR-34c The results in vivo also confirmed that knockdown of NEAT1 sensitized the OS cells to DPP-induced tumor regression, delayed the tumor growth with reduced levels of Ki-67, BCL-2, and cyclin D1 signals, suggesting that NEAT1 is an oncogene and chemotherapy resistant factor in OS. Cisplatin 60-69 BCL2 apoptosis regulator Homo sapiens 317-322 29548748-7 2018 MALAT1 knockdown enhanced CDDP-induced apoptosis in vivo, as indicated by upregulation of Bax protein expression and downregulation of Bcl-2 protein expression. Cisplatin 26-30 BCL2 apoptosis regulator Homo sapiens 135-140 29760419-6 2018 Our siRNA-loaded PLGA nanoparticles for co-delivering MDR1 and BCL2 siRNA provide an efficient combination therapy strategy to overcome the chemoresistance of paclitaxel and cisplatin on the paclitaxel-resistant SKOV3-TR and cisplatin-resistant A2780-CP20 ovarian cancer respectively. Cisplatin 174-183 BCL2 apoptosis regulator Homo sapiens 63-67 29760419-6 2018 Our siRNA-loaded PLGA nanoparticles for co-delivering MDR1 and BCL2 siRNA provide an efficient combination therapy strategy to overcome the chemoresistance of paclitaxel and cisplatin on the paclitaxel-resistant SKOV3-TR and cisplatin-resistant A2780-CP20 ovarian cancer respectively. Cisplatin 225-234 BCL2 apoptosis regulator Homo sapiens 63-67 29207009-3 2018 Recently, the B-cell lymphoma 2 (Bcl-2) BH4 domain has been reported to mediate the prosurvival activity of Bcl-2 in cancer; however, the involvement of the BH4 domain of Bcl-2 in the cisplatin resistance of ovarian carcinoma cells is not entirely clear. Cisplatin 184-193 BCL2 apoptosis regulator Homo sapiens 14-31 29534504-8 2018 Finally, formononetin-inhibited c-Jun N-terminal kinase (JNK) phosphorylation, cleavage of caspase-8 and caspase-3, and the ratio of Bax to Bcl-2 increased with cisplatin. Cisplatin 161-170 BCL2 apoptosis regulator Homo sapiens 140-145 29286126-0 2018 Bcl-2 overexpression reduces cisplatin cytotoxicity by decreasing ER-mitochondrial Ca2+ signaling in SKOV3 cells. Cisplatin 29-38 BCL2 apoptosis regulator Homo sapiens 0-5 29286126-4 2018 Bcl-2 is reported to block cisplatin-induced apoptosis via regulating Ca2+ signaling in a variety of cancer cell lines. Cisplatin 27-36 BCL2 apoptosis regulator Homo sapiens 0-5 29286126-6 2018 The present study revealed that Bcl-2 overexpression reduced cisplatin-induced growth inhibition and apoptosis in SKOV3 human ovarian cancer cells. Cisplatin 61-70 BCL2 apoptosis regulator Homo sapiens 32-37 29286126-7 2018 Furthermore, Bcl-2 inhibited cisplatin-induced Ca2+ release from the ER to the cytoplasm and mitochondria, which reduced cisplatin-induced ER stress-mediated apoptosis through the mitochondrial apoptotic pathway. Cisplatin 29-38 BCL2 apoptosis regulator Homo sapiens 13-18 29286126-7 2018 Furthermore, Bcl-2 inhibited cisplatin-induced Ca2+ release from the ER to the cytoplasm and mitochondria, which reduced cisplatin-induced ER stress-mediated apoptosis through the mitochondrial apoptotic pathway. Cisplatin 121-130 BCL2 apoptosis regulator Homo sapiens 13-18 29286126-8 2018 The overexpression of Bcl-2 inhibited the cisplatin-induced increase in the number of ER-mitochondrial contact sites in SKOV3 human ovarian cancer cells. Cisplatin 42-51 BCL2 apoptosis regulator Homo sapiens 22-27 29286126-9 2018 In addition, the present study provided evidence that Bcl-2 reduced the anticancer activity of cisplatin towards ovarian cancer cells in vivo. Cisplatin 95-104 BCL2 apoptosis regulator Homo sapiens 54-59 29286126-10 2018 These results revealed that Bcl-2 attenuates cisplatin cytotoxicity via downregulating ER-mitochondrial Ca2+ signaling transduction. Cisplatin 45-54 BCL2 apoptosis regulator Homo sapiens 28-33 29203930-7 2018 The expression levels of Bax and Cyt-c proteins were upregulated, but the expression levels of Bcl-2 and Bcl-xL proteins were downregulated by blocking CDH17 gene in gastric cancer BGC823 cells after treatment with cisplatin. Cisplatin 215-224 BCL2 apoptosis regulator Homo sapiens 95-100 29352505-3 2018 Cisplatin produces anticancer effects primarily via activation of the DNA damage response, followed by inducing BCL-2 family dependent mitochondrial apoptosis. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 112-117 29352505-4 2018 We have previously demonstrated that cisplatin induces the expression of proapoptotic BCL-2 family protein, Noxa, that can bind to the prosurvival BCL-2 family protein, MCL-1, to inactivate its function and induce cell death. Cisplatin 37-46 BCL2 apoptosis regulator Homo sapiens 86-91 29352505-4 2018 We have previously demonstrated that cisplatin induces the expression of proapoptotic BCL-2 family protein, Noxa, that can bind to the prosurvival BCL-2 family protein, MCL-1, to inactivate its function and induce cell death. Cisplatin 37-46 BCL2 apoptosis regulator Homo sapiens 147-152 29196192-7 2018 Moreover, macrovipecetin alone or combined with cisplatin induced the expression of TRADD, p53, Bax, Bim and Bad and down-regulated the Bcl-2 expression and ROS levels in SK-MEL-28 cells. Cisplatin 48-57 BCL2 apoptosis regulator Homo sapiens 136-141 29568392-0 2018 MicroRNA-630 may confer favorable cisplatin-based chemotherapy and clinical outcomes in non-small cell lung cancer by targeting Bcl-2. Cisplatin 34-43 BCL2 apoptosis regulator Homo sapiens 128-133 29568392-4 2018 The aim was to examine the possible association between miR-630 (and its targeting of Bcl-2 expression) and the response to cisplatin-based chemotherapy. Cisplatin 124-133 BCL2 apoptosis regulator Homo sapiens 86-91 29568392-5 2018 Patients with tumors expressing low miR-630, high Bcl-2, and a combination of both were more likely than their counterparts to show unfavorable responses to cisplatin-based chemotherapy. Cisplatin 157-166 BCL2 apoptosis regulator Homo sapiens 50-55 29568392-9 2018 Mechanistically, low miR-630 expression conferred cisplatin resistance and colony formation by de-targeting Bcl-2 in NSCLC cells. Cisplatin 50-59 BCL2 apoptosis regulator Homo sapiens 108-113 29207009-3 2018 Recently, the B-cell lymphoma 2 (Bcl-2) BH4 domain has been reported to mediate the prosurvival activity of Bcl-2 in cancer; however, the involvement of the BH4 domain of Bcl-2 in the cisplatin resistance of ovarian carcinoma cells is not entirely clear. Cisplatin 184-193 BCL2 apoptosis regulator Homo sapiens 33-38 29207009-3 2018 Recently, the B-cell lymphoma 2 (Bcl-2) BH4 domain has been reported to mediate the prosurvival activity of Bcl-2 in cancer; however, the involvement of the BH4 domain of Bcl-2 in the cisplatin resistance of ovarian carcinoma cells is not entirely clear. Cisplatin 184-193 BCL2 apoptosis regulator Homo sapiens 108-113 29207009-3 2018 Recently, the B-cell lymphoma 2 (Bcl-2) BH4 domain has been reported to mediate the prosurvival activity of Bcl-2 in cancer; however, the involvement of the BH4 domain of Bcl-2 in the cisplatin resistance of ovarian carcinoma cells is not entirely clear. Cisplatin 184-193 BCL2 apoptosis regulator Homo sapiens 108-113 29207009-6 2018 The present study demonstrated that TAT-fused inositol 1,4,5-trisphosphate receptor-derived peptide (TAT-IDPS), which targets the BH4 domain of Bcl-2, increased cisplatin-induced Ca2+ flux from the endoplasmic reticulum (ER) into the cytosol and mitochondria. Cisplatin 161-170 BCL2 apoptosis regulator Homo sapiens 144-149 29352235-8 2018 In silico predictions by DR_MOMP revealed substantial differences in treatment responses of BCL(X)L, BCL2 or MCL1 inhibitors combinations with cisplatin that were successfully validated in cell lines. Cisplatin 143-152 BCL2 apoptosis regulator Homo sapiens 101-105 29136958-7 2018 Cellular function of miR-182-5p indicated that miR-182-5p suppression in AML cells could decrease cell proliferation and reverse cisplatin (DDP) resistance via targeting BCL2L12 and BCL2 expression. Cisplatin 129-138 BCL2 apoptosis regulator Homo sapiens 170-174 29091869-0 2018 Galangin (GG) combined with cisplatin (DDP) to suppress human lung cancer by inhibition of STAT3-regulated NF-kappaB and Bcl-2/Bax signaling pathways. Cisplatin 28-37 BCL2 apoptosis regulator Homo sapiens 121-126 31938109-7 2018 We also found that the expression of Bcl-2 was increased, and the levels of cleaved caspase-9 and cleaved PARP were reduced after gamma-radiation combined with cisplatin treatment of HeLa-siIER5 cells. Cisplatin 160-169 BCL2 apoptosis regulator Homo sapiens 37-42 29322787-0 2018 Beclin1 enhances cisplatin-induced apoptosis via Bcl-2-modulated autophagy in laryngeal carcinoma cells Hep-2. Cisplatin 17-26 BCL2 apoptosis regulator Homo sapiens 49-54 29322787-8 2018 The effect of Bcl-2 overexpression on increased cisplatin-sensitivity and autophagy induced by Beclin1 was investigated using Bcl-2 cDNA transfection. Cisplatin 48-57 BCL2 apoptosis regulator Homo sapiens 14-19 29322787-13 2018 Overexpression of Bcl-2 decreased the cisplatin-induced apoptosis and inhibited Beclin1-induced autophagy. Cisplatin 38-47 BCL2 apoptosis regulator Homo sapiens 18-23 29322787-14 2018 In conclusion, Beclin1 enhances cisplatin-induced apoptosis in laryngeal carcinoma cells Hep-2 via Bcl-2 modulated autophagy. Cisplatin 32-41 BCL2 apoptosis regulator Homo sapiens 99-104 28963947-2 2017 High expression level of BCL2 family proteins is a characteristic feature of cancer cells, especially in cisplatin-resistant cancer cells. Cisplatin 105-114 BCL2 apoptosis regulator Homo sapiens 25-29 28963947-5 2017 Here, we report that the BCL2/BCLXL inhibitor ABT737 induced apoptosis more potently in cisplatin-resistant SKOV3/DDP ovarian cancer cells than in cisplatin-sensitive SKOV3 ovarian cancer cells. Cisplatin 88-97 BCL2 apoptosis regulator Homo sapiens 25-29 28963947-5 2017 Here, we report that the BCL2/BCLXL inhibitor ABT737 induced apoptosis more potently in cisplatin-resistant SKOV3/DDP ovarian cancer cells than in cisplatin-sensitive SKOV3 ovarian cancer cells. Cisplatin 147-156 BCL2 apoptosis regulator Homo sapiens 25-29 29243778-10 2017 In the apatinib combined with DDP group, the levels of cleaved caspase-3, cleaved caspase-9 and B-cell lymphoma-2 (Bcl-2)-associated X (BAX) proteins were significantly upregulated, while the level of Bcl-2 proteins was downregulated. Cisplatin 30-33 BCL2 apoptosis regulator Homo sapiens 96-113 29243778-10 2017 In the apatinib combined with DDP group, the levels of cleaved caspase-3, cleaved caspase-9 and B-cell lymphoma-2 (Bcl-2)-associated X (BAX) proteins were significantly upregulated, while the level of Bcl-2 proteins was downregulated. Cisplatin 30-33 BCL2 apoptosis regulator Homo sapiens 201-206 29173002-7 2017 CONCLUSION: Our study demonstrates that miR-509-3p could sensitize ovarian cancer cells to cisplatin treatment by targeting multiple anti-apoptosis genes including BCL2. Cisplatin 91-100 BCL2 apoptosis regulator Homo sapiens 164-168 28979680-10 2017 After treatment of cisplatin, SKOV3 and hey cells showed increased apoptotic rate in flow cytometry assay, increased protein levels of cleaved caspase 3, cleaved PARP and Bax, and decreased protein levels of Bcl-2 and Bcl-XL. Cisplatin 19-28 BCL2 apoptosis regulator Homo sapiens 208-213 27689466-10 2017 Moreover, Pretreatment with E2 followed by cisplatin decreased the expression of cleaved PARP, and increased the expression of anti-apoptotic protein Bcl-2. Cisplatin 43-52 BCL2 apoptosis regulator Homo sapiens 150-155 28214344-5 2017 Furthermore our results revealed that neferine combined with cisplatin down regulate the expression of Bcl-2 and up regulate the expression of Bax, Bad, Bak, release of cytochrome c, p53 levels, then activated cleavage forms of caspase-9, caspase-3, and PARP. Cisplatin 61-70 BCL2 apoptosis regulator Homo sapiens 103-108 29084683-8 2017 The treatment of crocin plus cisplatin significantly increased the expression of p53 and Bax (p< 0.05), and significantly decreased the Bcl-2 expression (p<0.05). Cisplatin 29-38 BCL2 apoptosis regulator Homo sapiens 139-144 28696828-6 2017 And our results reveal that chemotherapeutics, Cisplatin (CDDP) and 5-Fluoracil (5-FU), result in the greater decrease of protein level of Bcl-2 and Mcl-1 in NPC cells than those in NPE cells. Cisplatin 47-56 BCL2 apoptosis regulator Homo sapiens 139-144 28789701-7 2017 Ad5/F11p-PSCAE-UPII-E1A plus cisplatin could upregulate the proteins expression of p53, Bax, and cleaved caspase-3, and downregulated Bcl-2 protein expression in T24, EJ and 5637 cells. Cisplatin 29-38 BCL2 apoptosis regulator Homo sapiens 134-139 28696828-6 2017 And our results reveal that chemotherapeutics, Cisplatin (CDDP) and 5-Fluoracil (5-FU), result in the greater decrease of protein level of Bcl-2 and Mcl-1 in NPC cells than those in NPE cells. Cisplatin 58-62 BCL2 apoptosis regulator Homo sapiens 139-144 28502300-12 2017 Moreover, with the down-regulation of SphK1, the expressions of ki67 and Bcl-2 were depressed; the expressions of caspase-9 and caspase-3 were raised, especially after treated with DDP. Cisplatin 181-184 BCL2 apoptosis regulator Homo sapiens 73-78 28597042-2 2017 In our study, we investigated the mechanism by which cisplatin induces LRP, Bcl-2, Bcl-xL, XIAP, and Survivin expression in human lung adenocarcinoma A549 cells and human H446 small cell lung cancer cells at mRNA and protein levels. Cisplatin 53-62 BCL2 apoptosis regulator Homo sapiens 76-81 28597042-6 2017 RESULTS: Cisplatin increased Bcl-2, LRP, and Survivin expression, but decreased Bcl-xL and XIAP expression in a dose-dependent manner. Cisplatin 9-18 BCL2 apoptosis regulator Homo sapiens 29-34 28690214-0 2017 [MiR-503 sensitizes human hepatocellular carcinoma cells to cisplatin by targeting bcl-2]. Cisplatin 60-69 BCL2 apoptosis regulator Homo sapiens 83-88 28393225-7 2017 However, treatment of MKN45 cells with cisplatin induced upregulation of p53beta and downregulation of bcl-2 mRNA expression levels, and these effects were enhanced by combination treatment with rmhTNF. Cisplatin 39-48 BCL2 apoptosis regulator Homo sapiens 103-108 28518145-5 2017 The RAP1-mediated cisplatin resistance was associated with the activation of NF-kappaB signaling and the upregulation of the antiapoptosis factor BCL-2. Cisplatin 18-27 BCL2 apoptosis regulator Homo sapiens 146-151 28518145-7 2017 Furthermore, in established cisplatin-resistant A549 cells, RAP1 depletion caused BCL2 depletion, caspase activation and dramatic lethality to the cells. Cisplatin 28-37 BCL2 apoptosis regulator Homo sapiens 82-86 28518145-8 2017 Hence, our results demonstrate that the cytoplasmic RAP1-NF-kappaB-BCL2 axis represents a key pathway to cisplatin resistance in NSCLC cells, identifying RAP1 as a marker and a potential therapeutic target for cisplatin resistance of NSCLC. Cisplatin 105-114 BCL2 apoptosis regulator Homo sapiens 67-71 28518145-8 2017 Hence, our results demonstrate that the cytoplasmic RAP1-NF-kappaB-BCL2 axis represents a key pathway to cisplatin resistance in NSCLC cells, identifying RAP1 as a marker and a potential therapeutic target for cisplatin resistance of NSCLC. Cisplatin 210-219 BCL2 apoptosis regulator Homo sapiens 67-71 28574829-5 2017 Consistent with these clinical observations, in vitro assays, we found that the subpopulation of EpCAM-positive ovarian cancer cells shows a significantly higher viability compared with EpCAM-negative cells in response to cisplatin treatment by preventing chemotherapy-induced apoptosis, which is regulated by EpCAM-Bcl-2 axis. Cisplatin 222-231 BCL2 apoptosis regulator Homo sapiens 316-321 28107698-11 2017 The combination of the IC50 doses of apigenin (15muM) and cisplatin (7.5muM) for 48h significantly enhanced cisplatin"s cytotoxic and apoptotic effects through downregulation of Bcl-2, sharpin and survivin; and upregulation of caspase-8, Apaf-1 and p53 mRNA expression. Cisplatin 58-67 BCL2 apoptosis regulator Homo sapiens 178-183 28454469-10 2017 Baicalein and baicalein-cisplatin combination treatments also inhibited B cell lymphoma-2 (Bcl-2) and increased Bcl-2-associated X protein (Bax) expression. Cisplatin 24-33 BCL2 apoptosis regulator Homo sapiens 72-89 28454469-10 2017 Baicalein and baicalein-cisplatin combination treatments also inhibited B cell lymphoma-2 (Bcl-2) and increased Bcl-2-associated X protein (Bax) expression. Cisplatin 24-33 BCL2 apoptosis regulator Homo sapiens 91-96 28355175-8 2017 Cisplatin combined with beta-elemene decreased the expressions of p-STAT3, p-JAK2, and Bcl-2, and increased the expressions of Bax and caspase-3 significantly compared to cisplatin only treatment, as well as in the xenograft model. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 87-92 28386348-5 2017 Firstly, we found cisplatin induced cell apoptosis in mesangial cells shown by increased number of apoptotic cells in parallel with the upregulation of Bax and the downregulation of Bcl-2. Cisplatin 18-27 BCL2 apoptosis regulator Homo sapiens 182-187 28386348-7 2017 Importantly, inhibition of COX-2 via a specific COX-2 inhibitor celecoxib markedly blocked cisplatin-induced mesangial cell apoptosis as evidenced by the decreased number of apoptotic cells, blocked increments of cleaved caspase-3 and Bax, and reversed Bcl-2 downregulation. Cisplatin 91-100 BCL2 apoptosis regulator Homo sapiens 253-258 28471109-8 2017 In addition, cisplatin increased the ratio of Bax to Bcl-2 in K562, which can influence the mitochondrial membrane permeability. Cisplatin 13-22 BCL2 apoptosis regulator Homo sapiens 53-58 28454332-4 2017 Furthermore, pretreatment with zoledronic acid (ZOL) appeared to resensitize the CDDP-resistant cells by inducing S-phase cell cycle arrest and the mitochondrial apoptotic pathway by upregulating the expression of B-cell lymphoma-2 (BCL-2)-associated X protein and caspase-9 and downregulating the expression of BCL-2. Cisplatin 81-85 BCL2 apoptosis regulator Homo sapiens 214-231 28256505-0 2017 miR-125b-5p enhances chemotherapy sensitivity to cisplatin by down-regulating Bcl2 in gallbladder cancer. Cisplatin 49-58 BCL2 apoptosis regulator Homo sapiens 78-82 28056551-11 2017 Hepatitis B X-interacting protein and cisplatin cooperated to induce apoptosis and increase the expression of c-caspase 3 as well as the Bax/Bcl-2 ratio. Cisplatin 38-47 BCL2 apoptosis regulator Homo sapiens 141-146 28291789-5 2017 We showed recently that La protects cells against cisplatin treatment by stimulating the protein synthesis of the anti-apoptotic factor Bcl2. Cisplatin 50-59 BCL2 apoptosis regulator Homo sapiens 136-140 28347251-8 2017 Meanwhile, knockdown of methyl methanesulfonate and ultraviolet-sensitive gene clone 81 activated the p53/Bcl-2 pathway in response to cisplatin. Cisplatin 135-144 BCL2 apoptosis regulator Homo sapiens 106-111 28454332-4 2017 Furthermore, pretreatment with zoledronic acid (ZOL) appeared to resensitize the CDDP-resistant cells by inducing S-phase cell cycle arrest and the mitochondrial apoptotic pathway by upregulating the expression of B-cell lymphoma-2 (BCL-2)-associated X protein and caspase-9 and downregulating the expression of BCL-2. Cisplatin 81-85 BCL2 apoptosis regulator Homo sapiens 233-238 28454332-4 2017 Furthermore, pretreatment with zoledronic acid (ZOL) appeared to resensitize the CDDP-resistant cells by inducing S-phase cell cycle arrest and the mitochondrial apoptotic pathway by upregulating the expression of B-cell lymphoma-2 (BCL-2)-associated X protein and caspase-9 and downregulating the expression of BCL-2. Cisplatin 81-85 BCL2 apoptosis regulator Homo sapiens 312-317 28124680-9 2017 The level of Bcl-2 decreased, while the levels of Bax, caspase-3, and caspase-9 increased in cisplatin combined with APS treatment compared to cisplatin only treatment. Cisplatin 93-102 BCL2 apoptosis regulator Homo sapiens 13-18 28124680-10 2017 The ratio of Bax to Bcl-2 was significantly enhanced by the APS to cisplatin. Cisplatin 67-76 BCL2 apoptosis regulator Homo sapiens 20-25 28124680-11 2017 CONCLUSIONS APS enhanced the anti-proliferative and apoptotic effect of cisplatin by modulating expression of Bax/Bcl-2 ratio and caspases on nasopharyngeal carcinoma cells and in the xenograft model. Cisplatin 72-81 BCL2 apoptosis regulator Homo sapiens 114-119 27935869-0 2017 The involvement of Bcl-2 family proteins in AKT-regulated cell survival in cisplatin resistant epithelial ovarian cancer. Cisplatin 75-84 BCL2 apoptosis regulator Homo sapiens 19-24 27935869-12 2017 The combination of cisplatin and Bcl-2 family protein inhibitor could be a strategy for the treatment of cisplatin-resistant ovarian cancer. Cisplatin 105-114 BCL2 apoptosis regulator Homo sapiens 33-38 28123844-6 2017 Further mechanism studies showed that the combined treatment of melatonin and cisplatin enhanced the cleavage of caspase-3, caspase-9 and poly-(ADP-ribose) polymerase (PARP), decreased the expression of Bcl-2 and p-IKKalpha/beta, suppressed the nuclear translocation of NF-kappaB p50/p65 proteins, and abrogated the binding of p65 to COX-2 promoter, thereby inhibiting COX-2 expression. Cisplatin 78-87 BCL2 apoptosis regulator Homo sapiens 203-208 28618418-8 2017 In addition, upregulation of miR-7 increases the sensitivity of LA cells to CDDP via induction of apoptosis by targeting Bcl-2. Cisplatin 76-80 BCL2 apoptosis regulator Homo sapiens 121-126 27935869-2 2017 The aim of this study was to examine the potential involvement of the Bcl-2 family proteins in AKT-regulated cell survival in response to cisplatin treatment. Cisplatin 138-147 BCL2 apoptosis regulator Homo sapiens 70-75 27591926-4 2016 CDDP/RSV increased ROS production and depolarization of mitochondrial membrane potential with an increase in the Bax/Bcl-2 ratio. Cisplatin 0-4 BCL2 apoptosis regulator Homo sapiens 117-122 27748803-2 2016 However, the function of Bcl-2 in cisplatin resistance in human ovarian cancer cells is not fully understood. Cisplatin 34-43 BCL2 apoptosis regulator Homo sapiens 25-30 27748803-3 2016 In this study, we found that the pharmacological inhibitor ABT737 or genetic knockdown of Bcl-2 increased cisplatin cytotoxicity in cisplatin-resistant ovarian cancer cells. Cisplatin 106-115 BCL2 apoptosis regulator Homo sapiens 90-95 27748803-3 2016 In this study, we found that the pharmacological inhibitor ABT737 or genetic knockdown of Bcl-2 increased cisplatin cytotoxicity in cisplatin-resistant ovarian cancer cells. Cisplatin 132-141 BCL2 apoptosis regulator Homo sapiens 90-95 27748803-4 2016 Additionally, treatment with ABT737 or Bcl-2 siRNA increased cisplatin-induced free Ca2+ levels in the cytosol and mitochondria, which increased endoplasmic reticulum (ER)-associated and mitochondria-mediated apoptosis. Cisplatin 61-70 BCL2 apoptosis regulator Homo sapiens 39-44 27748803-5 2016 In addition, ABT737 or Bcl-2 siRNA increased the ER-mitochondria contact sites induced by cisplatin in cisplatin-resistant SKOV3/DDP ovarian cancer cells. Cisplatin 90-99 BCL2 apoptosis regulator Homo sapiens 23-28 27748803-5 2016 In addition, ABT737 or Bcl-2 siRNA increased the ER-mitochondria contact sites induced by cisplatin in cisplatin-resistant SKOV3/DDP ovarian cancer cells. Cisplatin 103-112 BCL2 apoptosis regulator Homo sapiens 23-28 27748803-7 2016 Collectively, these results indicate that pharmacological inhibitors or genetic knockdown of Bcl-2 may be a potential strategy for improving cisplatin treatment of ovarian cancer. Cisplatin 141-150 BCL2 apoptosis regulator Homo sapiens 93-98 26744308-8 2016 More importantly, we proved that miR-125b increased the chemosensitivity of osteosarcoma cell lines to cisplatin by targeting Bcl-2. Cisplatin 103-112 BCL2 apoptosis regulator Homo sapiens 126-131 27895723-5 2016 The present study also demonstrated that cisplatin substantially inhibited beta-catenin, causing a marked downregulation of survivin and B-cell lymphoma (Bcl)-2. Cisplatin 41-50 BCL2 apoptosis regulator Homo sapiens 137-160 27895723-6 2016 Taken together, the present results uncovered a novel mechanism of cisplatin that could simultaneously trigger the inhibition of three prominent antiapoptotic effector molecules (Bcl-2, survivin and GRP78) and effectively promote GSH depletion by inhibiting gamma-GCSh. Cisplatin 67-76 BCL2 apoptosis regulator Homo sapiens 179-184 27588477-9 2016 Furthermore, we found that the PI3K/AKT pathway and Bcl-2/Bax ratio might be responsible for the eIF4E-induced cisplatin resistance in ESCC. Cisplatin 111-120 BCL2 apoptosis regulator Homo sapiens 52-57 27419628-5 2016 The results showed that both glutamine deprivation and BPTES pretreatments increased the toxic effects of cisplatin and etoposide on HCC1937 cells, as demonstrated by their reduced proliferation, increased expression of apoptosis-related proteins (cleaved-PARP, cleaved-caspase 9, and cleaved-caspase 3) and decreased Bcl-2/BAX ratio. Cisplatin 106-115 BCL2 apoptosis regulator Homo sapiens 318-323 27484725-11 2016 This suggested that the enhanced cisplatin chemosensitivity with Ad-ING4-P53 gene therapy in hypopharyngeal cancer xenografts may be associated with apoptosis induction through upregulation of Bax expression and downregulation of Bcl-2. Cisplatin 33-42 BCL2 apoptosis regulator Homo sapiens 230-235 27484725-10 2016 The results of immunohistochemistry analysis demonstrated that Bax expression was increased and Bcl-2 was decreased in the Ad-ING4-P53 + cisplatin group. Cisplatin 137-146 BCL2 apoptosis regulator Homo sapiens 96-101 26392091-4 2016 The analysis of the changes in the expression of genes involved in the response to DNA damage (CDKN1A, GADD45A, MDM2), apoptosis (BAX, BCL2) and oncogenesis (MYC, JUN) showed that 5-FU, CDDP and ET upregulated the genes involved in DNA damage response, while the anti-apoptotic gene BCL2 and oncogene MYC were downregulated. Cisplatin 186-190 BCL2 apoptosis regulator Homo sapiens 135-139 27494891-6 2016 Mechanistic studies suggested that treatment of cells with PHPO or with PHPO + cisplatin differentially inhibited the PI3K/Akt, MAPK and ATM/Chk2 pathways, which consequently suppressed the anti-apoptotic factors Bcl-xL, Bcl-2 and XIAP, but activated the pro-apoptotic factors Bad, Bax, p53, caspase 9, caspase 8, caspase 7 and PARP. Cisplatin 79-88 BCL2 apoptosis regulator Homo sapiens 221-226 27138804-4 2016 The aim of the present study is to investigate the value of Pan-Bcl-2 inhibitor as sensitizer for the chemotherapy of cisplatin-resistant non-small cell lung cancer (NSCLC) cells. Cisplatin 118-127 BCL2 apoptosis regulator Homo sapiens 64-69 27082738-8 2016 Fluorescent microscopy revealed that Bcl-2-overexpression had no effect on the docetaxel-induced death of DU145 cells, but significantly decreased DU145 cell death induced by cisplatin or TNF-alpha. Cisplatin 175-184 BCL2 apoptosis regulator Homo sapiens 37-42 29714913-1 2016 Lung cancer is the leading cause of cancer-related deaths worldwide.Despite the development and use of several targeting drugs for lung cancer therapy,the five-year survival rate has remained as low as 15%for the past three decades.Cisplatin-based chemotherapy is considered the first-line therapeutic strategy for lung cancer.However,developments of chemoresistance is a major obstacle for the successful treatment.Therefore,the development of novel therapy against cisplatin-resistance lung cancer is imperative.Photodynamic therapy(PDT),which is a non-invasive combinatorial therapeutic modality using light,photosensitizer(PS)and oxygen,may provide an unprecedented tool to develop more effective treatments.To provide experimental basis for its application in cisplatin-resistance lung cancer,we will discuss the biological effects of MPPa-photodynamic therapy in human cisplatin-resistance lung cancer cells in this article.Human cisplatin-resistance lung cancer cells A549/DDP were co-cultured with MPPa(0,1,2,4,8,16mumol/L)and exposed to light(0,0.6,1.2,2.4,3.6,4.8J/cm2),and cell viability was determined with CCK-8assay.Flow cytometry was used to detect apoptosis,DCFH-DA staining was employed to observe reactive oxygen species(ROS),and Western blot was used to detect the expressions of B-cell lymphoma-2(Bcl-2)protein and Bcl-2associated X protein(Bax).The proliferation of A549/DDP cells was suppressed by PDT.The apoptotic rate in the PDT group was significantly higher than that in the control,MPPa or light group(P<0.05).The level of ROS was increased.The expression of Bax was increased,and that of Bcl-2was decreased.MPPa-photodynamic therapy can significantly suppress cell viability,and induce apoptosis in human cisplatin-resistance lung cancer cells. Cisplatin 232-241 BCL2 apoptosis regulator Homo sapiens 1317-1322 29714913-1 2016 Lung cancer is the leading cause of cancer-related deaths worldwide.Despite the development and use of several targeting drugs for lung cancer therapy,the five-year survival rate has remained as low as 15%for the past three decades.Cisplatin-based chemotherapy is considered the first-line therapeutic strategy for lung cancer.However,developments of chemoresistance is a major obstacle for the successful treatment.Therefore,the development of novel therapy against cisplatin-resistance lung cancer is imperative.Photodynamic therapy(PDT),which is a non-invasive combinatorial therapeutic modality using light,photosensitizer(PS)and oxygen,may provide an unprecedented tool to develop more effective treatments.To provide experimental basis for its application in cisplatin-resistance lung cancer,we will discuss the biological effects of MPPa-photodynamic therapy in human cisplatin-resistance lung cancer cells in this article.Human cisplatin-resistance lung cancer cells A549/DDP were co-cultured with MPPa(0,1,2,4,8,16mumol/L)and exposed to light(0,0.6,1.2,2.4,3.6,4.8J/cm2),and cell viability was determined with CCK-8assay.Flow cytometry was used to detect apoptosis,DCFH-DA staining was employed to observe reactive oxygen species(ROS),and Western blot was used to detect the expressions of B-cell lymphoma-2(Bcl-2)protein and Bcl-2associated X protein(Bax).The proliferation of A549/DDP cells was suppressed by PDT.The apoptotic rate in the PDT group was significantly higher than that in the control,MPPa or light group(P<0.05).The level of ROS was increased.The expression of Bax was increased,and that of Bcl-2was decreased.MPPa-photodynamic therapy can significantly suppress cell viability,and induce apoptosis in human cisplatin-resistance lung cancer cells. Cisplatin 232-241 BCL2 apoptosis regulator Homo sapiens 1335-1340 27177238-7 2016 After treatment of BBR and cisplatin, the cellular pro-apoptotic capase-3 and cleaved capspase-3 and caspase-9 were upregulated and the anti-apoptotic Bcl-2 was downregulated. Cisplatin 27-36 BCL2 apoptosis regulator Homo sapiens 151-156 29797935-5 2016 Meanwhile, we confirmed that CXCR4 affected the expression of bcl-2 through regulating the expression of let-7a to modulate the chemoresistance of CNE2/DPP to cisplatin. Cisplatin 159-168 BCL2 apoptosis regulator Homo sapiens 62-67 27083050-0 2016 Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2. Cisplatin 52-61 BCL2 apoptosis regulator Homo sapiens 103-108 27083050-7 2016 Bcl-2 de-targeted by E6-mediated miR- 184 reduction was responsible for cisplatin resistance. Cisplatin 72-81 BCL2 apoptosis regulator Homo sapiens 0-5 27083050-12 2016 Patients with low-mR-184, E6-positive, high-Bcl-2 tumors, and both combinations were more prevalently occurred unfavorable response to cisplatin-based chemotherapy than their counterparts. Cisplatin 135-144 BCL2 apoptosis regulator Homo sapiens 44-49 27083050-13 2016 In conclusion, a decrease in miR-184 level by E6 oncoprotein may predict unfavorable response to cisplatin-based chemotherapy in HPV-infected NSCLC patients via increasing Bcl-2 expression. Cisplatin 97-106 BCL2 apoptosis regulator Homo sapiens 172-177 27105491-7 2016 Altogether, our data support a novel model, whereby cancer-associated La protein contributes to cisplatin resistance by stimulating the translation of anti-apoptotic factor Bcl2 in HNSCC cells. Cisplatin 96-105 BCL2 apoptosis regulator Homo sapiens 173-177 27029054-6 2016 Furthermore, Exo-GF co-incubation with cisplatin increased autophagic activity and reduced apoptosis, as demonstrated by an upregulation of LC3-II and Bcl-2 protein levels and downregulation of p62 and Bax protein levels. Cisplatin 39-48 BCL2 apoptosis regulator Homo sapiens 151-156 27105491-0 2016 The La protein counteracts cisplatin-induced cell death by stimulating protein synthesis of anti-apoptotic factor Bcl2. Cisplatin 27-36 BCL2 apoptosis regulator Homo sapiens 114-118 27105491-3 2016 Our data demonstrate that depletion of the RNA-binding protein La in head and neck squamous cell carcinoma cells (HNSCC) increases the sensitivity toward cisplatin-induced cell death paralleled by reduced expression of the anti-apoptotic factor Bcl2. Cisplatin 154-163 BCL2 apoptosis regulator Homo sapiens 245-249 27105491-4 2016 Furthermore, it is shown that transient expression of Bcl2 in La-depleted cells protects against cisplatin-induced cell death. Cisplatin 97-106 BCL2 apoptosis regulator Homo sapiens 54-58 27105491-5 2016 By dissecting the underlying mechanism we report herein, that the La protein is required for Bcl2 protein synthesis in cisplatin-treated cells. Cisplatin 119-128 BCL2 apoptosis regulator Homo sapiens 93-97 26996126-4 2016 In contrast, the expression of proapoptotic multidomain Bcl-2-family members, Bak and Bax, was induced by cisplatin in p53-dependent and -independent manners, respectively. Cisplatin 106-115 BCL2 apoptosis regulator Homo sapiens 56-61 27110775-7 2016 Smad3 upregulated p21(Waf1/Cip1) and downregulated c-myc and bcl2 with the treatment of cisplatin. Cisplatin 88-97 BCL2 apoptosis regulator Homo sapiens 61-65 27044825-14 2016 sCD40L in combination with cisplatin decreased the expression levels of GST-pi, LRP, Survivin, p53 and Bcl-2 in both epithelial ovarian cancer cell lines. Cisplatin 27-36 BCL2 apoptosis regulator Homo sapiens 103-108 26482622-9 2016 Patients with high Bcl-2-expressing tumors treated with cisplatin-based chemotherapy showed unfavorable predictive values in a subset of this study population. Cisplatin 56-65 BCL2 apoptosis regulator Homo sapiens 19-24 26482622-10 2016 Therefore, we suggest that cytoplasmic p27 (N-/C+) via ERK-activated Bcl-2 expression may predict an unfavorable response to cisplatin-based chemotherapy and poor outcomes in NSCLC. Cisplatin 125-134 BCL2 apoptosis regulator Homo sapiens 69-74 26865836-11 2015 ICC analysis for bcl2 and p53 also confirmed our results; in treated samples for the dose of LD50 in 24 and 48 h of cisplatin and hypercin, more cells expressed p53 (guardian of cells in front of tumor formation/progression) and less expressed bcl2 (which has anti apoptotic activity) compared to untreated samples. Cisplatin 116-125 BCL2 apoptosis regulator Homo sapiens 17-21 26865836-11 2015 ICC analysis for bcl2 and p53 also confirmed our results; in treated samples for the dose of LD50 in 24 and 48 h of cisplatin and hypercin, more cells expressed p53 (guardian of cells in front of tumor formation/progression) and less expressed bcl2 (which has anti apoptotic activity) compared to untreated samples. Cisplatin 116-125 BCL2 apoptosis regulator Homo sapiens 244-248 25381586-6 2016 CONCLUSION: The miR-21 in osteosarcoma cells is a significant modulator of the anti-tumor effect of CDDP by regulating the expression of bcl-2, and the study reveals a novel mechanism of osteosarcoma drug resistance. Cisplatin 100-104 BCL2 apoptosis regulator Homo sapiens 137-142 26692364-7 2016 Moreover, phloretin facilitated the effects of cisplatin on deregulation of Bcl-2, MMP-2 and -9, and upregulation of cleaved-caspase-3 and -9. Cisplatin 47-56 BCL2 apoptosis regulator Homo sapiens 76-81 26729257-4 2016 We showed that a pretreatment with morphine (1 mug/ml) inhibited the sensitivity of CNE-2 cells to cisplatin by inhibiting cisplatin-induced CNE-2 cell apoptosis, decreasing caspase-3 activity and increasing the Bcl-2/Bax ratio. Cisplatin 99-108 BCL2 apoptosis regulator Homo sapiens 212-217 27226901-4 2016 We show that the chemotherapeutic drug cisplatin initiates an apoptotic pathway by phosphorylation of a pro-survival Bcl-2 family member, Bcl-xL, by cyclin-dependent kinase 2. Cisplatin 39-48 BCL2 apoptosis regulator Homo sapiens 117-122 26575528-12 2016 In KKU-100 cells, growth inhibition was accompanied by upregulation of p53 and p21 and downregulation of CDK4 and Bcl-2 due to exposure to cisplatin, SAHA and TSA alone or in combination. Cisplatin 139-148 BCL2 apoptosis regulator Homo sapiens 114-119 26966728-10 2016 CONCLUSIONS: The BCL2, MCM7, and CCNE1 genes might play distinctive roles in cisplatin resistance in BC. Cisplatin 77-86 BCL2 apoptosis regulator Homo sapiens 17-21 26323558-0 2015 MiR-873 acts as a novel sensitizer of glioma cells to cisplatin by targeting Bcl-2. Cisplatin 54-63 BCL2 apoptosis regulator Homo sapiens 77-82 26718738-12 2016 In addition, in the cells targeted with FEN1-siRNA and exposed to CDDP, the levels of Bcl-2-associated X protein were significantly increased, whereas the expression levels of Bcl-2 and Bcl-extra large were effectively decreased, compared with the cells exposed to negative control-siRNA and CDDP. Cisplatin 66-70 BCL2 apoptosis regulator Homo sapiens 86-91 26718738-12 2016 In addition, in the cells targeted with FEN1-siRNA and exposed to CDDP, the levels of Bcl-2-associated X protein were significantly increased, whereas the expression levels of Bcl-2 and Bcl-extra large were effectively decreased, compared with the cells exposed to negative control-siRNA and CDDP. Cisplatin 66-70 BCL2 apoptosis regulator Homo sapiens 176-181 26497680-6 2015 Among the Nrf2 downstream genes, Bcl-2 and Bcl-xL contribute more strongly to Nrf2-mediated cisplatin resistance when compared with heme oxygenase 1 (HO-1). Cisplatin 92-101 BCL2 apoptosis regulator Homo sapiens 33-38 26497680-7 2015 Cox regression analysis showed that patients with high-Nrf2, high-Bcl-2, high-Bcl-xL mRNA tumors were more commonly occurred unfavorable response to cisplatin-based chemotherapy than their counterparts. Cisplatin 149-158 BCL2 apoptosis regulator Homo sapiens 66-71 26314326-5 2015 Above all, resveratrol enhanced the effects of cisplatin on inhibition of cancer cell proliferation, induction of cell apoptosis, depolarization of mitochondrial membrane potential, release of cytochrome c and regulation on expression of Bcl-2 and Bax. Cisplatin 47-56 BCL2 apoptosis regulator Homo sapiens 238-243 26966728-0 2016 Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines. Cisplatin 57-66 BCL2 apoptosis regulator Homo sapiens 26-30 26966728-0 2016 Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines. Cisplatin 133-142 BCL2 apoptosis regulator Homo sapiens 26-30 26966728-0 2016 Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines. Cisplatin 133-142 BCL2 apoptosis regulator Homo sapiens 26-30 26966728-9 2016 Western blot analyses also confirmed the upregulation of BCL2, MCM7, and CCNE1 at the protein level, indicating their crucial association with cisplatin resistance. Cisplatin 143-152 BCL2 apoptosis regulator Homo sapiens 57-61 26586936-8 2015 When As4S4 was combined with chemotherapy drug cisplatin or COX2 inhibitor celecoxib, its inhibition of COX2, BCL2, and p38 expression was enhanced. Cisplatin 47-56 BCL2 apoptosis regulator Homo sapiens 110-114 26474854-0 2015 Bcl-2 confers survival in cisplatin treated cervical cancer cells: circumventing cisplatin dose-dependent toxicity and resistance. Cisplatin 26-35 BCL2 apoptosis regulator Homo sapiens 0-5 26474854-0 2015 Bcl-2 confers survival in cisplatin treated cervical cancer cells: circumventing cisplatin dose-dependent toxicity and resistance. Cisplatin 81-90 BCL2 apoptosis regulator Homo sapiens 0-5 26474854-3 2015 Bcl-2 up-regulation has been implicated in the resistance to cisplatin in a variety of cancer cell lines, however its role in cervical cancer is confounding. Cisplatin 61-70 BCL2 apoptosis regulator Homo sapiens 0-5 26474854-5 2015 Bcl-2 expression was determined through Western blotting and immunocytochemistry before and after treatment with cisplatin. Cisplatin 113-122 BCL2 apoptosis regulator Homo sapiens 0-5 26474854-6 2015 To assess the reliance of the cervical cancer cells on Bcl-2 in the presence of cisplatin, Bcl-2 knock-down was achieved through RNA interference, where after apoptosis was assessed through PARP cleavage (Western blotting), Caspase activity (Caspase-Glo( )) and PI inclusion analysis (Flow cytometry). Cisplatin 80-89 BCL2 apoptosis regulator Homo sapiens 55-60 26474854-8 2015 RESULTS: Cervical cancer cells upregulate Bcl-2 when treated with a non-cytotoxic concentration of cisplatin, which when silenced, effectively enhanced cisplatin sensitivity, and therefore significantly induced apoptosis. Cisplatin 99-108 BCL2 apoptosis regulator Homo sapiens 42-47 26474854-8 2015 RESULTS: Cervical cancer cells upregulate Bcl-2 when treated with a non-cytotoxic concentration of cisplatin, which when silenced, effectively enhanced cisplatin sensitivity, and therefore significantly induced apoptosis. Cisplatin 152-161 BCL2 apoptosis regulator Homo sapiens 42-47 26310353-14 2015 FoxO3a target genes involved in cell cycle progression and apoptosis were also investigated, and combined treatment with butein and cisplatin resulted in the downregulation of cyclin D1 and Bcl-2 and the upregulation of p27 and Bax. Cisplatin 132-141 BCL2 apoptosis regulator Homo sapiens 190-195 26323558-8 2015 A luciferase reporter assay further confirmed that Bcl-2 was a direct target of miR-873, and miR-873 decreased the level of the Bcl-2 protein in cisplatin-resistant glioma cells. Cisplatin 145-154 BCL2 apoptosis regulator Homo sapiens 51-56 26323558-8 2015 A luciferase reporter assay further confirmed that Bcl-2 was a direct target of miR-873, and miR-873 decreased the level of the Bcl-2 protein in cisplatin-resistant glioma cells. Cisplatin 145-154 BCL2 apoptosis regulator Homo sapiens 128-133 26323558-9 2015 Notably, re-expression of Bcl-2 attenuated the function of miR-873 in cisplatin-resistant glioma cells and the sensitivity of the cells to cisplatin. Cisplatin 70-79 BCL2 apoptosis regulator Homo sapiens 26-31 26323558-9 2015 Notably, re-expression of Bcl-2 attenuated the function of miR-873 in cisplatin-resistant glioma cells and the sensitivity of the cells to cisplatin. Cisplatin 139-148 BCL2 apoptosis regulator Homo sapiens 26-31 26151347-4 2015 Various molecular techniques were used to assess the expression of FOXO3a and B cell lymphoma 2 (Bcl-2)-interacting mediator of cell death (Bim) in cisplatin-sensitive and -resistant ovarian cancer cells. Cisplatin 148-157 BCL2 apoptosis regulator Homo sapiens 78-95 26151347-4 2015 Various molecular techniques were used to assess the expression of FOXO3a and B cell lymphoma 2 (Bcl-2)-interacting mediator of cell death (Bim) in cisplatin-sensitive and -resistant ovarian cancer cells. Cisplatin 148-157 BCL2 apoptosis regulator Homo sapiens 97-102 26313152-8 2015 Expression of anti-apoptotic proteins Bcl-2 and Mcl-1 and DNA repair associated molecules ATM, CHK1, TP73, p53, and ERCC1 were significantly up regulated in cisplatin-treated A549sc and H157sc cells, but no increase was detected in A549IL-6si and H157IL-6si cells. Cisplatin 157-166 BCL2 apoptosis regulator Homo sapiens 38-43 25936772-3 2015 Bcl-2 family proteins play critical roles in orchestrating mitochondrial dynamics, and are involved in the resistance to cisplatin. Cisplatin 121-130 BCL2 apoptosis regulator Homo sapiens 0-5 26403741-6 2015 The STOML-2-overexpressing cells exhibited an obvious resistance to IC50 Cisplatin-induced apoptosis as shown by both fluorescence microscopy and flow cytometry and presented with decreased expressions of cleaved caspase-3, Bax, and cytosol Cyt C and increased expressions of caspase-3, Bcl-2, and mitochondrial Cyt C. Cisplatin 73-82 BCL2 apoptosis regulator Homo sapiens 287-292 26396928-3 2015 Our study revealed that cisplatin and AITC combination synergistically inhibits cancer cell growth and colony formation, and enhances apoptosis in association with the downregulation of antiapoptotic proteins Bcl-2 and survivin. Cisplatin 24-33 BCL2 apoptosis regulator Homo sapiens 209-214 25894537-7 2015 In addition, decreased Bcl-2 expression and increased BID cleavage and cytochrome C release were detected in C2 cells after cisplatin challenge. Cisplatin 124-133 BCL2 apoptosis regulator Homo sapiens 23-28 25894537-8 2015 Treating the cells with cisplatin, in combination with a Bcl-2 inhibitor, decreased the viability of NT3 cells to the same level as C2 cells after cisplatin. Cisplatin 24-33 BCL2 apoptosis regulator Homo sapiens 57-62 25894537-8 2015 Treating the cells with cisplatin, in combination with a Bcl-2 inhibitor, decreased the viability of NT3 cells to the same level as C2 cells after cisplatin. Cisplatin 147-156 BCL2 apoptosis regulator Homo sapiens 57-62 26550150-0 2015 MicroRNA 192 regulates chemo-resistance of lung adenocarcinoma for gemcitabine and cisplatin combined therapy by targeting Bcl-2. Cisplatin 83-92 BCL2 apoptosis regulator Homo sapiens 123-128 25936772-11 2015 ABT737 might enhance cholangiocarcinoma sensitivity to cisplatin through regulation of mitochondrial dynamics and the balance within Bcl-2 family proteins. Cisplatin 55-64 BCL2 apoptosis regulator Homo sapiens 133-138 26710702-8 2015 CONCLUSIONS: PinX1 gene can enhance the chemotherapy sensitivity of nasopharyngeal carcinoma cells in response to Cisplatin, which may be mediated by the down-regulation of telomerase activity and the inhibition of LRP and Bcl-2 gene in nasopharyngeal carcinoma cells. Cisplatin 114-123 BCL2 apoptosis regulator Homo sapiens 223-228 26089640-0 2015 Small-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in non-small-cell lung cancer. Cisplatin 93-102 BCL2 apoptosis regulator Homo sapiens 35-40 26171069-6 2015 It was observed that combined administration of cisplatin and bortezomib induced upregulation of caspase-3, -8 and -9, B-cell lymphoma-2 (Bcl-2)-like 11 and Bcl-2-interacting killer, but downregulated Bcl-2 and Bcl-extra large protein expression levels in T24 cells in a dose-dependent manner. Cisplatin 48-57 BCL2 apoptosis regulator Homo sapiens 119-136 26171069-6 2015 It was observed that combined administration of cisplatin and bortezomib induced upregulation of caspase-3, -8 and -9, B-cell lymphoma-2 (Bcl-2)-like 11 and Bcl-2-interacting killer, but downregulated Bcl-2 and Bcl-extra large protein expression levels in T24 cells in a dose-dependent manner. Cisplatin 48-57 BCL2 apoptosis regulator Homo sapiens 138-143 26171069-6 2015 It was observed that combined administration of cisplatin and bortezomib induced upregulation of caspase-3, -8 and -9, B-cell lymphoma-2 (Bcl-2)-like 11 and Bcl-2-interacting killer, but downregulated Bcl-2 and Bcl-extra large protein expression levels in T24 cells in a dose-dependent manner. Cisplatin 48-57 BCL2 apoptosis regulator Homo sapiens 157-162 25904702-9 2015 Western blot analysis showed higher expression of P-Erk1/2, Bcl-2, SOD-1, and HO-1 in the HK-2 cells exposed to cisplatin in the presence of CM from melatonin-pretreated hASCs. Cisplatin 112-121 BCL2 apoptosis regulator Homo sapiens 60-65 25499851-3 2015 Therefore, we hypothesized that MnSOD-mediated NF-kappaB activation might confer cisplatin resistance in lung adenocarcinoma via the NF-kappaB/Bcl-2/Snail pathway. Cisplatin 81-90 BCL2 apoptosis regulator Homo sapiens 143-148 25604244-0 2015 TTP mediates cisplatin-induced apoptosis of head and neck cancer cells by down-regulating the expression of Bcl-2. Cisplatin 13-22 BCL2 apoptosis regulator Homo sapiens 108-113 25604244-2 2015 B-cell lymphoma 2 (Bcl-2) is an anti-apoptotic protein that is overexpressed in cancer cells and confers resistance to cisplatin. Cisplatin 119-128 BCL2 apoptosis regulator Homo sapiens 0-17 25604244-2 2015 B-cell lymphoma 2 (Bcl-2) is an anti-apoptotic protein that is overexpressed in cancer cells and confers resistance to cisplatin. Cisplatin 119-128 BCL2 apoptosis regulator Homo sapiens 19-24 25604244-3 2015 Thus, inhibition of Bcl-2 expression may enhance the cisplatin sensitivity of cancer cells. Cisplatin 53-62 BCL2 apoptosis regulator Homo sapiens 20-25 25604244-5 2015 Cisplatin-sensitive HNSCC cells express high levels of TTP and low levels of Bcl-2, while cisplatin-resistant HNSCC cells have low levels of TTP and high levels of Bcl-2. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 77-82 25604244-5 2015 Cisplatin-sensitive HNSCC cells express high levels of TTP and low levels of Bcl-2, while cisplatin-resistant HNSCC cells have low levels of TTP and high levels of Bcl-2. Cisplatin 90-99 BCL2 apoptosis regulator Homo sapiens 164-169 25604244-8 2015 Together, the results of the present study suggest that TTP expression enhances cisplatin sensitivity in HNSCC cells by reducing levels of Bcl-2. Cisplatin 80-89 BCL2 apoptosis regulator Homo sapiens 139-144 25770930-4 2015 Combination of chrysin and cisplatin increased the phosphorylation and accumulation of p53 through activating ERK1/2 in Hep G2 cells, which led to the overexpression of the pro-apoptotic proteins Bax and DR5 and the inhibition of the anti-apoptotic protein Bcl-2. Cisplatin 27-36 BCL2 apoptosis regulator Homo sapiens 257-262 25885284-9 2015 Cisplatin- and gemcitabine-resistant bladder cancer cells exhibit enhanced basal and drug-induced autophagosome formation and lysosomal activity which is accompanied by an attenuated apoptotic cell death after treatment with both (-)-gossypol and ABT-737, a Bcl-2 inhibitor which spares Mcl-1, in comparison to parental cells. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 258-263 25405848-0 2015 Downregulation of osteopontin enhances the sensitivity of glioma U251 cells to temozolomide and cisplatin by targeting the NF-kappaB/Bcl-2 pathway. Cisplatin 96-105 BCL2 apoptosis regulator Homo sapiens 133-138 25823945-0 2015 Small-molecule inhibitor of Bcl-2 (TW-37) suppresses growth and enhances cisplatin-induced apoptosis in ovarian cancer cells. Cisplatin 73-82 BCL2 apoptosis regulator Homo sapiens 28-33 25582599-2 2015 The proapoptotic Bcl-2 family proteins Bax and Bak are essential for cisplatin-induced apoptosis. Cisplatin 69-78 BCL2 apoptosis regulator Homo sapiens 17-22 26055133-1 2015 Nakai ex Kitam ethanol extract against cisplatin-induced apoptosis of human HaCaT keratinocytes: Involvement of NF-kappa B- and Bcl-2-controlled mitochondrial signaling. Cisplatin 39-48 BCL2 apoptosis regulator Homo sapiens 128-133 26055133-14 2015 CONCLUSION: Collectively, our results suggest that Aa-EE protects HaCaT cells by inhibiting cisplatin-induced mitochondrial damage associated with Bcl-2 activity and by inhibiting nuclear translocation of NF-kappaB. Cisplatin 92-101 BCL2 apoptosis regulator Homo sapiens 147-152 25492481-0 2015 Involvement of miR-143 in cisplatin resistance of gastric cancer cells via targeting IGF1R and BCL2. Cisplatin 26-35 BCL2 apoptosis regulator Homo sapiens 95-99 25492481-7 2015 It was also downregulated in cisplatin-resistant gastric cancer cell line SGC7901/cisplatin (DDP), which was concurrent with the upregulation of IGF1R and BCL2, compared with the parental SGC7901 cell line, respectively. Cisplatin 29-38 BCL2 apoptosis regulator Homo sapiens 155-159 25492481-7 2015 It was also downregulated in cisplatin-resistant gastric cancer cell line SGC7901/cisplatin (DDP), which was concurrent with the upregulation of IGF1R and BCL2, compared with the parental SGC7901 cell line, respectively. Cisplatin 82-91 BCL2 apoptosis regulator Homo sapiens 155-159 25492481-11 2015 Our findings suggested that hsa-miR-143 could modulate cisplatin resistance of human gastric cancer cell line at least in part by targeting IGF1R and BCL2. Cisplatin 55-64 BCL2 apoptosis regulator Homo sapiens 150-154 25499851-6 2015 Mechanistically, an increase in Bcl-2 by MnSOD-mediated NF-kappaB activation confers greater cisplatin resistance than cIAP2, Bcl-xL, Mcl-1, and Snail. Cisplatin 93-102 BCL2 apoptosis regulator Homo sapiens 32-37 25499851-7 2015 MnSOD-mediated cisplatin resistance can be overcome by a Bcl-2 antagonist (ABT-199) or IKKbeta inhibitor (curcumin) in cells and xenograft tumors. Cisplatin 15-24 BCL2 apoptosis regulator Homo sapiens 57-62 25499851-9 2015 A retrospective study indicated that it was more common for MnSOD-positive, nuclear p65-positive, or high Bcl-2 mRNA tumors to have an unfavorable response to cisplatin-based chemotherapy than their counterparts. Cisplatin 159-168 BCL2 apoptosis regulator Homo sapiens 106-111 26366416-6 2015 Our study found that cisplatin induced apoptosis of Hela cell through inhibiting expression of Bcl-2, upregulating the expression of Bax, Fas-L, and the enzyme activity of caspase-3 (p < 0.05); LPA significantly provided protection against the apoptosis induced by cisplatin by inhibiting the above alterations in apoptotic factor caused by cisplatin (p < 0.05). Cisplatin 21-30 BCL2 apoptosis regulator Homo sapiens 95-100 26645893-8 2015 Finally, melatonin was able to strengthen cisplatin-mediated antitumour effects in human gastric carcinoma cells by up-regulating the expression of Bax, down-regulating the expression of Bcl-2 and activating the caspase-dependent apoptotic pathway. Cisplatin 42-51 BCL2 apoptosis regulator Homo sapiens 187-192 25348020-9 2015 Moreover, our results demonstrated that the mechanism of TXNL1 regulating cisplatin-induced apoptosis was closely associated with Bcl-2 mediated mitochondria apoptosis pathway. Cisplatin 74-83 BCL2 apoptosis regulator Homo sapiens 130-135 25348361-9 2015 In conclusion, DNA-PKcs suppression had complementary effects in combination with CDDP and 5-Fu treatment in HepG2 cells, which was associated with suppression of NF-kappaB signaling pathway cascade, activation of caspase-3 and p53, as well as down-regulation of Bcl-2 and GSH. Cisplatin 82-86 BCL2 apoptosis regulator Homo sapiens 263-268 25107702-3 2014 Here we report another frequent alteration accompanying CDDP resistance, namely upregulation of the antiapoptotic BCL-2 family protein MCL-1. Cisplatin 56-60 BCL2 apoptosis regulator Homo sapiens 114-119 24990093-7 2014 Cisplatin and [Pt(O,O"-acac)(gamma-acac)(DMS)] caused activation of caspases, proteolysis of PARP and modulation of Bcl-2, Bax and Bid. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 116-121 25175462-11 2014 Western blotting and densitometric assay showed that the expression of Bcl-2 was decreased after the combined treatment of ginsenoside Rg3 and cisplatin, whereas the expression of cytochrome c and caspase-3 were increased, suggesting the activation of the intrinsic apoptotic pathway. Cisplatin 143-152 BCL2 apoptosis regulator Homo sapiens 71-76 25290311-11 2014 Furthermore, ADP sensitized HUVEC to cisplatin-induced cell death by the down-regulation of Bcl-2 expression. Cisplatin 37-46 BCL2 apoptosis regulator Homo sapiens 92-97 24096476-10 2014 Patients with tumors positive for PXN, phosphorylated PXN, phosphorylated ERK and Bcl-2 more commonly showed a poorer response to cisplatin-based chemotherapy than did patients with negative tumors. Cisplatin 130-139 BCL2 apoptosis regulator Homo sapiens 82-87 25092426-5 2014 Following treatment with cisplatin, the protein expression of GPR40 in the kidneys was decreased in association with an increase in serum creatinine levels and the Bax/Bcl-2 expression ratio. Cisplatin 25-34 BCL2 apoptosis regulator Homo sapiens 168-173 25092426-10 2014 Treatment with cisplatin increased the Bax/Bcl-2 expression ratio and cleaved caspase-3 expression, and promoted the activation of nuclear factor-kappaB (NF-kappaB). Cisplatin 15-24 BCL2 apoptosis regulator Homo sapiens 43-48 24096476-11 2014 Collectively, PXN phosphorylation might contribute to cisplatin resistance via activating ERK-mediated Bcl-2 transcription. Cisplatin 54-63 BCL2 apoptosis regulator Homo sapiens 103-108 24507386-14 2014 The tumor tissues were harvested after treatment, and ACBP-L and Cisplatin treatment suppressed Bcl-2, and induced Bax, Caspase 3, and Caspase 8 molecules as detected by RT-PCR and immunohistochemistry. Cisplatin 65-74 BCL2 apoptosis regulator Homo sapiens 96-101 24096476-2 2014 We hypothesized that phosphorylation of PXN by the EGFR/Src pathway might contribute to cisplatin resistance via increased Bcl-2 expression. Cisplatin 88-97 BCL2 apoptosis regulator Homo sapiens 123-128 24096476-7 2014 A subsequent increase in Bcl-2 levels by a PXN/ERK axis was responsible for the resistance to cisplatin. Cisplatin 94-103 BCL2 apoptosis regulator Homo sapiens 25-30 24824514-9 2014 Moreover, the ability of doxorubicin, SN-38 and CDDP to induce proapoptotic signals was weaker in Rho cells, as evidenced by survivin upregulation and reductions in Bax/Bcl-2 expression ratios. Cisplatin 48-52 BCL2 apoptosis regulator Homo sapiens 169-174 24932256-14 2014 As for the apoptosis signaling genes, the combination of cisplatin and fractionated IR therapy resulted in a significant decrease in Bcl-2 expression and a marked upregulation of p21 expression. Cisplatin 57-66 BCL2 apoptosis regulator Homo sapiens 133-138 24829158-4 2014 CDDP induced apoptosis within cells through the generation of reactive oxygen species (ROS), regulated the ROS-mediated expression of Bax, Bcl-2, and p53, and induced the degradation of the poly (ADP-ribosyl) polymerase (PARP). Cisplatin 0-4 BCL2 apoptosis regulator Homo sapiens 139-144 24563380-6 2014 The addition of Andro to CDDP induced synergistic apoptosis, which could be corroborated to the changes in protein and mRNA levels of Bax and Bcl-2, and the increased Fas/FasL association in these cells, resulting in increased release of cytochrome c, and activation of caspases. Cisplatin 25-29 BCL2 apoptosis regulator Homo sapiens 142-147 24323562-0 2014 p21 overexpression sensitizes osteosarcoma U2OS cells to cisplatin via evoking caspase-3 and Bax/Bcl-2 cascade. Cisplatin 57-66 BCL2 apoptosis regulator Homo sapiens 97-102 24323562-7 2014 However, U2O3-p21 cells underwent more obvious apoptotic morphological changes than U2OS and U2OS-vec cells after being treated with cisplatin (5 mug) for 72 h. Besides, increased expression of cleaved caspase-3 and Bax/Bcl-2 ratio was observed in cisplatin-treated U2O3-p21 cells. Cisplatin 133-142 BCL2 apoptosis regulator Homo sapiens 220-225 24323562-8 2014 These data clearly indicated that exogenous p21 gene transfection could enhance the cisplatin-induced cytotoxicity against human osteosarcoma U2OS cells, at least in part, by activating caspase-3 cascade and increasing Bax/Bcl-2 ratio. Cisplatin 84-93 BCL2 apoptosis regulator Homo sapiens 223-228 24338158-6 2014 Additionally, hASCs modified by empty-vector inhibited caspase-3 expression and up-regulated Bcl-2 expression in cisplatin-treated HK-2 cells, an effect even more pronounced with hASCs modified by HIF-1alpha. Cisplatin 113-122 BCL2 apoptosis regulator Homo sapiens 93-98 24249678-1 2014 UNLABELLED: Elevated expression of the antiapoptotic factor Bcl-2 is believed to be one of the contributing factors to an increased relapse rate associated with multiple cisplatin-resistant cancers. Cisplatin 170-179 BCL2 apoptosis regulator Homo sapiens 60-65 24249678-2 2014 DNA damage-binding protein complex subunit 2 (DDB2) has recently been revealed to play an important role in sensitizing human ovarian cancer cells to cisplatin-induced apoptosis through the downregulation of Bcl-2, but the underlying molecular mechanism remains poorly defined. Cisplatin 150-159 BCL2 apoptosis regulator Homo sapiens 208-213 24627125-12 2014 The combination of beta-ELE and cisplatin enhanced the protein expression of cytochrome c, caspase-3 and Bad, and reduced protein levels of Bcl-2 and procaspase-3 in the A549/DDP lung cancer cells. Cisplatin 32-41 BCL2 apoptosis regulator Homo sapiens 140-145 24548862-0 2014 Nicotine increases the resistance of lung cancer cells to cisplatin through enhancing Bcl-2 stability. Cisplatin 58-67 BCL2 apoptosis regulator Homo sapiens 86-91 24548862-6 2014 In this process, Bcl-2 was persistently phosphorylated in the cells cotreated with nicotine and cisplatin. Cisplatin 96-105 BCL2 apoptosis regulator Homo sapiens 17-22 24548862-7 2014 Furthermore, Akt was proven to be responsible for sustained activation of Bcl-2 by nicotine, which further antagonised cisplatin-mediated apoptotic signalling. Cisplatin 119-128 BCL2 apoptosis regulator Homo sapiens 74-79 24248414-0 2014 miR-449a Regulates proliferation and chemosensitivity to cisplatin by targeting cyclin D1 and BCL2 in SGC7901 cells. Cisplatin 57-66 BCL2 apoptosis regulator Homo sapiens 94-98 24286513-6 2014 Genes displaying increase in expression of apoptosis, related to cisplatin treatment, were Casp8, Bcl10, Bcl2, Bcl2l1, Bcl2l2, Bid, Naip1, Bnip3l, Card6, Pak7, Cd40, Trp 53inp1, Cideb and Cd70. Cisplatin 65-74 BCL2 apoptosis regulator Homo sapiens 105-109 24337183-10 2014 Bcl-2 was markedly downregulated in dose-dependent cisplatin-treated Barkor-transfected-Saos-2 cells. Cisplatin 51-60 BCL2 apoptosis regulator Homo sapiens 0-5 24239278-3 2014 MATERIALS AND METHODS: The expression of EGFR, p53, Cyclin D1, p16, p21, p27, p-AKT, HIF-1alpha, Caspase 3 and BCL2 was analyzed by immunohistochemistry in 41 primary laryngeal/hypopharyngeal squamous cell carcinomas of patients that received induction chemotherapy (cisplatin and 5-fluorouracil) as part of their treatment. Cisplatin 267-276 BCL2 apoptosis regulator Homo sapiens 111-115 24875127-0 2014 miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2. Cisplatin 19-28 BCL2 apoptosis regulator Homo sapiens 111-115 24568489-5 2014 CONCLUSION: ASMq total phenolics, combined with cisplatin and docetaxel, could promote the apoptosis of Hela cells possibly through reducing the expression of Bcl-2 and survivin. Cisplatin 48-57 BCL2 apoptosis regulator Homo sapiens 159-164 24606472-0 2014 Expression of bcl-2 and p53 in induction of esophageal cancer cell apoptosis by ECRG2 in combination with cisplatin. Cisplatin 106-115 BCL2 apoptosis regulator Homo sapiens 14-19 23856992-0 2013 miR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2. Cisplatin 72-81 BCL2 apoptosis regulator Homo sapiens 95-100 24931256-0 2014 MiR-503 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R and BCL2. Cisplatin 18-27 BCL2 apoptosis regulator Homo sapiens 97-101 24348832-12 2014 Cisplatin reduced the expression of Bcl-2 protein, while VX680 did not. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 36-41 23970333-7 2013 In addition, the ratio of Bax to Bcl-2 was increased by CDDP treatment in SNU-1 cells, but not in SNU-16 cells. Cisplatin 56-60 BCL2 apoptosis regulator Homo sapiens 33-38 23792636-6 2013 Further, PXN mutants, through their interactions with BCL-2 and DRP-1, could regulate cisplatin drug resistance in human lung cancer cells. Cisplatin 86-95 BCL2 apoptosis regulator Homo sapiens 54-59 24931256-8 2014 Additionally, downregulation of miR-503 in the cisplatin (DDP)-resistant gastric cancer cell line SGC7901/DDP was concurrent with the upregulation of insulin-like growth factor-1 receptor (IGF1R) and B-cell lymphoma 2 (BCL2) expression compared with the parental SGC7901 cell line. Cisplatin 47-56 BCL2 apoptosis regulator Homo sapiens 200-217 24931256-8 2014 Additionally, downregulation of miR-503 in the cisplatin (DDP)-resistant gastric cancer cell line SGC7901/DDP was concurrent with the upregulation of insulin-like growth factor-1 receptor (IGF1R) and B-cell lymphoma 2 (BCL2) expression compared with the parental SGC7901 cell line. Cisplatin 47-56 BCL2 apoptosis regulator Homo sapiens 219-223 24931256-12 2014 CONCLUSION: Our findings suggest that hsa-miR-503 modulates cisplatin resistance of human gastric cancer cells at least in part by targeting IGF1R and BCL2. Cisplatin 60-69 BCL2 apoptosis regulator Homo sapiens 151-155 24854102-2 2014 When compared with a blank control group, the proportion of apoptotic cells undergoing Beclin 1 interfering increased significantly after cisplatin treatment, accompanied by reduction in mitochondrial membrane potential, increase in activities of caspase-9/3 and cytoplasmic cytochrome C, elevation of Bax expression, and reduction in Bcl-2 expression. Cisplatin 138-147 BCL2 apoptosis regulator Homo sapiens 335-340 23764753-8 2013 Interestingly, de4 EGFR transfectants displayed significantly lower sensitivity to cisplatin than EGFR transfectants, which could be ascribed to the upregulation of Bcl-2 and downregulation of BAD in the de4 EGFR transfectants. Cisplatin 83-92 BCL2 apoptosis regulator Homo sapiens 165-170 23975218-7 2013 The markers ERCC-1, XAF and anti-apoptotic proteins of the Bcl-2 family seem to represent the most promising biomarkers associated with response to adjuvant cisplatin-based chemotherapy. Cisplatin 157-166 BCL2 apoptosis regulator Homo sapiens 59-64 23027129-6 2013 Silencing of FGFR2 sensitized NB cells to cisplatin-induced apoptosis, which was regulated by the downregulation of the anti-apoptotic proteins BCL2 and BCLXL. Cisplatin 42-51 BCL2 apoptosis regulator Homo sapiens 144-148 23900224-3 2013 After identifying the overexpressed resistance-related antiapoptotic genes (survivin and bcl-2) in cisplatin-resistant cells, the siRNA sequences were designed and screened to select the most efficacious candidates. Cisplatin 99-108 BCL2 apoptosis regulator Homo sapiens 89-94 23287709-4 2013 Cisplatin induced apoptosis of HK-2 cells in which down-regulation of Bcl-2 and activation of caspase-3 were possibly involved. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 70-75 23444126-7 2013 Treatment of fibroblast cell cultures with cisplatin induced a significant increase in beclin 1 and caspase 3 protein levels but a reduction in Bcl-2 expression. Cisplatin 43-52 BCL2 apoptosis regulator Homo sapiens 144-149 23755153-5 2014 Cisplatin treatment was shown to induce apoptosis, grossly observed by reduced tumor formation, through reduced Bcl-2 and survivin protein expression levels with an increase in caspase 3 expression compared to control tumors. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 112-117 23612742-7 2013 Consistent with its anti-apoptotic target BCL2, miR-205 promoted apoptosis in prostate cancer cells in response to DNA damage by cisplatin and doxorubicin in the prostate cancer cell lines PC3 and LnCap. Cisplatin 129-138 BCL2 apoptosis regulator Homo sapiens 42-46 23665025-8 2013 We found that the combination of cisplatin and STAT3 siRNA resulted in the collapse of the mitochondrial membrane potential, attenuated the expression of Bcl-xL and Bcl-2, and increased the release of cytochrome C and expression of Bax. Cisplatin 33-42 BCL2 apoptosis regulator Homo sapiens 165-170 24001324-9 2013 Activated caspase 3 and Bax/Bcl-2 ratio were significantly increased in Cisplatin-treated cells. Cisplatin 72-81 BCL2 apoptosis regulator Homo sapiens 28-33 23533654-9 2013 In combination with NVP-BEZ235 and CDDP, there was dramatic synergy in shrinking tumor volumes and inducing apoptosis through increasing Noxa, Bax and decreasing Mcl-1, Bcl-2. Cisplatin 35-39 BCL2 apoptosis regulator Homo sapiens 169-174 23188704-5 2013 From among a panel of apoptosis-related factors (p53, Bcl-2, Bcl-XL, BAX, and survivin), the expression of Livin was upregulated after cisplatin treatment in a dose-dependent manner. Cisplatin 135-144 BCL2 apoptosis regulator Homo sapiens 54-59 23302226-8 2013 We identified Noxa as the only Bcl-2 family protein to be highly correlated with Oct-4 status and cisplatin sensitivity. Cisplatin 98-107 BCL2 apoptosis regulator Homo sapiens 31-36 23856142-14 2013 CONCLUSION: Targeting to inhibit antiapoptotic mitochondrial gene Bcl-2 expression in A549 cells specifically decreased the mRNA of ERCC1, TYMS, and TOP2alpha genes, and significantly increased the sensitivities of A549 cells to chemotherapeutic agents such as etoposide, cisplatin, paclitaxel and navelbine. Cisplatin 272-281 BCL2 apoptosis regulator Homo sapiens 66-71 23076534-6 2013 Periostin-overexpressing cells treated with cisplatin or 5-FU showed significantly (p < 0.05) decreased expression of Bax and p53 proteins and increased expression of Bcl-2 protein, when compared to drug-treated mock counterparts. Cisplatin 44-53 BCL2 apoptosis regulator Homo sapiens 170-175 22920753-0 2012 Knock-down of NDRG2 sensitizes cervical cancer Hela cells to cisplatin through suppressing Bcl-2 expression. Cisplatin 61-70 BCL2 apoptosis regulator Homo sapiens 91-96 24033949-11 2013 Meanwhile, CoCl2-induced Bcl-2 overexpression was down-regulated in the presence of cisplatin when NF-kappaB activity was inhibited. Cisplatin 84-93 BCL2 apoptosis regulator Homo sapiens 25-30 24033949-12 2013 CONCLUSION: Up-regulating Bcl-2 might be involved in NF-kappaB activation induced resistance to cisplatin in A549 cells under CoCl2-induced chemical hypoxia. Cisplatin 96-105 BCL2 apoptosis regulator Homo sapiens 26-31 25045421-8 2012 Expressions of pro-apoptotic factors (cleaved caspase-3/-8/-9 and bax) were increased by the combinational treatment with PQ1 and cisplatin; whereas, the pro-survival factor, bcl-2, was decreased by the combinational treatment. Cisplatin 130-139 BCL2 apoptosis regulator Homo sapiens 175-180 22562580-7 2012 In addition, siRNA against NOX3 reduced apoptosis as demonstrated by TUNEL staining, and prevented the increased expression of Bax and abrogated the decrease in Bcl2 expression following cisplatin administration. Cisplatin 187-196 BCL2 apoptosis regulator Homo sapiens 161-165 22467215-7 2012 Importantly, Bcl-2 silencing sensitizes these cells to chemotherapy (cisplatin) suggesting a potential new therapeutic approach for treating breast cancers with HER2(+)-status. Cisplatin 69-78 BCL2 apoptosis regulator Homo sapiens 13-18 22920753-15 2012 CONCLUSIONS: These data suggested that down-regulation of NDRG2 could enhance sensitivity of Hela cells to cisplatin through inhibiting Bcl-2 protein expression, which might be mediated by up-regulating miR-15b and miR-16. Cisplatin 107-116 BCL2 apoptosis regulator Homo sapiens 136-141 22112972-11 2012 By repairing the apoptotic machinery, we were able to sensitize chondrosarcoma cells to doxorubicin and cisplatin, indicating an important role for BCL-2 family members in chemoresistance and a promising new treatment strategy for inoperable chondrosarcoma. Cisplatin 104-113 BCL2 apoptosis regulator Homo sapiens 148-153 22699051-9 2012 Compared with tunicamycin and cisplatin alone, the combined treatment significantly increased Bax expression and decreased Bcl-2 expression in the cells; tunicamycin up-regulated the expression of GRP-78 and enhanced the activity of caspase-3. Cisplatin 30-39 BCL2 apoptosis regulator Homo sapiens 123-128 22238053-12 2012 Cisplatin and etoposide induced a major down-regulation in the BCL2 mRNA levels after 72 h of treatment, while the BAX mRNA levels were slightly up-regulated. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 63-67 22445428-3 2012 Here we show that cisplatin induced several platelet apoptotic events including up-regulation of Bax and Bak, down-regulation of Bcl-2 and Bcl-X(L), mitochondrial translocation of Bax, mitochondrial inner transmembrane potential depolarization, caspase-3 activation and phosphatidylserine (PS) exposure. Cisplatin 18-27 BCL2 apoptosis regulator Homo sapiens 129-134 21618512-1 2012 Human carcinomas often show resistance to cisplatin and Bcl-2 is associated with resistance to cisplatin. Cisplatin 95-104 BCL2 apoptosis regulator Homo sapiens 56-61 22326969-6 2012 Instead, the over expression of anti-apoptotic Bcl-2, anti-oxidative heme oxygenase-1 (HO-1) and cell cycle regulator p16INK4 seemed to be more important for the gaining of cisplatin in these human urothelial carcinoma cell. Cisplatin 173-182 BCL2 apoptosis regulator Homo sapiens 47-52 21618512-2 2012 However, Bcl-2 regulation on cisplatin treatment in human cancers is unknown. Cisplatin 29-38 BCL2 apoptosis regulator Homo sapiens 9-14 21618512-3 2012 Here, we show a novel mechanism by which cisplatin treatment promotes resistance by increasing the expression of Bcl-2 mRNA. Cisplatin 41-50 BCL2 apoptosis regulator Homo sapiens 113-118 21618512-4 2012 Bcl-2 mRNA and protein expression was increased in cisplatin-resistant endometrial cancer cell lines (KLE and HEC-1-A), but not in cisplatin-sensitive cell line (Ishikawa). Cisplatin 51-60 BCL2 apoptosis regulator Homo sapiens 0-5 21618512-4 2012 Bcl-2 mRNA and protein expression was increased in cisplatin-resistant endometrial cancer cell lines (KLE and HEC-1-A), but not in cisplatin-sensitive cell line (Ishikawa). Cisplatin 131-140 BCL2 apoptosis regulator Homo sapiens 0-5 21618512-5 2012 Cisplatin-mediated increase in Bcl-2 expression was blocked by combination with either actinomycin D or cycloheximide. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 31-36 21618512-7 2012 Inhibition of protein kinase C (PKC) activity prevented cisplatin-dependant increase in Bcl-2 mRNA, and induced apoptosis in KLE cells. Cisplatin 56-65 BCL2 apoptosis regulator Homo sapiens 88-93 21618512-9 2012 Cells stably expressing shRNA for Akt isoforms revealed that Akt2 was involved in cisplatin-dependant increase in Bcl-2 and apoptosis. Cisplatin 82-91 BCL2 apoptosis regulator Homo sapiens 114-119 21618512-10 2012 Overexpression of Akt2 in Akt2-deficient cells led to increased Bcl-2 expression on cisplatin treatment. Cisplatin 84-93 BCL2 apoptosis regulator Homo sapiens 64-69 21618512-11 2012 Our data suggest a novel regulation pathway of Bcl-2 by cisplatin, via the activation of PKC and Akt2, which has a profound impact on resistance to cisplatin-induced apoptosis in endometrial cancer cells. Cisplatin 56-65 BCL2 apoptosis regulator Homo sapiens 47-52 21618512-11 2012 Our data suggest a novel regulation pathway of Bcl-2 by cisplatin, via the activation of PKC and Akt2, which has a profound impact on resistance to cisplatin-induced apoptosis in endometrial cancer cells. Cisplatin 148-157 BCL2 apoptosis regulator Homo sapiens 47-52 22266706-8 2012 Furthermore, treatment with SG511 alone or in combination with cisplatin resulted in reduced expression the anti-apoptotic Bcl-2 family member Mcl-1 in HeLa and HT-29 cells. Cisplatin 75-84 BCL2 apoptosis regulator Homo sapiens 147-152 22238053-0 2012 Quantitative expression analysis of the apoptosis-related genes BCL2, BAX and BCL2L12 in gastric adenocarcinoma cells following treatment with the anticancer drugs cisplatin, etoposide and taxol. Cisplatin 164-173 BCL2 apoptosis regulator Homo sapiens 64-68 22238053-11 2012 Treatment of AGS cells with 10 muM cisplatin, 0.5 muM etoposide and 10 nM taxol affected the BCL2, BAX and BCL2L12 mRNA levels, compared to the untreated cells. Cisplatin 35-44 BCL2 apoptosis regulator Homo sapiens 93-97 22020779-8 2012 Silencing HERG inhibited the apoptosis induced by cisplatin both in vitro and in vivo, by attenuating the cisplatin effects on Bcl-2, Bax and active caspase-3. Cisplatin 62-71 BCL2 apoptosis regulator Homo sapiens 139-144 22267549-10 2012 The involvement of Bcl-XL inhibition in sensitization was corroborated by the use of the pan-Bcl-2 inhibitor 2MAM-3 whereby the treated cells were sensitive to both CDDP- and TRAIL-induced apoptosis. Cisplatin 165-169 BCL2 apoptosis regulator Homo sapiens 93-98 21793937-10 2012 Finally, Western blot showed that higher expressions of MRP1, LRP, and BCL2 and lower expression of TopoIIbeta were observed in SCC-15/cisplatin cells than in clinical samples. Cisplatin 135-144 BCL2 apoptosis regulator Homo sapiens 71-75 22020779-8 2012 Silencing HERG inhibited the apoptosis induced by cisplatin both in vitro and in vivo, by attenuating the cisplatin effects on Bcl-2, Bax and active caspase-3. Cisplatin 118-127 BCL2 apoptosis regulator Homo sapiens 139-144 22071691-3 2011 Cisplatin exposure modulated the levels of target proteins (reduced BCL2, AKT1, ATG16L2, and ULK2, while activated MDM4) in cisplatin-sensitive wild type DeltaNp63alpha cells leading to distinct changes in cell viability. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 68-72 22033244-0 2012 Suppression of BCL-2 synergizes cisplatin sensitivity in nasopharyngeal carcinoma cells. Cisplatin 32-41 BCL2 apoptosis regulator Homo sapiens 15-20 22033244-5 2012 Our results demonstrate that inhibition of BCL-2 by small-hairpin RNA (shRNA) or the BCL-2 inhibitor YC137, synergizes cisplatin sensitivity in NPC cells that overexpress BCL-2. Cisplatin 119-128 BCL2 apoptosis regulator Homo sapiens 43-48 22033244-5 2012 Our results demonstrate that inhibition of BCL-2 by small-hairpin RNA (shRNA) or the BCL-2 inhibitor YC137, synergizes cisplatin sensitivity in NPC cells that overexpress BCL-2. Cisplatin 119-128 BCL2 apoptosis regulator Homo sapiens 85-90 22033244-5 2012 Our results demonstrate that inhibition of BCL-2 by small-hairpin RNA (shRNA) or the BCL-2 inhibitor YC137, synergizes cisplatin sensitivity in NPC cells that overexpress BCL-2. Cisplatin 119-128 BCL2 apoptosis regulator Homo sapiens 85-90 22033244-6 2012 We also show that YC137 enhance cisplatin-induced apoptosis in HK1 and CNE1 cells through suppression of BCL-2 protein expression, induction of mitochondrial depolarization and activation of caspase 9 and caspase 3/7. Cisplatin 32-41 BCL2 apoptosis regulator Homo sapiens 105-110 22524836-9 2012 The increased apoptotic sensitivity of SGC7901/ DDP to cisplatin was due to the decreasing proportion of Bcl-2/Bax via down-regulating NF-kB. Cisplatin 55-64 BCL2 apoptosis regulator Homo sapiens 105-110 22355465-0 2012 BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin. Cisplatin 87-96 BCL2 apoptosis regulator Homo sapiens 0-4 22355465-2 2012 Recently, it has been demonstrated that the phosphorylation status of the BCL2 antagonist of cell death (BAD) protein may influence ovarian cancer (OVCA) cell sensitivity to cisplatin. Cisplatin 174-183 BCL2 apoptosis regulator Homo sapiens 74-78 22590594-4 2012 In this study, we found that genetic variants of Bcl-2 proteins exist among cisplatin-sensitive and -resistant ovarian cancer cells, and the responses of NOXA and Bax to cisplatin are regulated mainly by p53. Cisplatin 76-85 BCL2 apoptosis regulator Homo sapiens 49-54 22590594-4 2012 In this study, we found that genetic variants of Bcl-2 proteins exist among cisplatin-sensitive and -resistant ovarian cancer cells, and the responses of NOXA and Bax to cisplatin are regulated mainly by p53. Cisplatin 170-179 BCL2 apoptosis regulator Homo sapiens 49-54 22431999-9 2012 In vitro studies demonstrated that MVs up-regulated in cisplatin-treated human tubular epithelial cells anti-apoptotic genes, such as Bcl-xL, Bcl2 and BIRC8 and down-regulated genes that have a central role in the execution-phase of cell apoptosis such as Casp1, Casp8 and LTA. Cisplatin 55-64 BCL2 apoptosis regulator Homo sapiens 142-146 21935568-0 2011 The potent peptide antagonist to angiogenesis, C16Y, and cisplatin act synergistically in the down-regulation of the Bcl-2/Bax ratio and the induction of apoptosis in human ovarian cancer cells. Cisplatin 57-66 BCL2 apoptosis regulator Homo sapiens 117-122 21935568-2 2011 We examined the effect of cisplatin alone and in combination with C16Y, a newly-identified anti-angiogenic peptide from the NH2-terminal domains of the gamma-chain of laminin-1, on the modulation of Bcl-2/Bax expression and induction of apoptosis in ovarian cancer cells (OVACAR3). Cisplatin 26-35 BCL2 apoptosis regulator Homo sapiens 199-204 21935568-8 2011 Furthermore, Bcl-2 protein expression levels were markedly reduced by C16Y alone and cisplatin alone in a dose-dependent manner. Cisplatin 85-94 BCL2 apoptosis regulator Homo sapiens 13-18 21935568-9 2011 The combination of C16Y and cisplatin resulted in a further dramatic reduction in Bcl-2, underscoring the pronounced synergy produced by cisplatin and C16Y together. Cisplatin 28-37 BCL2 apoptosis regulator Homo sapiens 82-87 21935568-9 2011 The combination of C16Y and cisplatin resulted in a further dramatic reduction in Bcl-2, underscoring the pronounced synergy produced by cisplatin and C16Y together. Cisplatin 137-146 BCL2 apoptosis regulator Homo sapiens 82-87 21935568-11 2011 These observations suggest that the suppression of the Bcl-2/Bax ratio may play an important role in mediating the synergistic effect of cisplatin and C16Y on the induction of apoptosis in OVACAR3 cells. Cisplatin 137-146 BCL2 apoptosis regulator Homo sapiens 55-60 22340096-0 2011 [Bcl-2 inhibitor ABT-737 enhances the cisplatin-induced apoptosis in breast cancer T47D cells]. Cisplatin 38-47 BCL2 apoptosis regulator Homo sapiens 1-6 22340096-12 2011 CONCLUSION: The Bcl-2 inhibitor ABT-737 can significantly enhance cisplatin-induced apoptosis in human breast cancer T47D cells in vitro. Cisplatin 66-75 BCL2 apoptosis regulator Homo sapiens 16-21 22555068-12 2012 CONCLUSION: Collectively, the results from the present study revealed a new role for DAP5 in cisplatin-induced apoptosis: DAP5/p97 and DAP5/p86 enhanced the translation of the anti-apoptotic protein Bcl-2 and inhibited cisplatin-induced apoptosis. Cisplatin 93-102 BCL2 apoptosis regulator Homo sapiens 199-204 22555068-12 2012 CONCLUSION: Collectively, the results from the present study revealed a new role for DAP5 in cisplatin-induced apoptosis: DAP5/p97 and DAP5/p86 enhanced the translation of the anti-apoptotic protein Bcl-2 and inhibited cisplatin-induced apoptosis. Cisplatin 219-228 BCL2 apoptosis regulator Homo sapiens 199-204 22032837-0 2012 The BCL2 antagonist of cell death pathway influences endometrial cancer cell sensitivity to cisplatin. Cisplatin 92-101 BCL2 apoptosis regulator Homo sapiens 4-8 22032837-1 2012 OBJECTIVE: To identify pathways that influence endometrial cancer (EC) cell sensitivity to cisplatin and to characterize the BCL2 antagonist of cell death (BAD) pathway as a therapeutic target to increase cisplatin sensitivity. Cisplatin 205-214 BCL2 apoptosis regulator Homo sapiens 125-129 22071691-3 2011 Cisplatin exposure modulated the levels of target proteins (reduced BCL2, AKT1, ATG16L2, and ULK2, while activated MDM4) in cisplatin-sensitive wild type DeltaNp63alpha cells leading to distinct changes in cell viability. Cisplatin 124-133 BCL2 apoptosis regulator Homo sapiens 68-72 22071691-4 2011 Finally, miR-885-3p modulated the cisplatin-induced TP53-dependent mitochondrial apoptosis by up regulation of MDM4 levels and down regulation of BCL2 levels in mitochondria. Cisplatin 34-43 BCL2 apoptosis regulator Homo sapiens 146-150 21609759-0 2011 Thymoquinone from Nigella sativa was more potent than cisplatin in eliminating of SiHa cells via apoptosis with down-regulation of Bcl-2 protein. Cisplatin 54-63 BCL2 apoptosis regulator Homo sapiens 131-136 21609759-9 2011 In conclusion, thymoquinone from N. sativa was more potent than cisplatin in elimination of SiHa cells via apoptosis with down-regulation of Bcl-2 protein. Cisplatin 64-73 BCL2 apoptosis regulator Homo sapiens 141-146 21052098-4 2011 We demonstrated that Ad-ING4 plus CDDP induced synergistic growth inhibition, enhanced apoptosis, and had an additive effect on upregulation of Fas, Bax, Bak, cleaved Bid, cleaved caspase-8, caspase-9, caspase-3 and cleaved PARP, and on downregulation of Bcl-2 and Bcl-X(L) in SMMC-7721 hepatocarcinoma cells. Cisplatin 34-38 BCL2 apoptosis regulator Homo sapiens 255-260 21573972-0 2011 Hydroxyl radical mediates cisplatin-induced apoptosis in human hair follicle dermal papilla cells and keratinocytes through Bcl-2-dependent mechanism. Cisplatin 26-35 BCL2 apoptosis regulator Homo sapiens 124-129 21573972-7 2011 The mechanism by which hydroxyl radical mediates the apoptotic effect of cisplatin was shown to involve down-regulation of the anti-apoptotic protein Bcl-2 through ubiquitin-proteasomal degradation. Cisplatin 73-82 BCL2 apoptosis regulator Homo sapiens 150-155 21573972-9 2011 Together, our results indicate an essential role of hydroxyl radical in cisplatin-induced cell death of hair follicle cells through Bcl-2 regulation. Cisplatin 72-81 BCL2 apoptosis regulator Homo sapiens 132-137 21527773-9 2011 Furthermore, unidentified Bcl-2- and mitochondria-independent pathways are induced by pronecrotic and not by proapoptotic concentrations of cisplatin. Cisplatin 140-149 BCL2 apoptosis regulator Homo sapiens 26-31 21527773-11 2011 Yet, Bcl-2-independent effects lead to cell death, which may pose potential targets for pharmacological intervention aimed at reducing cisplatin nephrotoxicity. Cisplatin 135-144 BCL2 apoptosis regulator Homo sapiens 5-10 21228225-3 2011 Here we demonstrate that HBx enhances cisplatin-induced hepatotoxicity by a mechanism involving degradation of Mcl-1, an antiapoptotic member of the Bcl-2 family. Cisplatin 38-47 BCL2 apoptosis regulator Homo sapiens 149-154 21496427-9 2011 CONCLUSIONS: Cisplatin resistance of lung cancer cells is associated with overexpression of GRP75 gene, which could regulate the expressions of p53 and bcl-2. Cisplatin 13-22 BCL2 apoptosis regulator Homo sapiens 152-157 21503959-8 2011 In addition, P2Y11 sensitized endothelial cells to cisplatin-induced cell death by down-regulation of the expression of Bcl-2. Cisplatin 51-60 BCL2 apoptosis regulator Homo sapiens 120-125 21823019-0 2011 miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1. Cisplatin 55-64 BCL2 apoptosis regulator Homo sapiens 92-97 21561860-3 2011 Here we show that degradation of the Bcl-2 homology 3-only proapoptotic protein Bim plays an important role in cisplatin resistance in ovarian cancer. Cisplatin 111-120 BCL2 apoptosis regulator Homo sapiens 37-42 21388661-4 2011 Modulation of protein expression of the Bcl-2 family after treatment with metformin and/or cisplatin was determined by Western blotting. Cisplatin 91-100 BCL2 apoptosis regulator Homo sapiens 40-45 21252285-6 2011 Treatment with cisplatin/TRAIL also inhibited the expression of EGFR, p63, survivin, Bcl-2, and Bcl-xL in TNBC cells. Cisplatin 15-24 BCL2 apoptosis regulator Homo sapiens 85-90 20477830-7 2010 B-cell CCL/lymphoma 2 (BCL2)-like 1 (BCL2L1) exhibited significant upregulation, while BCL2 showed partial derepression in PDAM-silenced cells after cisplatin treatment, suggesting that alteration of anti-apoptotic genes contributed in part to cisplatin resistance. Cisplatin 244-253 BCL2 apoptosis regulator Homo sapiens 23-27 21278889-8 2010 This potentiation of cisplatin activity was associated with HDAC inhibitor-mediated down-regulation of Bcl-2 and XIAP. Cisplatin 21-30 BCL2 apoptosis regulator Homo sapiens 103-108 22545969-7 2010 beta-Elemene augmented the cisplatin-induced activation of caspase-3/7/10 and caspase-9, cleavage of caspase-3 and -9, suppression of Bcl-2 and Bcl-X(L) expression, and release of cytochrome c from mitochondria in these cells. Cisplatin 27-36 BCL2 apoptosis regulator Homo sapiens 134-139 20922271-6 2010 In contrast to previous reports about the use of ODN, a heterogeneous and up to 80% sequence-specific Bcl-2 protein knockdown was observed in the SW2, H2171 and H69 SCLC cell lines, although without significant sequence-specific reduction of cell viability, cell growth, or sensitization to cisplatin. Cisplatin 291-300 BCL2 apoptosis regulator Homo sapiens 102-107 21214929-8 2011 RESULTS: Combination treatments of alpha-TEA plus DOXO or CDDP act cooperatively to induce apoptosis, caspase-8 and caspase-9 cleavage, p73, phospho-c-Ab1 and phospho-JNK protein expression, and increase expression of p53 downstream mediators; namely, death receptor-5, CD95/APO-1 (Fas), Bax and Noxa, as well as Yap nuclear translocation - plus reduce expression of Bcl-2. Cisplatin 58-62 BCL2 apoptosis regulator Homo sapiens 367-372 19560836-0 2010 Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy. Cisplatin 106-115 BCL2 apoptosis regulator Homo sapiens 14-19 20428827-2 2010 Our results showed that miR-16, miR-34a-c, miR-17-5p and miR-125 were up-regulated, and their associated oncogenes (BCL2, E2F1 and E2F3, respectively) were down-regulated after cisplatin treatment. Cisplatin 177-186 BCL2 apoptosis regulator Homo sapiens 116-120 19560836-11 2010 CONCLUSIONS: High expression of Bcl-2 may be a useful prognostic factor in locally advanced NSCLC patients treated with cisplatin-based CCRT. Cisplatin 120-129 BCL2 apoptosis regulator Homo sapiens 32-37 20372863-7 2010 Cisplatin treatment induced caspase-3, -9, p53, Bax, NF-kappaB and MAPK expression, and suppressed Bcl-2 and Bcl-xl expression, whereas cells transfected with pcDNA3.1-ARL6IP1 showed lower levels of cisplatin-induced caspase-3, -9, p53, Bax, NF-kappaB and MAPK up-regulation and higher levels of cisplatin-suppressed Bcl-2 and Bcl-xl down-regulation. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 99-104 20372863-8 2010 These novel findings collectively suggest that ARL6IP1 may play a key role in cisplatin-induced apoptosis in CaSki cervical cancer cells by regulating the expression of apoptosis-associated proteins such as caspase-3, -9, p53, NF-kappaB, MAPK, Bcl-2, Bcl-xl, and Bax. Cisplatin 78-87 BCL2 apoptosis regulator Homo sapiens 244-249 20372863-7 2010 Cisplatin treatment induced caspase-3, -9, p53, Bax, NF-kappaB and MAPK expression, and suppressed Bcl-2 and Bcl-xl expression, whereas cells transfected with pcDNA3.1-ARL6IP1 showed lower levels of cisplatin-induced caspase-3, -9, p53, Bax, NF-kappaB and MAPK up-regulation and higher levels of cisplatin-suppressed Bcl-2 and Bcl-xl down-regulation. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 317-322 20163198-0 2010 The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin. Cisplatin 25-34 BCL2 apoptosis regulator Homo sapiens 85-90 20163198-0 2010 The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin. Cisplatin 109-118 BCL2 apoptosis regulator Homo sapiens 85-90 20163198-7 2010 This review focuses on the relationship between glutathione and BCL-2 and their protective role in cDDP-induced reactive oxygen species formation and cDDP resistance. Cisplatin 99-103 BCL2 apoptosis regulator Homo sapiens 64-69 20163198-7 2010 This review focuses on the relationship between glutathione and BCL-2 and their protective role in cDDP-induced reactive oxygen species formation and cDDP resistance. Cisplatin 150-154 BCL2 apoptosis regulator Homo sapiens 64-69 20646542-10 2010 (4) The expression level of NF-kappaB and the high expression rate of bcl-2 were: in HCE1/MCS of control group, 0.67 and 60%; in HCE1/MCS of cisplatin group, 0.85 and 83%; in HCE1/MCS of MG132 group, 0.39 and 20%; in HCE1/MCS of MG132+cisplatin group, 0.47 and 33%. Cisplatin 141-150 BCL2 apoptosis regulator Homo sapiens 70-75 20215556-8 2010 The canonical antiapoptotic protein Bcl-2 was downregulated in vivo and in vitro after L-nil treatment, which was associated with increased susceptibility to cisplatin-mediated tumor death. Cisplatin 158-167 BCL2 apoptosis regulator Homo sapiens 36-41 20646542-10 2010 (4) The expression level of NF-kappaB and the high expression rate of bcl-2 were: in HCE1/MCS of control group, 0.67 and 60%; in HCE1/MCS of cisplatin group, 0.85 and 83%; in HCE1/MCS of MG132 group, 0.39 and 20%; in HCE1/MCS of MG132+cisplatin group, 0.47 and 33%. Cisplatin 235-244 BCL2 apoptosis regulator Homo sapiens 70-75 20646542-12 2010 (2) MG132 could induce the inhibition and apoptosis of HCE1/MCS cells and partially reverse the natural resistance of HCE1/MCS to cisplatin, of which partially reverse the natural resistance may be in relation to the down-regulation of NF-kappaB and bcl-2 expression. Cisplatin 130-139 BCL2 apoptosis regulator Homo sapiens 250-255 19285749-8 2009 Treatment with cisplatin revealed that the expression of anti-apoptotic protein, bcl-2, was down-regulated in SBC-3/NEO cells, while that of SBC-3/OPN cells was not altered. Cisplatin 15-24 BCL2 apoptosis regulator Homo sapiens 81-86 19238538-0 2010 Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells. Cisplatin 79-88 BCL2 apoptosis regulator Homo sapiens 19-24 19238538-0 2010 Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells. Cisplatin 79-88 BCL2 apoptosis regulator Homo sapiens 103-108 19238538-4 2010 Furthermore, when we transiently silenced Bcl-2, both cisplatin and paclitaxel induced apoptosis more than parental cells. Cisplatin 54-63 BCL2 apoptosis regulator Homo sapiens 42-47 19238538-10 2010 Enforced Bcl-2 expression in MDA-MB-231 cells abrogated the sensitizing effect of HA14-1 in cisplatin induced apoptosis. Cisplatin 92-101 BCL2 apoptosis regulator Homo sapiens 9-14 19285749-11 2009 Our results suggest that OPN enhances chemo-resistance of cisplatin in SBC-3 cells by suppressing bcl-2 protein down-regulation, thereby blocking the caspase-9- and caspase-3-dependent cell apoptosis. Cisplatin 58-67 BCL2 apoptosis regulator Homo sapiens 98-103 20196784-5 2009 The mechanisms underlying the protective effect of autophagy apparently involved the interference with cisplatin-induced modulation of Bcl-2 family proteins, as inhibition of autophagy potentiated cisplatin-mediated up-regulation of proapoptotic Bax and down-regulation of anti-apoptotic Bcl-2. Cisplatin 103-112 BCL2 apoptosis regulator Homo sapiens 135-140 20079076-0 2009 [Adenovirus-mediated delivery of bcl-2 gene attenuates cisplatin-induced degeneration of cultured spiral ganglion cells.]. Cisplatin 55-64 BCL2 apoptosis regulator Homo sapiens 33-38 20079076-1 2009 OBJECTIVE: To assess the protection against cisplatin-induced ototoxicity by adenovirus-mediated overexpression of the bcl-2 gene in cultured spiral ganglion cells (SGC). Cisplatin 44-53 BCL2 apoptosis regulator Homo sapiens 119-124 20079076-10 2009 Expression of bcl-2 in the SGC provided a significant level of protection against cisplatin-induced SGC degeneration. Cisplatin 82-91 BCL2 apoptosis regulator Homo sapiens 14-19 20079076-12 2009 Adenovirus-mediated delivery of the bcl-2 gene attenuates cisplatin-induced SGC degeneration. Cisplatin 58-67 BCL2 apoptosis regulator Homo sapiens 36-41 19724896-9 2009 Our results indicate that SNPs in DNA repair genes (XRCC3241 and XPD751) influence the ICS and together with the expression of EGFR, Hsp70, Bax, and Bcl-2, they could predict the cisplatin sensitivity of head and neck cancer cell lines (r=0.614, p<or=0.001). Cisplatin 179-188 BCL2 apoptosis regulator Homo sapiens 149-154 19821098-6 2009 After cisplatin was added, the expression levels of Bcl-2 mRNA were reduced, and those of Bax, caspase-3, and survivin mRNA were increased in transfection group as compared with those in control group (P<0.05). Cisplatin 6-15 BCL2 apoptosis regulator Homo sapiens 52-57 19821098-7 2009 It was concluded that shRNA expression vector targeting Livin gene could inhibit the expression of Livin gene in HeLa cells and enhance the apoptosis induced by cisplatin, which was related to the decreased expression of Bcl-2 and activation of Bax and caspase-3. Cisplatin 161-170 BCL2 apoptosis regulator Homo sapiens 221-226 19755862-0 2009 Involvement of MKP-1 and Bcl-2 in acquired cisplatin resistance in ovarian cancer cells. Cisplatin 43-52 BCL2 apoptosis regulator Homo sapiens 25-30 19755862-6 2009 In TOV112D cells, on the other hand, acquired cisplatin resistance is associated with increased levels of Bcl-2 protein. Cisplatin 46-55 BCL2 apoptosis regulator Homo sapiens 106-111 19755862-7 2009 By inhibiting the activity of Bcl-2 protein with its pharmacological inhibitor gossypol or knocking down Bcl-2 expression by siRNA, cisplatin-resistant TOV112D cells became cisplatin-sensitive and subsequently increased cisplatin-induced apoptosis. Cisplatin 132-141 BCL2 apoptosis regulator Homo sapiens 30-35 19755862-7 2009 By inhibiting the activity of Bcl-2 protein with its pharmacological inhibitor gossypol or knocking down Bcl-2 expression by siRNA, cisplatin-resistant TOV112D cells became cisplatin-sensitive and subsequently increased cisplatin-induced apoptosis. Cisplatin 132-141 BCL2 apoptosis regulator Homo sapiens 105-110 19755862-7 2009 By inhibiting the activity of Bcl-2 protein with its pharmacological inhibitor gossypol or knocking down Bcl-2 expression by siRNA, cisplatin-resistant TOV112D cells became cisplatin-sensitive and subsequently increased cisplatin-induced apoptosis. Cisplatin 173-182 BCL2 apoptosis regulator Homo sapiens 30-35 19755862-7 2009 By inhibiting the activity of Bcl-2 protein with its pharmacological inhibitor gossypol or knocking down Bcl-2 expression by siRNA, cisplatin-resistant TOV112D cells became cisplatin-sensitive and subsequently increased cisplatin-induced apoptosis. Cisplatin 173-182 BCL2 apoptosis regulator Homo sapiens 105-110 19755862-7 2009 By inhibiting the activity of Bcl-2 protein with its pharmacological inhibitor gossypol or knocking down Bcl-2 expression by siRNA, cisplatin-resistant TOV112D cells became cisplatin-sensitive and subsequently increased cisplatin-induced apoptosis. Cisplatin 173-182 BCL2 apoptosis regulator Homo sapiens 30-35 19755862-7 2009 By inhibiting the activity of Bcl-2 protein with its pharmacological inhibitor gossypol or knocking down Bcl-2 expression by siRNA, cisplatin-resistant TOV112D cells became cisplatin-sensitive and subsequently increased cisplatin-induced apoptosis. Cisplatin 173-182 BCL2 apoptosis regulator Homo sapiens 105-110 20196784-5 2009 The mechanisms underlying the protective effect of autophagy apparently involved the interference with cisplatin-induced modulation of Bcl-2 family proteins, as inhibition of autophagy potentiated cisplatin-mediated up-regulation of proapoptotic Bax and down-regulation of anti-apoptotic Bcl-2. Cisplatin 197-206 BCL2 apoptosis regulator Homo sapiens 288-293 20196784-5 2009 The mechanisms underlying the protective effect of autophagy apparently involved the interference with cisplatin-induced modulation of Bcl-2 family proteins, as inhibition of autophagy potentiated cisplatin-mediated up-regulation of proapoptotic Bax and down-regulation of anti-apoptotic Bcl-2. Cisplatin 197-206 BCL2 apoptosis regulator Homo sapiens 135-140 19240170-0 2009 Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma. Cisplatin 13-22 BCL2 apoptosis regulator Homo sapiens 0-5 19283527-0 2009 Curcumin sensitizes lung cancer cells to cisplatin-induced apoptosis through superoxide anion-mediated Bcl-2 degradation. Cisplatin 41-50 BCL2 apoptosis regulator Homo sapiens 103-108 19283527-3 2009 Co-treatment of the cells with curcumin and cisplatin resulted in increased apoptosis and reversal of Bcl-2-mediated cisplatin resistance. Cisplatin 44-53 BCL2 apoptosis regulator Homo sapiens 102-107 19283527-3 2009 Co-treatment of the cells with curcumin and cisplatin resulted in increased apoptosis and reversal of Bcl-2-mediated cisplatin resistance. Cisplatin 117-126 BCL2 apoptosis regulator Homo sapiens 102-107 19283527-4 2009 The mechanism by which curcumin down-regulates Bcl-2 and sensitizes cells to cisplatin-induced apoptosis involves proteasomal degradation of Bcl-2. Cisplatin 77-86 BCL2 apoptosis regulator Homo sapiens 141-146 19283527-5 2009 These findings indicate a novel pathway for curcumin regulation of Bcl-2, which could benefit the development of a cisplatin sensitizing agent. Cisplatin 115-124 BCL2 apoptosis regulator Homo sapiens 67-72 19578044-0 2009 Cisplatin overcomes Bcl-2-mediated resistance to apoptosis via preferential engagement of Bak: critical role of Noxa-mediated lipid peroxidation. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 20-25 19578044-3 2009 Here, we show that cisplatin triggers a Bak-dependent pathway to induce apoptosis in Bcl-2-overexpressing MCF-7 cells. Cisplatin 19-28 BCL2 apoptosis regulator Homo sapiens 85-90 19578044-8 2009 In conclusion, our findings suggest a novel mode of action for cisplatin to overcome Bcl-2-mediated protection against apoptosis, which requires preferential activation of Bak and p53-mediated upregulation of Noxa protein levels and lipid peroxidation. Cisplatin 63-72 BCL2 apoptosis regulator Homo sapiens 85-90 19513519-5 2009 Consistent with these results, the protein levels of Bax and phospho-Bcl-2 increased and those of Bcl-2 and XIAP decreased in cells treated with beta-elemene in combination with cisplatin, compared with the levels in cells treated with either agent alone. Cisplatin 178-187 BCL2 apoptosis regulator Homo sapiens 69-74 19513519-5 2009 Consistent with these results, the protein levels of Bax and phospho-Bcl-2 increased and those of Bcl-2 and XIAP decreased in cells treated with beta-elemene in combination with cisplatin, compared with the levels in cells treated with either agent alone. Cisplatin 178-187 BCL2 apoptosis regulator Homo sapiens 98-103 19550397-4 2009 Besides, it was shown that antiapoptotic mechanisms (decrease of Bcl-2 expression) and intracellular glutathione detoxifying system are involved in the process of cisplatin resistance development in MCF-7 cells. Cisplatin 163-172 BCL2 apoptosis regulator Homo sapiens 65-70 19240170-2 2009 EXPERIMENTAL DESIGN: Levels of Bcl-2, Bcl-XL, and Bcl-w were determined and correlated with resistance to cisplatin in a large panel of cell lines derived from squamous cell carcinoma of the head and neck (HNSCC). Cisplatin 106-115 BCL2 apoptosis regulator Homo sapiens 31-36 19240170-4 2009 RESULTS: In HNSCC cell lines, high endogenous Bcl-2 expression was associated with increased cisplatin resistance, and experimental overexpression of Bcl-2 promoted cisplatin resistance. Cisplatin 93-102 BCL2 apoptosis regulator Homo sapiens 46-51 19240170-4 2009 RESULTS: In HNSCC cell lines, high endogenous Bcl-2 expression was associated with increased cisplatin resistance, and experimental overexpression of Bcl-2 promoted cisplatin resistance. Cisplatin 165-174 BCL2 apoptosis regulator Homo sapiens 150-155 19428505-4 2009 Both oxaliplatin and cisplatin induced a dose-dependent neuronal apoptosis, modulated by the proteins of Bcl-2 family. Cisplatin 21-30 BCL2 apoptosis regulator Homo sapiens 105-110 19117992-0 2009 PCPH/ENTPD5 expression confers to prostate cancer cells resistance against cisplatin-induced apoptosis through protein kinase Calpha-mediated Bcl-2 stabilization. Cisplatin 75-84 BCL2 apoptosis regulator Homo sapiens 142-147 18824293-4 2009 RAD001 in combination with cisplatin induced a significant increase in the number of apoptotic cells, downregulated the expression of pro-survival molecules, Bcl-2, survivin and cyclinD1, and increased the cleavage of PARP, compared to RAD001 or cisplatin alone. Cisplatin 27-36 BCL2 apoptosis regulator Homo sapiens 158-163 19117992-8 2009 Consistently, Bcl-2 knockdown sensitized PCa cells to cisplatin treatment and, more importantly, reversed the cisplatin resistance of PCa cells expressing the mt-PCPH oncoprotein. Cisplatin 54-63 BCL2 apoptosis regulator Homo sapiens 14-19 19117992-8 2009 Consistently, Bcl-2 knockdown sensitized PCa cells to cisplatin treatment and, more importantly, reversed the cisplatin resistance of PCa cells expressing the mt-PCPH oncoprotein. Cisplatin 110-119 BCL2 apoptosis regulator Homo sapiens 14-19 19117992-9 2009 Moreover, reexpression of Bcl-2 in PCPH/mt-PCPH knockdown PCa cells reversed the cisplatin sensitization caused by PCPH or mt-PCPH down-regulation. Cisplatin 81-90 BCL2 apoptosis regulator Homo sapiens 26-31 18160625-8 2008 Expression of wild-type and mitochondrial Bcl-2 showed significant inhibitory effects on tubular cell apoptosis that was induced by cisplatin or ATP depletion; however, ER-Bcl-2 was much less effective. Cisplatin 132-141 BCL2 apoptosis regulator Homo sapiens 42-47 18585380-3 2008 Interestingly in one cisplatin resistant cell line which expresses BCL2/BCLxL, treatment with mTOR inhibitor (CCI-779) results in decreased levels of these anti-apoptotic proteins and may contribute to increasing apoptosis. Cisplatin 21-30 BCL2 apoptosis regulator Homo sapiens 67-71 18566236-2 2008 Molecular targeting of Bcl-X(L) and/or Bcl-2 in HNSCC cells has been shown to promote apoptosis signaling and to sensitize cells to chemotherapy drugs, including cisplatin, which is commonly used in the treatment of HNSCC. Cisplatin 162-171 BCL2 apoptosis regulator Homo sapiens 39-44 18078766-7 2008 Phosphoinositide-3-kinase (PI3K)/Akt, survivin, bcl-2 were significantly downregulated in cells treated with the combination of celecoxib and cisplatin, and decreased survivin and bcl-2 levels were found in cells with wortmannin, a specific PI3K inhibitor. Cisplatin 142-151 BCL2 apoptosis regulator Homo sapiens 48-53 18078766-7 2008 Phosphoinositide-3-kinase (PI3K)/Akt, survivin, bcl-2 were significantly downregulated in cells treated with the combination of celecoxib and cisplatin, and decreased survivin and bcl-2 levels were found in cells with wortmannin, a specific PI3K inhibitor. Cisplatin 142-151 BCL2 apoptosis regulator Homo sapiens 180-185 18756958-15 2008 The protein expression levels of the antiapoptotic proteins Bcl-2, survivin, and XIAP were of the HER-2 siRNA III + cisplatin group were significantly lower than those of the cisplatin group, and the protein expression level of the apoptotic protein Smac of the HER-2 siRNA III + cisplatin group significantly higher than that of the cisplatin group (all P < 0.05). Cisplatin 175-184 BCL2 apoptosis regulator Homo sapiens 60-65 18756958-15 2008 The protein expression levels of the antiapoptotic proteins Bcl-2, survivin, and XIAP were of the HER-2 siRNA III + cisplatin group were significantly lower than those of the cisplatin group, and the protein expression level of the apoptotic protein Smac of the HER-2 siRNA III + cisplatin group significantly higher than that of the cisplatin group (all P < 0.05). Cisplatin 175-184 BCL2 apoptosis regulator Homo sapiens 60-65 18756958-15 2008 The protein expression levels of the antiapoptotic proteins Bcl-2, survivin, and XIAP were of the HER-2 siRNA III + cisplatin group were significantly lower than those of the cisplatin group, and the protein expression level of the apoptotic protein Smac of the HER-2 siRNA III + cisplatin group significantly higher than that of the cisplatin group (all P < 0.05). Cisplatin 175-184 BCL2 apoptosis regulator Homo sapiens 60-65 18756958-17 2008 The mechanism of induction of cell apoptosis by HER-2 siRNA III + cisplatin may be related to the downregulation of Bcl-2, survivin and XIAP protein and the up-regulation of Smac protein. Cisplatin 66-75 BCL2 apoptosis regulator Homo sapiens 116-121 18852117-7 2008 Analysis of the lung cancer cell lines identified the bcl-2 pathway to be associated with cisplatin resistance and the AKT pathway enriched in cisplatin- and docetaxel-resistant cell lines. Cisplatin 90-99 BCL2 apoptosis regulator Homo sapiens 54-59 18451495-4 2008 Combined treatment with berberine and cisplatin acted in concert to induce loss of mitochondrial membrane potential (Delta Psi m), release of cytochrome-c from mitochondria, and decreased expression of antiapoptotic Bcl-2, Bcl-x/L, resulting in activation of caspases and apoptosis. Cisplatin 38-47 BCL2 apoptosis regulator Homo sapiens 216-221 18196976-0 2008 NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts. Cisplatin 107-116 BCL2 apoptosis regulator Homo sapiens 89-94 18756958-15 2008 The protein expression levels of the antiapoptotic proteins Bcl-2, survivin, and XIAP were of the HER-2 siRNA III + cisplatin group were significantly lower than those of the cisplatin group, and the protein expression level of the apoptotic protein Smac of the HER-2 siRNA III + cisplatin group significantly higher than that of the cisplatin group (all P < 0.05). Cisplatin 116-125 BCL2 apoptosis regulator Homo sapiens 60-65 17955488-7 2008 Overexpression of Bcl-2 in HN4 cells prevented loss of MMP, nuclear translocation of EndoG and protected cells from the delayed apoptosis induced by cisplatin in the presence of z-VAD-fmk. Cisplatin 149-158 BCL2 apoptosis regulator Homo sapiens 18-23 17505826-0 2008 A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells. Cisplatin 86-95 BCL2 apoptosis regulator Homo sapiens 21-26 18196976-7 2008 Taken together, the results clearly suggested that NCX-4016 causes significant induction of cell cycle arrest and apoptosis in cisplatin-resistant human ovarian cancer cells via down-regulation of EGFR/PI3K/STAT3 signaling and modulation of Bcl-2 family proteins. Cisplatin 127-136 BCL2 apoptosis regulator Homo sapiens 241-246 17619073-7 2007 Similar to function way of SM, cDDP causes cancer cell apoptosis though caspase-8/caspase-3 and Bax/cytochrome c pathways, but the resistance to cDDP is correlated with Bcl-2 and Bcl-xL overexpression. Cisplatin 145-149 BCL2 apoptosis regulator Homo sapiens 169-174 18519232-4 2008 Cisplatin added to the culture medium leads to the significant increase of P53 expression and decrease of BCL-2 expression. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 106-111 17911532-5 2008 Apoptosis induced by cisplatin was mediated through the mitochondrial death pathway, which requires caspase-9 activation and is regulated by Bcl-2. Cisplatin 21-30 BCL2 apoptosis regulator Homo sapiens 141-146 17911532-6 2008 Cisplatin induced down-regulation of Bcl-2 through a process that involves dephosphorylation and ubiquitination of the protein, which facilitates its degradation by proteasome. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 37-42 17911532-15 2008 Together, our results indicate an essential role of H(2)O(2) in the regulation of Bcl-2 and apoptotic cell death induced by cisplatin. Cisplatin 124-133 BCL2 apoptosis regulator Homo sapiens 82-87 18645262-9 2008 CONCLUSION: The ZNRD1 gene might be involved in the cisplatin resistance of EC109 cells by regulating the expression of ERCC1 and Bcl-2. Cisplatin 52-61 BCL2 apoptosis regulator Homo sapiens 130-135 18089824-8 2007 In addition, we showed that down-regulation of ERK2 or MKP-1 decreases the basal level of Bcl-2 protein and that inhibition of Bcl-2 activity sensitizes ovarian cancer cells to cisplatin. Cisplatin 177-186 BCL2 apoptosis regulator Homo sapiens 127-132 17989874-0 2007 Bcl-2 small interfering RNA sensitizes cisplatin-resistant human lung adenocarcinoma A549/DDP cell to cisplatin and diallyl disulfide. Cisplatin 39-48 BCL2 apoptosis regulator Homo sapiens 0-5 17989874-0 2007 Bcl-2 small interfering RNA sensitizes cisplatin-resistant human lung adenocarcinoma A549/DDP cell to cisplatin and diallyl disulfide. Cisplatin 102-111 BCL2 apoptosis regulator Homo sapiens 0-5 17989874-2 2007 In this study, we investigated the inhibitory effect of the hairpin Bcl-2 small interfering (si)RNA on the expression of the Bcl-2 gene in the cisplatin (DDP)-resistant human lung adenocarcinoma cell line A549/DDP, and the effect of Bcl-2 siRNA on drug sensitization in A549/DDP cells. Cisplatin 143-152 BCL2 apoptosis regulator Homo sapiens 68-73 17989874-2 2007 In this study, we investigated the inhibitory effect of the hairpin Bcl-2 small interfering (si)RNA on the expression of the Bcl-2 gene in the cisplatin (DDP)-resistant human lung adenocarcinoma cell line A549/DDP, and the effect of Bcl-2 siRNA on drug sensitization in A549/DDP cells. Cisplatin 143-152 BCL2 apoptosis regulator Homo sapiens 125-130 17989874-2 2007 In this study, we investigated the inhibitory effect of the hairpin Bcl-2 small interfering (si)RNA on the expression of the Bcl-2 gene in the cisplatin (DDP)-resistant human lung adenocarcinoma cell line A549/DDP, and the effect of Bcl-2 siRNA on drug sensitization in A549/DDP cells. Cisplatin 143-152 BCL2 apoptosis regulator Homo sapiens 125-130 17619073-9 2007 The combined treatment of SM and cDDP significantly reduced Bcl-2 and Bcl-xL expressions, and enhanced Bax, cytochrome c, caspase-9 and -3 expressions in breast cancer cells. Cisplatin 33-37 BCL2 apoptosis regulator Homo sapiens 60-65 17581297-6 2007 Combination treatment of Bcl-2 small interfering RNA with cisplatin resulted in a synergistic activity. Cisplatin 58-67 BCL2 apoptosis regulator Homo sapiens 25-30 17581297-0 2007 Bcl-2 downregulation sensitizes nonsmall cell lung cancer cells to cisplatin, but not to docetaxel. Cisplatin 67-76 BCL2 apoptosis regulator Homo sapiens 0-5 17581297-8 2007 Of note, docetaxel treatment resulted in Bcl-2 phosphorylation of nonsmall cell lung cancer cells, whereas cisplatin increased the Bcl-2 overall expression and abrogated Bcl-2 phosphorylation. Cisplatin 107-116 BCL2 apoptosis regulator Homo sapiens 131-136 17581297-3 2007 We investigated the Bcl-2 expression status of nonsmall cell lung cancer cells in response to cisplatin or docetaxel and its effect on sensitizing nonsmall cell lung cancer cells by Bcl-2 downregulation employing a small interfering RNA approach. Cisplatin 94-103 BCL2 apoptosis regulator Homo sapiens 20-25 17581297-8 2007 Of note, docetaxel treatment resulted in Bcl-2 phosphorylation of nonsmall cell lung cancer cells, whereas cisplatin increased the Bcl-2 overall expression and abrogated Bcl-2 phosphorylation. Cisplatin 107-116 BCL2 apoptosis regulator Homo sapiens 131-136 17581297-9 2007 On the basis of our findings, a Bcl-2 silencing approach appears to be a suitable strategy for sensitizing nonsmall cell lung cancer to cisplatin, but not to docetaxel. Cisplatin 136-145 BCL2 apoptosis regulator Homo sapiens 32-37 17544840-4 2007 Intracellular galectin-3 in particular, which contains the NWGR anti-death motif of the Bcl-2 family, inhibits cell apoptosis induced by chemotherapeutic agent such as cisplatin and etoposide in some types of cancer cells. Cisplatin 168-177 BCL2 apoptosis regulator Homo sapiens 88-93 17452997-0 2007 Bcl-2 cleavages at two adjacent sites by different caspases promote cisplatin-induced apoptosis. Cisplatin 68-77 BCL2 apoptosis regulator Homo sapiens 0-5 17452997-3 2007 We report herein that Bcl-2 protein was cleaved to produce two fragments of around 23 kDa in human hepatocarcinoma BEL-7404 cells or in Bcl-2 overexpressing CHO cells induced by cisplatin. Cisplatin 178-187 BCL2 apoptosis regulator Homo sapiens 22-27 17452997-3 2007 We report herein that Bcl-2 protein was cleaved to produce two fragments of around 23 kDa in human hepatocarcinoma BEL-7404 cells or in Bcl-2 overexpressing CHO cells induced by cisplatin. Cisplatin 178-187 BCL2 apoptosis regulator Homo sapiens 136-141 17452997-7 2007 These results indicate that Bcl-2 can be cleaved into two close fragments by different caspases during cisplatin-induced apoptosis, both of which contribute to the acceleration of apoptotic process. Cisplatin 103-112 BCL2 apoptosis regulator Homo sapiens 28-33 17446929-7 2007 Thus, in response to treatment with cisplatin, but not other chemotherapeutic agents, TAp73 underwent c-Abl-dependent phosphorylation, which promoted dissociation of the DeltaNp63alpha/TAp73 protein complex, TAp73-dependent transcription of proapoptotic Bcl-2 family members, and apoptosis. Cisplatin 36-45 BCL2 apoptosis regulator Homo sapiens 254-259 17575115-7 2007 Our data show that Bcl-2 can protect antiestrogen-resistant breast cancer cells from cisplatin-induced cell death, indicating that the reduced expression of Bcl-2 in the antiestrogen-resistant cells plays a role in sensitizing the cells to cisplatin treatment. Cisplatin 240-249 BCL2 apoptosis regulator Homo sapiens 157-162 17287256-2 2007 In particular, the overexpression of Bcl-2-family members interferes with apoptosis initiation by DNA-damaging agents (e.g., cisplatin) or soluble death ligands (e.g., TRAIL). Cisplatin 125-134 BCL2 apoptosis regulator Homo sapiens 37-42 17088977-0 2006 Enhancing cisplatin sensitivity in MCF-7 human breast cancer cells by down-regulation of Bcl-2 and cyclin D1. Cisplatin 10-19 BCL2 apoptosis regulator Homo sapiens 89-94 17404015-3 2007 The drugs cisplatin, carboplatin, and doxorubicin exhibit anticancer activity, the mechanism of which is not yet completely clarified, although they are known to modulate the expression of several genes including apoptosis-related genes, such as members of the BCL2 (Bcl-2) family. Cisplatin 10-19 BCL2 apoptosis regulator Homo sapiens 261-265 17404015-3 2007 The drugs cisplatin, carboplatin, and doxorubicin exhibit anticancer activity, the mechanism of which is not yet completely clarified, although they are known to modulate the expression of several genes including apoptosis-related genes, such as members of the BCL2 (Bcl-2) family. Cisplatin 10-19 BCL2 apoptosis regulator Homo sapiens 267-272 17575115-7 2007 Our data show that Bcl-2 can protect antiestrogen-resistant breast cancer cells from cisplatin-induced cell death, indicating that the reduced expression of Bcl-2 in the antiestrogen-resistant cells plays a role in sensitizing the cells to cisplatin treatment. Cisplatin 85-94 BCL2 apoptosis regulator Homo sapiens 19-24 17575115-7 2007 Our data show that Bcl-2 can protect antiestrogen-resistant breast cancer cells from cisplatin-induced cell death, indicating that the reduced expression of Bcl-2 in the antiestrogen-resistant cells plays a role in sensitizing the cells to cisplatin treatment. Cisplatin 85-94 BCL2 apoptosis regulator Homo sapiens 157-162 17575115-7 2007 Our data show that Bcl-2 can protect antiestrogen-resistant breast cancer cells from cisplatin-induced cell death, indicating that the reduced expression of Bcl-2 in the antiestrogen-resistant cells plays a role in sensitizing the cells to cisplatin treatment. Cisplatin 240-249 BCL2 apoptosis regulator Homo sapiens 19-24 17088977-5 2006 Therefore, Bcl-2 and cyclin D1 were chosen as putative targets for increasing cell death and growth arrest induced by cisplatin, thereby enhancing the drug sensitivity in MCF-7. Cisplatin 118-127 BCL2 apoptosis regulator Homo sapiens 11-16 17088977-6 2006 RNA interference, using Bcl-2- and cyclin D1- siRNAs sensitized MCF-7 cells to cisplatin treatment and by simultaneous knockdown of both Bcl-2 and cyclin D1 further sensitization was seen. Cisplatin 79-88 BCL2 apoptosis regulator Homo sapiens 24-29 16442262-9 2006 In addition, cisplatin-induced apoptosis is abrogated by the overexpression of either Bcl-2 or Bcl-x(L), which diminished changes of mitochondrial membrane potential and decreased the amount of cytochrome c released from mitochondria. Cisplatin 13-22 BCL2 apoptosis regulator Homo sapiens 86-91 16928686-5 2006 Importantly, the Bcl-2 homology domain 3-only (BH3-only) protein Noxa was found to be strongly induced in cisplatin-resistant SCC cells by PS-341 but not by cisplatin. Cisplatin 106-115 BCL2 apoptosis regulator Homo sapiens 17-22 16533421-7 2006 Fhit could also partially restore sensitivity to cisplatin in Bcl-2- and Bcl-x(L)-overexpressing H460 cells that are normally resistant to this drug. Cisplatin 49-58 BCL2 apoptosis regulator Homo sapiens 62-67 16477627-14 2006 Our studies have demonstrated that the Bcl-2 antisense oligodeoxynucleotide, G3139, has proapoptotic effects in C666-1, and in combination with CDDP, is curative in C666-1 NPC xenograft tumors in vivo. Cisplatin 144-148 BCL2 apoptosis regulator Homo sapiens 39-44 16699961-12 2006 Bcl-2 over expressing PC-3 cells, which were resistant to cisplatin induced apoptosis, underwent apoptosis following treatment with all the titanocene compounds. Cisplatin 58-67 BCL2 apoptosis regulator Homo sapiens 0-5 16596182-6 2006 It was also found that CDDP can increase the ratio of pro-apoptotic/pro-survival Bcl-2 members. Cisplatin 23-27 BCL2 apoptosis regulator Homo sapiens 81-86 16640863-0 2006 [Study of bcl-2 antisense oligodeoxynucleotides on reversal of cisplatin resistance in ovarian cancer cell line A2780/DDP]. Cisplatin 63-72 BCL2 apoptosis regulator Homo sapiens 10-15 16640863-1 2006 OBJECTIVE: To evaluate the influence of bcl-2 antisense oligodeoxynucleotides (AODN) on reversing cisplatin (DDP) resistance in ovarian carcinoma cell lines. Cisplatin 98-107 BCL2 apoptosis regulator Homo sapiens 40-45 18156740-0 2006 Modulation of telomerase activity and human telomerase reverse transcriptase expression by caspases and bcl-2 family proteins in Cisplatin-induced cell death. Cisplatin 129-138 BCL2 apoptosis regulator Homo sapiens 104-109 18156740-7 2006 This finding suggests that Bcl-2-induced telomerase activity exerts an antiapoptotic effect in cisplatin-induced death. Cisplatin 95-104 BCL2 apoptosis regulator Homo sapiens 27-32 18156740-11 2006 CONCLUSIONS: Bcl-2-induced telomerase activity inhibits cisplatin-induced apoptosis in HeLa cells, and can be regulated via both caspases and the interaction of Bcl-2 and Bak. Cisplatin 56-65 BCL2 apoptosis regulator Homo sapiens 13-18 18156740-11 2006 CONCLUSIONS: Bcl-2-induced telomerase activity inhibits cisplatin-induced apoptosis in HeLa cells, and can be regulated via both caspases and the interaction of Bcl-2 and Bak. Cisplatin 56-65 BCL2 apoptosis regulator Homo sapiens 161-166 16778213-0 2006 Nitric oxide regulates cell sensitivity to cisplatin-induced apoptosis through S-nitrosylation and inhibition of Bcl-2 ubiquitination. Cisplatin 43-52 BCL2 apoptosis regulator Homo sapiens 113-118 16778213-7 2006 Cisplatin resistance in H-460 cells is mediated by Bcl-2, and NO up-regulates its expression by preventing the degradation of Bcl-2 via ubiquitin-proteasome pathway. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 51-56 16778213-7 2006 Cisplatin resistance in H-460 cells is mediated by Bcl-2, and NO up-regulates its expression by preventing the degradation of Bcl-2 via ubiquitin-proteasome pathway. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 126-131 16778213-8 2006 Cisplatin-induced generation of reactive oxygen species causes dephosphorylation and degradation of Bcl-2. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 100-105 16778213-10 2006 These findings indicate a novel pathway for NO regulation of Bcl-2, which provides a key mechanism for cisplatin resistance and its potential modulation for improved cancer chemotherapy. Cisplatin 103-112 BCL2 apoptosis regulator Homo sapiens 61-66 16009487-0 2006 Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells. Cisplatin 41-50 BCL2 apoptosis regulator Homo sapiens 16-21 16009487-8 2006 In contrast, overexpressed Bcl-2 protein inhibited cisplatin-induced Bax translocation and its downstream events in T24R2. Cisplatin 51-60 BCL2 apoptosis regulator Homo sapiens 27-32 16009487-9 2006 Downregulation of Bcl-2 by RNAi potentiated the redistribution of Bax and cytochrome c and reversed cisplatin-resistance. Cisplatin 100-109 BCL2 apoptosis regulator Homo sapiens 18-23 16009487-10 2006 Our results indicate that upregulation of Bcl-2 contributes to the development of cisplatin-resistance and usage of siRNA which targets the Bcl-2 gene may offer a potential tool to reverse the resistance to cisplatin in bladder cancer. Cisplatin 82-91 BCL2 apoptosis regulator Homo sapiens 42-47 16009487-10 2006 Our results indicate that upregulation of Bcl-2 contributes to the development of cisplatin-resistance and usage of siRNA which targets the Bcl-2 gene may offer a potential tool to reverse the resistance to cisplatin in bladder cancer. Cisplatin 82-91 BCL2 apoptosis regulator Homo sapiens 140-145 16009487-10 2006 Our results indicate that upregulation of Bcl-2 contributes to the development of cisplatin-resistance and usage of siRNA which targets the Bcl-2 gene may offer a potential tool to reverse the resistance to cisplatin in bladder cancer. Cisplatin 207-216 BCL2 apoptosis regulator Homo sapiens 140-145 16115953-9 2005 The attenuation of cisplatin-induced cell death in cyclin D1-overexpressing cells was correlated with the up-regulation of nuclear factor-kappaB activity and maintenance of bcl-2 and bcl-xl protein levels. Cisplatin 19-28 BCL2 apoptosis regulator Homo sapiens 173-178 16244579-4 2005 RESULTS: It has been shown that the formation of the resistance to cisplatin in A2780/DDP8 cells is accompanied by the increase of expression of glutathione-S-transferase and Bcl-2, by the decrease of expression of CD95-antigene and proliferation potential of the cells, by appearance of EGF receptors and elevation of expression level of E-cadherin, alpha- and beta-catenins, proving the enhancement of adhesive properties of tumor cells. Cisplatin 67-76 BCL2 apoptosis regulator Homo sapiens 175-180 16244579-5 2005 CONCLUSION: Antiapoptotic program seems to be the leading mechanism of the development of the resistance to cisplatin in A2780/DDP8 cells and is realized via high expression of Bcl-2. Cisplatin 108-117 BCL2 apoptosis regulator Homo sapiens 177-182 16374644-11 2006 Liposomal-mediated anti-bcl-2 siRNA transfer led to a significant improvement of cisplatin treatment in HUH6 cells. Cisplatin 81-90 BCL2 apoptosis regulator Homo sapiens 24-29 16315863-7 2005 Treatment of MKN-45 cells with AS Bcl-2 increased sensitivity to adriamycin (ADM), cisplatin (CDDP), and paclitaxel (PTX) in vitro and in vivo. Cisplatin 83-92 BCL2 apoptosis regulator Homo sapiens 34-39 16315863-7 2005 Treatment of MKN-45 cells with AS Bcl-2 increased sensitivity to adriamycin (ADM), cisplatin (CDDP), and paclitaxel (PTX) in vitro and in vivo. Cisplatin 94-98 BCL2 apoptosis regulator Homo sapiens 34-39 16020667-6 2005 Bcl-x(L) expression increased in the cisplatin-resistant lines relative to the parental lines, whereas Bcl-2 expression was high in the parental lines and decreased in the cisplatin-resistant lines. Cisplatin 172-181 BCL2 apoptosis regulator Homo sapiens 103-108 15958577-2 2005 One of the underlying factors that contribute to cisplatin resistance is the elevated level of BCL-2 and/or BCL-XL, which promotes cell survival. Cisplatin 49-58 BCL2 apoptosis regulator Homo sapiens 95-100 15958577-10 2005 Moreover, Siva-1 augments cisplatin-mediated cell death in MCF7 cells stably expressing BCL-2. Cisplatin 26-35 BCL2 apoptosis regulator Homo sapiens 88-93 15913739-9 2005 Treatment with cisplatin resulted in more cells accumulating in S phase in Bcl-2-overexpressing SKOV3 cells, while the inhibition of Bcl-2 abolished delayed entry into G2M phase without affecting cisplatin-induced apoptosis. Cisplatin 15-24 BCL2 apoptosis regulator Homo sapiens 75-80 15826766-15 2005 Only a minor increase of cisplatin effectivity was noted after asON preincubation of cells with lower bcl-2 expression. Cisplatin 25-34 BCL2 apoptosis regulator Homo sapiens 102-107 15643508-5 2005 We examined the association between Bcl-2 and P-gp expression and in vitro chemosensitivity to DOC and CDDP. Cisplatin 103-107 BCL2 apoptosis regulator Homo sapiens 36-41 16020667-8 2005 We tested a small-molecule BH3 mimetic, (-)-gossypol, which binds to the BH3 domain of Bcl-2 and Bcl-x(L), for activity against the parental and cisplatin-resistant cell lines. Cisplatin 145-154 BCL2 apoptosis regulator Homo sapiens 87-92 15735033-5 2005 The increased cisplatin sensitivity in MAD2 transfectants was associated with mitotic arrest and activation of apoptosis pathway evidenced by the increased mitotic index and apoptosis rate as well as decreased Bcl-2 and Bax ratio and expression of cleaved poly(ADP-ribose) polymerase and caspase 3. Cisplatin 14-23 BCL2 apoptosis regulator Homo sapiens 210-215 15514848-0 2004 Suppression of bcl-2 gene by RNA interference increases chemosensitivity to cisplatin in nasopharyngeal carcinoma cell line CNE1. Cisplatin 76-85 BCL2 apoptosis regulator Homo sapiens 15-20 15514848-4 2004 The results showed that: stable transfection of CNE1 cells with vectors expressing shRNAs against bcl-2 decreased the expression of BCL-2 protein; suppression of BCL-2 expression did not affect cell proliferation but could increase the chemosensitivity to cisplatin in CNE1 cells. Cisplatin 256-265 BCL2 apoptosis regulator Homo sapiens 98-103 15514848-4 2004 The results showed that: stable transfection of CNE1 cells with vectors expressing shRNAs against bcl-2 decreased the expression of BCL-2 protein; suppression of BCL-2 expression did not affect cell proliferation but could increase the chemosensitivity to cisplatin in CNE1 cells. Cisplatin 256-265 BCL2 apoptosis regulator Homo sapiens 162-167 15246562-4 2004 We report here that cisplatin-resistant cell lines overexpress Bcl-2 family protein Bcl-2-related gene expressed in fetal liver (Bfl-1)/A1 as compared with their parental cell. Cisplatin 20-29 BCL2 apoptosis regulator Homo sapiens 63-68 15476281-8 2004 Drug sensitivity to doxorubicin, cisplatin, and paclitaxel (TXL) was increased 3-4-fold when used in combination with AS bcl-2, which was determined with 50% inhibitory concentration values, compared with the control group. Cisplatin 33-42 BCL2 apoptosis regulator Homo sapiens 121-126 15476281-10 2004 The antitumor effect of cisplatin and TXL in vivo was enhanced significantly in combination with AS bcl-2. Cisplatin 24-33 BCL2 apoptosis regulator Homo sapiens 100-105 15476281-12 2004 CONCLUSIONS: Combination treatment with AS bcl-2 and anticancer drugs, including cisplatin and TXL, may be a new strategy for enhancing chemotherapeutic effects in the treatment of gastric carcinoma. Cisplatin 81-90 BCL2 apoptosis regulator Homo sapiens 43-48 15492778-8 2004 In addition, it is generally accepted that cytotoxicity of cisplatin is mediated through induction of apoptosis and arrest of cell cycle resulting from its interaction with DNA, such as the formation of cisplatin-DNA adducts, which activates multiple signaling pathways, including those involving p53, Bcl-2 family, caspases, cyclins, CDKs, pRb, PKC, MAPK and PI3K/Akt. Cisplatin 59-68 BCL2 apoptosis regulator Homo sapiens 302-307 15492778-8 2004 In addition, it is generally accepted that cytotoxicity of cisplatin is mediated through induction of apoptosis and arrest of cell cycle resulting from its interaction with DNA, such as the formation of cisplatin-DNA adducts, which activates multiple signaling pathways, including those involving p53, Bcl-2 family, caspases, cyclins, CDKs, pRb, PKC, MAPK and PI3K/Akt. Cisplatin 203-212 BCL2 apoptosis regulator Homo sapiens 302-307 15390206-11 2004 Further investigation showed that SCCHN cells expressing predominantly mutant p53 and decreased Bcl-2 were more susceptible to cisplatin-induced apoptosis than vector-transfected controls (p < .0001). Cisplatin 127-136 BCL2 apoptosis regulator Homo sapiens 96-101 15246562-4 2004 We report here that cisplatin-resistant cell lines overexpress Bcl-2 family protein Bcl-2-related gene expressed in fetal liver (Bfl-1)/A1 as compared with their parental cell. Cisplatin 20-29 BCL2 apoptosis regulator Homo sapiens 84-89 15138626-7 2004 Although the expression of mRNA and protein of Bcl-2 decreased in 2008 cells after treatment with cisplatin, the expression of Bcl-2 remained unchanged in 2008 C-13 cells. Cisplatin 98-107 BCL2 apoptosis regulator Homo sapiens 47-52 15271313-0 2004 Cytotoxicity of cisplatin in bladder cancer is significantly enhanced by application of bcl-2 antisense oligonucleotides. Cisplatin 16-25 BCL2 apoptosis regulator Homo sapiens 88-93 15265716-11 2004 The combination of cisplatin/freezing resulted in a 4-fold increase in the ratio of Bax to Bcl-2 when compared to controls, which represented a 2-fold increase over the 5-FU/freezing-combination model. Cisplatin 19-28 BCL2 apoptosis regulator Homo sapiens 91-96 15156398-8 2004 CONCLUSION: We conclude that overexpression of antiapoptotic proteins Bcl-2 and Bcl-X(L) and down-regulation of caspase-3 activity may be associated with cisplatin resistance in human ovarian cancer. Cisplatin 154-163 BCL2 apoptosis regulator Homo sapiens 70-75 15315167-2 2004 Our results showed that (1) "DNA ladder" was observed in A2780 and AD6 after cisplatin treatment; (2) after 3.0, 6.0, 9.9 microg/ml of cisplatin treatment, a significant difference was noted in the rate of apoptosis between in A2780 and AD6 (P<0.05); (3) Bcl-2 and Bcl-xl genes were overexpressed in AD6. Cisplatin 135-144 BCL2 apoptosis regulator Homo sapiens 258-263 14712225-5 2004 On the other hand, p16 sensitized cells to cisplatin-mediated apoptosis through Bcl-2 decline. Cisplatin 43-52 BCL2 apoptosis regulator Homo sapiens 80-85 15566959-11 2004 However, anti-apoptotic Bcl-2 and Bcl-X(L) were elevated and the cell cycle regulator cyclin D1 was slightly upregulated with both 1 and 5 microM cisplatin treatment. Cisplatin 146-155 BCL2 apoptosis regulator Homo sapiens 24-29 15026553-0 2004 Down-regulation of Bcl-2 is associated with cisplatin resistance in human small cell lung cancer H69 cells. Cisplatin 44-53 BCL2 apoptosis regulator Homo sapiens 19-24 15026553-2 2004 In the present study, we have investigated if Bcl-2 contributes to the emergence of cisplatin resistance in SCLC H69 cells. Cisplatin 84-93 BCL2 apoptosis regulator Homo sapiens 46-51 15315167-3 2004 After cisplatin treatment, the expression of Bcl-2 and Bcl-xl genes was down-regulated in A2780 and AD6. Cisplatin 6-15 BCL2 apoptosis regulator Homo sapiens 45-50 15315167-0 2004 Difference in expression of Bcl-2 and Bcl-xl genes in cisplatin-sensitive and cisplatin-resistant human in ovarian cancer cell lines. Cisplatin 54-63 BCL2 apoptosis regulator Homo sapiens 28-33 15315167-0 2004 Difference in expression of Bcl-2 and Bcl-xl genes in cisplatin-sensitive and cisplatin-resistant human in ovarian cancer cell lines. Cisplatin 78-87 BCL2 apoptosis regulator Homo sapiens 28-33 13130506-9 2003 Expression of antisense bcl-2 in glioma cells resulted in significantly increased cytotoxicity of cisplatin. Cisplatin 98-107 BCL2 apoptosis regulator Homo sapiens 24-29 15033711-0 2003 Cisplatin-induced apoptosis in HL-60 human promyelocytic leukemia cells: differential expression of BCL2 and novel apoptosis-related gene BCL2L12. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 100-104 15033711-3 2003 In the present study, the expression of BCL2 and BCL2L12 genes during cisplatin-induced apoptosis in HL-60 leukemic cells was investigated. Cisplatin 70-79 BCL2 apoptosis regulator Homo sapiens 40-44 15033711-7 2003 Gradual, time-dependent downregulation of BCL2 gene was observed during cisplatin treatment. Cisplatin 72-81 BCL2 apoptosis regulator Homo sapiens 42-46 13130506-10 2003 In conclusion, antisense bcl-2 expression can effectively reduce glioma survival, including retarding in vitro growth, complete loss of tumorigenicity, and significantly enhanced cisplatin cytotoxicity. Cisplatin 179-188 BCL2 apoptosis regulator Homo sapiens 25-30 14512787-2 2003 To gain insight into the molecular mechanisms underlying chemotherapeutic drug resistance, we examined the role of the Bcl-2 family members Bcl-2 and Bax in cell death in the melanoma cell line G361 following stimulation with cisplatin (CDDP) or dacarbazine (DTIC). Cisplatin 226-235 BCL2 apoptosis regulator Homo sapiens 119-124 14512787-7 2003 CDDP-induced apoptosis and secondary necrosis were accompanied by activation of caspase-3 and modulation of Bcl-2 family members Bcl-2 and Bax. Cisplatin 0-4 BCL2 apoptosis regulator Homo sapiens 108-113 14512787-7 2003 CDDP-induced apoptosis and secondary necrosis were accompanied by activation of caspase-3 and modulation of Bcl-2 family members Bcl-2 and Bax. Cisplatin 0-4 BCL2 apoptosis regulator Homo sapiens 129-134 14512787-9 2003 Flow cytometry, which enables measurement of protein at the single-cell level, revealed that Bcl-2+/Bax- cells were decreased, with a slight concomitant rise in Bcl-2-/Bax+ cells on stimulation with CDDP. Cisplatin 199-203 BCL2 apoptosis regulator Homo sapiens 93-98 14512787-9 2003 Flow cytometry, which enables measurement of protein at the single-cell level, revealed that Bcl-2+/Bax- cells were decreased, with a slight concomitant rise in Bcl-2-/Bax+ cells on stimulation with CDDP. Cisplatin 199-203 BCL2 apoptosis regulator Homo sapiens 161-166 14512787-10 2003 These findings suggest that the chemotherapeutic agents CDDP and DTIC induce apoptosis and/or secondary necrosis depending on dose, probably involving the modulation of Bcl-2 family proteins. Cisplatin 56-60 BCL2 apoptosis regulator Homo sapiens 169-174 12950722-10 2003 The combined treatment with genistein and cisplatin significantly reduced bcl-2 and bcl-xL protein and increased Apaf-1 protein expression. Cisplatin 42-51 BCL2 apoptosis regulator Homo sapiens 74-79 12709826-0 2003 Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line. Cisplatin 43-52 BCL2 apoptosis regulator Homo sapiens 76-81 21310133-4 2003 Cisplatin could obviously down-regulate telomerase activity, decrease S phase cells, increase G0/G1 phase cells, decline the expressions of bcl-2 and PCNA proteins and induce the expression of p53 protein of SLC-89 cells in a concentration-dependent fashion. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 140-145 21310133-5 2003 CONCLUSIONS: Cisplatin can obviously inhibit the proliferation of SLC-89, change the distribution of cell cycle, decline telomerase activity and expressions of bcl-2 and PCNA proteins, and induce expression of p53 protein, which may be the important mechanisms of cisplatin"s anticancer action. Cisplatin 13-22 BCL2 apoptosis regulator Homo sapiens 160-165 12800189-7 2003 Our results demonstrate that Bcl-2 and Bcl-xL antisense treatment facilitates apoptosis in mesothelioma cells and suggest the use of Bcl-2/Bcl-xL bispecific antisense treatment in combination with cisplatin or gemcitabine for therapy of malignant pleural mesothelioma. Cisplatin 197-206 BCL2 apoptosis regulator Homo sapiens 29-34 12709826-0 2003 Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line. Cisplatin 103-112 BCL2 apoptosis regulator Homo sapiens 76-81 12709826-13 2003 CONCLUSIONS: These results indicate that exposure to TXL prior to CDDP plays a key role in circumventing CDDP resistance by phosphorylating Bcl-2 protein in the human epidermoid carcinoma cell line A431/CDDP2. Cisplatin 105-109 BCL2 apoptosis regulator Homo sapiens 140-145 12889121-12 2003 The study showed that 0.5 mumol.L-1 cisplatin or 1 x 10(-4) mumol.L-1 lidamycin alone decreased Bcl-2 protein level, while lidamycin in combination with cisplatin strongly inhibited expression of Bcl-2 proteins in BEL-7402 cells. Cisplatin 36-45 BCL2 apoptosis regulator Homo sapiens 96-101 12889121-12 2003 The study showed that 0.5 mumol.L-1 cisplatin or 1 x 10(-4) mumol.L-1 lidamycin alone decreased Bcl-2 protein level, while lidamycin in combination with cisplatin strongly inhibited expression of Bcl-2 proteins in BEL-7402 cells. Cisplatin 36-45 BCL2 apoptosis regulator Homo sapiens 196-201 12889121-13 2003 CONCLUSION: The results suggest that lidamycin enhancement of cisplatin-induced apoptosis associates with decrease of Bcl-2 protein expression, which may be useful for cancer chemotherapy. Cisplatin 62-71 BCL2 apoptosis regulator Homo sapiens 118-123 12644821-1 2003 In cell line studies, BCL-2, BAX, as well as novel MEK1 protein levels have strong influence on ovarian cancer response to cisplatin-based chemotherapy. Cisplatin 123-132 BCL2 apoptosis regulator Homo sapiens 22-27 12543781-0 2003 Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. Cisplatin 60-69 BCL2 apoptosis regulator Homo sapiens 45-50 12715170-23 2003 The increase in number of Bcl-2 positive cells after combined treatment and the consistently negative p21 status after any treatment in GLC4-CDDP may protect these tumor cells from apoptosis as a part of their resistance mechanism to cisplatin. Cisplatin 234-243 BCL2 apoptosis regulator Homo sapiens 26-31 12536078-4 2003 Cisplatin upregulated the expression of both death and decoy TRAIL receptors, as well as of TRAF5 and -6, downregulated the anti-apoptotic proteins, Bcl-2, and induced activation of caspases-3, -8 and -9. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 149-154 12536078-6 2003 Cisplatin/Apo2L/TRAIL combination resulted in further downregulation of expression of anti-apoptotic proteins, Bcl-2 and Bcl-xL, as well as an increase in mitochondrial permeability transition and activation of caspases-3, -8, and -10. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 111-116 12543781-7 2003 Treatment of MCF-7 lines with buthionine sulfoximine, an inhibitor of glutathione synthesis, normalized glutathione levels in Bcl-2 and control transfectants and completely abrogated Bcl-2-mediated cisplatin resistance without affecting Bcl-2 expression. Cisplatin 198-207 BCL2 apoptosis regulator Homo sapiens 183-188 12543781-7 2003 Treatment of MCF-7 lines with buthionine sulfoximine, an inhibitor of glutathione synthesis, normalized glutathione levels in Bcl-2 and control transfectants and completely abrogated Bcl-2-mediated cisplatin resistance without affecting Bcl-2 expression. Cisplatin 198-207 BCL2 apoptosis regulator Homo sapiens 183-188 12543781-9 2003 These results suggest that Bcl-2-mediated cisplatin resistance in MCF-7 cells is dependent on up-regulation of glutathione production, which contributes to cell survival by mechanisms independent of cisplatin inactivation or inhibition of DNA adduct formation. Cisplatin 42-51 BCL2 apoptosis regulator Homo sapiens 27-32 12543781-9 2003 These results suggest that Bcl-2-mediated cisplatin resistance in MCF-7 cells is dependent on up-regulation of glutathione production, which contributes to cell survival by mechanisms independent of cisplatin inactivation or inhibition of DNA adduct formation. Cisplatin 199-208 BCL2 apoptosis regulator Homo sapiens 27-32 12543781-10 2003 A similar dependence on glutathione for Bcl-2-mediated inhibition of cisplatin toxicity was confirmed in a second cell line, the lymphocytic precursor FL5.12. Cisplatin 69-78 BCL2 apoptosis regulator Homo sapiens 40-45 15314975-0 2003 Expression of p21 and bcl-2 proteins in paraffin-embedded preparations of non-small cell lung cancer in stage IIIA after Etoposide and Cisplatin induced chemotherapy. Cisplatin 135-144 BCL2 apoptosis regulator Homo sapiens 22-27 14716031-0 2003 Death receptor 5 and Bcl-2 protein expression as predictors of tumor response to gemcitabine and cisplatin in patients with advanced non-small-cell lung cancer. Cisplatin 97-106 BCL2 apoptosis regulator Homo sapiens 21-26 15000830-8 2003 However, if siRNA compounds targeting Bcl-2 were combined with the apoptosis-inducing chemotherapeutic agent cisplatin, a massive increase in apoptotic cell death compared with controls was observed. Cisplatin 109-118 BCL2 apoptosis regulator Homo sapiens 38-43 12520732-8 2002 CONCLUSIONS: Cisplatin-resistance in human ovarian cancer cell lines may associated with the overexpression of anti-apoptotic protein bcl-2 and downregulation of caspase-3 activity, but not associated with the expression of bax and bcl-xs. Cisplatin 13-22 BCL2 apoptosis regulator Homo sapiens 134-139 12421819-5 2003 Here we report that nicotine can induce Bcl2 phosphorylation exclusively at the serine 70 site in association with prolonged survival of SCLC H82 cells expressing wild-type but not the phosphorylation-deficient S70A mutant Bcl2 after treatment with chemotherapeutic agents (i.e. cisplatin or VP-16). Cisplatin 279-288 BCL2 apoptosis regulator Homo sapiens 40-44 12543781-6 2003 Bcl-2 overexpression in MCF-7 cells was associated with a nearly 3-fold increase in cellular glutathione levels and with increased resistance to cell death after cisplatin exposure. Cisplatin 162-171 BCL2 apoptosis regulator Homo sapiens 0-5 12403069-6 2002 The increase in Bax mRNA to Bcl-2 mRNA ratio after treatment with CDDP was suppressed in MDR1-overexpressing cells. Cisplatin 66-70 BCL2 apoptosis regulator Homo sapiens 28-33 12168083-0 2002 Quantitative analysis of expression levels of bax, bcl-2, and survivin in cancer cells during cisplatin treatment. Cisplatin 94-103 BCL2 apoptosis regulator Homo sapiens 51-56 12168083-7 2002 The changes in expression levels of three genes (bax, bcl-2, and survivin) during CDDP treatment were evaluated by real-time reverse transcriptase-polymerase chain reaction (RT-PCR). Cisplatin 82-86 BCL2 apoptosis regulator Homo sapiens 54-59 12168083-11 2002 Also, in LoVo cells, the expression level of bcl-2 mRNA decreased after 24 h treatment with CDDP. Cisplatin 92-96 BCL2 apoptosis regulator Homo sapiens 45-50 12168083-12 2002 On the other hand, during CDDP treatment, the expression levels of bcl-2 and survivin mRNA significantly increased in PANC-1 cells. Cisplatin 26-30 BCL2 apoptosis regulator Homo sapiens 67-72 11895917-9 2002 Decreased expression of additional proteins (Apaf-1, cIAP-1, cIAP-2, and XIAP) paralleled apoptosis detected at 24 h. CONCLUSIONS: These findings show that the selective down-regulation of Bcl-2 by rituximab leading to apoptosis in ARL cells by cisplatin is through the mitochondria-dependent caspase pathway. Cisplatin 245-254 BCL2 apoptosis regulator Homo sapiens 189-194 12390742-5 2002 CONCLUSION: Mifepristone may act to enhance the sensitivity of COC1/DDP cells to cisplatin, possibly through regulating Bcl-2 and Bax protein expressions. Cisplatin 81-90 BCL2 apoptosis regulator Homo sapiens 120-125 12081782-0 2002 Antisense Bcl2 oligonucleotide in cisplatin-resistant bladder cancer cell lines. Cisplatin 34-43 BCL2 apoptosis regulator Homo sapiens 10-14 12081782-1 2002 OBJECTIVE: To determine the change of expression of Bcl2 in cisplatin-resistant bladder cancer cell lines and the reversibility of chemoresistance to cisplatin with antisense oligonucleotide against Bcl2, as higher expression of Bcl2 is associated with drug resistance in many different cancer cell lines. Cisplatin 60-69 BCL2 apoptosis regulator Homo sapiens 52-56 12081782-1 2002 OBJECTIVE: To determine the change of expression of Bcl2 in cisplatin-resistant bladder cancer cell lines and the reversibility of chemoresistance to cisplatin with antisense oligonucleotide against Bcl2, as higher expression of Bcl2 is associated with drug resistance in many different cancer cell lines. Cisplatin 150-159 BCL2 apoptosis regulator Homo sapiens 199-203 12081782-1 2002 OBJECTIVE: To determine the change of expression of Bcl2 in cisplatin-resistant bladder cancer cell lines and the reversibility of chemoresistance to cisplatin with antisense oligonucleotide against Bcl2, as higher expression of Bcl2 is associated with drug resistance in many different cancer cell lines. Cisplatin 150-159 BCL2 apoptosis regulator Homo sapiens 199-203 12081782-2 2002 MATERIALS AND METHODS: In the cisplatin-resistant bladder tumour cell lines T24R1 and T24R2, the expression of Bcl2 was determined by reverse transcription-polymerase chain reaction and Western blot assay, and antisense oligonucleotide targeting of the Bcl2 coding sequence was administered with lipofectin. Cisplatin 30-39 BCL2 apoptosis regulator Homo sapiens 111-115 12081782-4 2002 Short-term exposure to cisplatin up-regulated Bcl2 mRNA and protein expression in parent T24 cells. Cisplatin 23-32 BCL2 apoptosis regulator Homo sapiens 46-50 12081782-5 2002 Treatment with antisense oligonucleotide down-regulated Bcl2 protein expression and significantly enhanced the cytotoxicity of cisplatin. Cisplatin 127-136 BCL2 apoptosis regulator Homo sapiens 56-60 12081782-6 2002 CONCLUSIONS: Up-regulation of Bcl2 protein expression might be one of the mechanisms of cisplatin resistance in bladder cancer cells, and antisense Bcl2 oligonucleotide may be helpful in chemotherapy for bladder cancer by reversing cisplatin resistance. Cisplatin 88-97 BCL2 apoptosis regulator Homo sapiens 30-34 12081782-6 2002 CONCLUSIONS: Up-regulation of Bcl2 protein expression might be one of the mechanisms of cisplatin resistance in bladder cancer cells, and antisense Bcl2 oligonucleotide may be helpful in chemotherapy for bladder cancer by reversing cisplatin resistance. Cisplatin 232-241 BCL2 apoptosis regulator Homo sapiens 30-34 12081782-6 2002 CONCLUSIONS: Up-regulation of Bcl2 protein expression might be one of the mechanisms of cisplatin resistance in bladder cancer cells, and antisense Bcl2 oligonucleotide may be helpful in chemotherapy for bladder cancer by reversing cisplatin resistance. Cisplatin 232-241 BCL2 apoptosis regulator Homo sapiens 148-152 10891529-0 2000 Theophylline and cisplatin synergize in down regulation of BCL-2 induction of apoptosis in human granulosa cells transformed by a mutated p53 (p53 val135) and Ha-ras oncogene. Cisplatin 17-26 BCL2 apoptosis regulator Homo sapiens 59-64 11703590-10 2001 Cisplatin-induced Akt/PKB activation was associated with Bad phosphorylation, suggesting induction of a cell survival signal mediated by the Bcl-2 family member, Bad. Cisplatin 0-9 BCL2 apoptosis regulator Homo sapiens 141-146 11692156-6 2001 Treatment with Bcl-2 antisense oligonucleotides is thus a promising novel approach to enhance antitumor activity of cisplatin or other drugs used in gastric cancer therapy and warrants further evaluation in clinical trials. Cisplatin 116-125 BCL2 apoptosis regulator Homo sapiens 15-20 11340162-1 2001 In a panel of four human melanoma cell lines, equitoxic doses of cisplatin induced the proapoptotic conformation of the Bcl-2 family protein Bak prior to the execution phase of apoptosis. Cisplatin 65-74 BCL2 apoptosis regulator Homo sapiens 120-125 11222695-5 2001 We show that wt HSV-1, but not the mutant viruses, maintains bcl-2 RNA and protein levels during infection and protects from the cisplatin-induced decrease in bcl-2 RNA; our data suggest that both ICP27 and ICP4 are required for this function. Cisplatin 129-138 BCL2 apoptosis regulator Homo sapiens 159-164 11775848-0 2000 Co-transfection of MRP and bcl-2 antisense S-oligodeoxynucleotides reduces drug resistance in cisplatin-resistant lung cancer cells. Cisplatin 94-103 BCL2 apoptosis regulator Homo sapiens 27-32 11775848-7 2000 Resistance to cisplatin in the cells treated with bcl-2 or/and MRP antisense S-ODN decreased by 60.6% (6.5 times), 56.4% (7.2 times) and 71.0% (4.8 times), respectively, which paralleled the decrease of bcl-2 and MRP expression. Cisplatin 14-23 BCL2 apoptosis regulator Homo sapiens 50-55 11775848-7 2000 Resistance to cisplatin in the cells treated with bcl-2 or/and MRP antisense S-ODN decreased by 60.6% (6.5 times), 56.4% (7.2 times) and 71.0% (4.8 times), respectively, which paralleled the decrease of bcl-2 and MRP expression. Cisplatin 14-23 BCL2 apoptosis regulator Homo sapiens 203-208 11775848-10 2000 Statistically significant dose- and concentration-dependent increases of apoptotic cells were observed in the groups exposed to 100 mumol/L cisplatin for 48 h after treatment by bcl-2 or/and MRP antisense. Cisplatin 140-149 BCL2 apoptosis regulator Homo sapiens 178-183 11775848-11 2000 CONCLUSION: Bcl-2 and MRP were at least additive and possibly synergistic in conferring drug resistance in a cisplatin-resistant lung adenocarcinoma cell line. Cisplatin 109-118 BCL2 apoptosis regulator Homo sapiens 12-17 11840333-7 2002 Further, the DNA cross-linking drugs BCNU and cisplatin, but not the microtubule poison vincristine, induced significant cell death in U87MG/hDkk cells, and this was accompanied by altered Bcl-2/Bax expression and a reduction in the amount of telomere DNA as visualized by fluorescence in situ hybridization. Cisplatin 46-55 BCL2 apoptosis regulator Homo sapiens 189-194 11748660-6 2002 The effect of LMP1 on the balance of Bcl-2 and Bax ratio may play a role in inducing susceptibility to cisplatin-induced cell death. Cisplatin 103-112 BCL2 apoptosis regulator Homo sapiens 37-42 11761456-4 2001 In the present study, we expanded our investigations to examine the effect of cisplatin-induced ERK activation on the expression of p53-targeted genes that have been shown to be important in the cellular response to DNA damage including Bax, Bcl-2, Bcl-x1, Cyclin G, Gadd45, p21WAF1, and Mdm2. Cisplatin 78-87 BCL2 apoptosis regulator Homo sapiens 242-247 11774739-5 2001 Western blot analysis using murine monoclonal anti-Bcl-2 antibody showed more than 5-fold Bcl-2 overexpression in Pt-resistant cells in response to cisplatin treatment. Cisplatin 148-157 BCL2 apoptosis regulator Homo sapiens 51-56 11774739-5 2001 Western blot analysis using murine monoclonal anti-Bcl-2 antibody showed more than 5-fold Bcl-2 overexpression in Pt-resistant cells in response to cisplatin treatment. Cisplatin 148-157 BCL2 apoptosis regulator Homo sapiens 90-95 11494156-0 2001 Cleavage of Bcl-2 in oxidant- and cisplatin-induced apoptosis of human melanoma cells. Cisplatin 34-43 BCL2 apoptosis regulator Homo sapiens 12-17 11494156-5 2001 In the floating apoptotic cells generated by either hydrogen peroxide or cisplatin, along with morphological and biochemical features of apoptosis, we detected a significant Bcl-2 cleavage, yielding the Bax-like fragment of 23 kDa. Cisplatin 73-82 BCL2 apoptosis regulator Homo sapiens 174-179 11494156-7 2001 The oxidant- and cisplatin-induced processing of Bcl-2 documented in the present study may represent a regulatory mechanism to circumvent the survival function of Bcl-2 upon apoptosis triggering and to enhance apoptotic response. Cisplatin 17-26 BCL2 apoptosis regulator Homo sapiens 49-54 11494156-7 2001 The oxidant- and cisplatin-induced processing of Bcl-2 documented in the present study may represent a regulatory mechanism to circumvent the survival function of Bcl-2 upon apoptosis triggering and to enhance apoptotic response. Cisplatin 17-26 BCL2 apoptosis regulator Homo sapiens 163-168 11497278-2 2001 We studied the mechanism of the growth-inhibitory effect of cisplatin (CDDP) on human pancreatic cancer cells in connection with the status of the p53 gene and expression of the bcl-2 family. Cisplatin 60-69 BCL2 apoptosis regulator Homo sapiens 178-183 11497278-2 2001 We studied the mechanism of the growth-inhibitory effect of cisplatin (CDDP) on human pancreatic cancer cells in connection with the status of the p53 gene and expression of the bcl-2 family. Cisplatin 71-75 BCL2 apoptosis regulator Homo sapiens 178-183 11497278-7 2001 Increased expression of bax and reduced expression of bcl-2 are involved in the growth-inhibitory effect of CDDP on pancreatic cancer cells with wild-type p53 gene. Cisplatin 108-112 BCL2 apoptosis regulator Homo sapiens 54-59 11778475-0 2000 [Bcl-2 antisense oligodeoxyribonucleotide increases apoptosis of lung carcinoma cells induced by cisplatin]. Cisplatin 97-106 BCL2 apoptosis regulator Homo sapiens 1-6 11778475-1 2000 OBJECTIVE: To study the effect of antisense oligodeoxyribonucleotide (ODN) to apoptotic suppress gene bcl-2 on apoptosis of lung carcinoma cells induced by cisplatin. Cisplatin 156-165 BCL2 apoptosis regulator Homo sapiens 102-107 11778475-14 2000 CONCLUSION: Antisense oligodeoxyribonucleotide to bcl-2 can inhibit significantly the expression of bcl-2 of lung cancer cells and increase apoptosis of cancer cells induced by cisplatin. Cisplatin 177-186 BCL2 apoptosis regulator Homo sapiens 50-55 11040047-7 2000 When treated with an anticancer drug (etoposide or cisplatin) or the kinase inhibitor staurosporin, the cells containing a high G(1) population and a high Bcl-2 protein level were much more resistant to the induced apoptosis than the cells containing a high S phase population and a low Bcl-2 protein level. Cisplatin 51-60 BCL2 apoptosis regulator Homo sapiens 155-160 11040047-7 2000 When treated with an anticancer drug (etoposide or cisplatin) or the kinase inhibitor staurosporin, the cells containing a high G(1) population and a high Bcl-2 protein level were much more resistant to the induced apoptosis than the cells containing a high S phase population and a low Bcl-2 protein level. Cisplatin 51-60 BCL2 apoptosis regulator Homo sapiens 287-292 10891529-2 2000 We have examined the effect of cisplatin alone and in combination with theophylline, a phoshodiesterase inhibitor, on modulation of Bcl-2/Bax expression and induction of apoptosis in human granulosa cells transformed by stable transfection with mutant p53 plus Ha-ras. Cisplatin 31-40 BCL2 apoptosis regulator Homo sapiens 132-137 10891529-9 2000 In contrast Bcl-2 protein expression levels were markedly reduced by theophylline and cisplatin in a dose-dependent manner. Cisplatin 86-95 BCL2 apoptosis regulator Homo sapiens 12-17 10891529-10 2000 The combination of theophylline and cisplatin resulted in a further dramatic reduction in Bcl-2, under-scoring the pronounced synergy of these two drugs. Cisplatin 36-45 BCL2 apoptosis regulator Homo sapiens 90-95 10891529-11 2000 These observations suggest that suppression of Bcl-2 expression may play an important role in mediating the synergistic effect of cisplatin and theophylline on induction of apoptosis in ovarian cancer cells. Cisplatin 130-139 BCL2 apoptosis regulator Homo sapiens 47-52 10807947-5 2000 A comparison of effects of drugs belonging to the same class but endowed with a different antitumor activity (i.e. cisplatin versus a novel multinuclear platinum complex and doxorubicin versus a disaccharide analogue) showed a correlation between drug efficacy, apoptotic response, and Bcl-2 phosphorylation. Cisplatin 115-124 BCL2 apoptosis regulator Homo sapiens 286-291 10646901-5 2000 Overexpression of BCL-2 in A2780 cells led to resistance to cisplatin compared to the vector control when assayed at 48 h post-drug incubation but a significant increase in sensitivity at 96 h. Relative rates of apoptosis at 48- and 96-h post-cisplatin exposure mirrored the growth inhibition. Cisplatin 60-69 BCL2 apoptosis regulator Homo sapiens 18-23 10731694-6 2000 MK enhanced the expression of Bcl-2, but not that of Bcl-x(L), in G401 cells in a dose-dependent manner, and it prevented the Bcl-2 reduction due to CDDP. Cisplatin 149-153 BCL2 apoptosis regulator Homo sapiens 126-131 10646901-5 2000 Overexpression of BCL-2 in A2780 cells led to resistance to cisplatin compared to the vector control when assayed at 48 h post-drug incubation but a significant increase in sensitivity at 96 h. Relative rates of apoptosis at 48- and 96-h post-cisplatin exposure mirrored the growth inhibition. Cisplatin 243-252 BCL2 apoptosis regulator Homo sapiens 18-23 10601800-8 2000 Our results indicate that the reduction of apoptosis was one of the CDDP-resistant mechanisms, and that reduced apoptosis in CDDP-resistant cells was influenced by Bcl-2 and CPP32 proteins. Cisplatin 125-129 BCL2 apoptosis regulator Homo sapiens 164-169 10601800-0 2000 Regulation of apoptosis reduction in the cisplatin-resistant A431 cell line by Bcl-2 and CPP32. Cisplatin 41-50 BCL2 apoptosis regulator Homo sapiens 79-84 10569615-0 1999 Synergistic enhancement of resistance to cisplatin in human bladder cancer cells by overexpression of mutant-type p53 and Bcl-2. Cisplatin 41-50 BCL2 apoptosis regulator Homo sapiens 122-127 10569615-1 1999 PURPOSE: The objective of this study was to characterize the effect of mutant-type p53 and Bcl-2 expression on the sensitivity to cisplatin in a human bladder cancer cell line both in vitro and in vivo. Cisplatin 130-139 BCL2 apoptosis regulator Homo sapiens 91-96 10569615-3 1999 The effects of the overexpression of mutant-type p53, Bcl-2, or both on the sensitivity to cisplatin and the apoptotic features in vitro were evaluated by the MTT assay, staining with Hoechst 33258 and a DNA fragmentation assay. Cisplatin 91-100 BCL2 apoptosis regulator Homo sapiens 54-59 10569615-5 1999 RESULTS: The introduction of mutant-type p53 or Bcl-2 conferred resistance to cisplatin on KoTCC-1 cells through the inhibition of apoptosis. Cisplatin 78-87 BCL2 apoptosis regulator Homo sapiens 48-53 10569615-7 1999 Furthermore, the KoTCC-1 cells transfected with both mutant-type p53 and Bcl-2 exhibited significantly higher resistance to cisplatin treatment than cells transfected with mutant-type p53 or Bcl-2 alone in experimental models in vivo. Cisplatin 124-133 BCL2 apoptosis regulator Homo sapiens 73-78 10569615-7 1999 Furthermore, the KoTCC-1 cells transfected with both mutant-type p53 and Bcl-2 exhibited significantly higher resistance to cisplatin treatment than cells transfected with mutant-type p53 or Bcl-2 alone in experimental models in vivo. Cisplatin 124-133 BCL2 apoptosis regulator Homo sapiens 191-196 10569615-8 1999 CONCLUSIONS: These findings suggest that the overexpression of both mutant-type p53 and Bcl-2 in bladder cancer cells synergistically interferes with the therapeutic effect of cisplatin through the inhibition of the apoptotic pathway. Cisplatin 176-185 BCL2 apoptosis regulator Homo sapiens 88-93 10615232-1 1999 This retrospective study of ovarian cancer aimed to elucidate whether expression of apoptosis-related proteins, bcl-2, p53 or MDM-2, is associated with resistance to chemotherapy, especially cisplatin (CDDP) based chemotherapy. Cisplatin 191-200 BCL2 apoptosis regulator Homo sapiens 112-117 11776616-10 1999 CONCLUSION: Bcl-2 and MRP genes are responsible for the induced resistance of A549DDP cells to cisplatin. Cisplatin 95-104 BCL2 apoptosis regulator Homo sapiens 12-17 10597253-8 1999 Apoptosis and activation of caspase-3 by cisplatin, but not DCVC, was prevented by bcl-2. Cisplatin 41-50 BCL2 apoptosis regulator Homo sapiens 83-88 10615232-1 1999 This retrospective study of ovarian cancer aimed to elucidate whether expression of apoptosis-related proteins, bcl-2, p53 or MDM-2, is associated with resistance to chemotherapy, especially cisplatin (CDDP) based chemotherapy. Cisplatin 202-206 BCL2 apoptosis regulator Homo sapiens 112-117 10067009-1 1999 OBJECTIVE: To study whether interleukin-6 (IL-6) changes the expression of the anti-apoptic Bcl-2 protein in the prevention of cis-diaminedichloroplatinum (II) (CDDP)-induced apoptosis of human ovarian cancer cells. Cisplatin 161-165 BCL2 apoptosis regulator Homo sapiens 92-97 10067009-1 1999 OBJECTIVE: To study whether interleukin-6 (IL-6) changes the expression of the anti-apoptic Bcl-2 protein in the prevention of cis-diaminedichloroplatinum (II) (CDDP)-induced apoptosis of human ovarian cancer cells. Cisplatin 127-159 BCL2 apoptosis regulator Homo sapiens 92-97 10397248-8 1999 Bcl-2 and Bcl-xL proteins remained relatively unchanged in expression for over 48 h after exposure to cisplatin in the A2780 cell lines. Cisplatin 102-111 BCL2 apoptosis regulator Homo sapiens 0-5 10344753-10 1999 These results suggest that cisplatin blocks paclitaxel-induced apoptosis at a point downstream of Bcl-2 degradation and independent of microtubule stabilization. Cisplatin 27-36 BCL2 apoptosis regulator Homo sapiens 98-103 10063313-0 1999 The relationship between cisplatin-induced apoptosis and p53, bcl-2 and bax expression in human lung cancer cells. Cisplatin 25-34 BCL2 apoptosis regulator Homo sapiens 62-67 10081494-0 1998 EAT/mcl-1, a member of the bcl-2 related genes, confers resistance to apoptosis induced by cis-diammine dichloroplatinum (II) via a p53-independent pathway. Cisplatin 91-120 BCL2 apoptosis regulator Homo sapiens 27-32 10063313-8 1999 Cancer cells with the natural expression of bcl-2 and p53 mutation may be more resistant to cisplatin and less susceptible to apoptosis. Cisplatin 92-101 BCL2 apoptosis regulator Homo sapiens 44-49 9635829-0 1998 Expression of p53, Bcl-2 and Bax in cisplatin-induced apoptosis in testicular germ cell tumour cell lines. Cisplatin 36-45 BCL2 apoptosis regulator Homo sapiens 19-24 9792147-2 1998 In the present study, the interactions between the bcl-2 antisense oligodeoxynucleotide 2009 and the chemotherapeutic agents etoposide, doxorubicin and cisplatin were investigated on small-cell lung cancer cell lines to search for synergistic combinations. Cisplatin 152-161 BCL2 apoptosis regulator Homo sapiens 51-56 9664115-3 1998 Treatment with cisplatin and carboplatin also provoked an increase in the level of p53 and p21, and a lowering in Bcl-2. Cisplatin 15-24 BCL2 apoptosis regulator Homo sapiens 114-119 9472640-7 1998 In the breast carcinoma MX-1, hypersensitive to cisplatin and to the lonidamine+cisplatin combination, the efficacy of drug treatment was associated with phosphorylation of bcl-2 followed by down-regulation of the protein. Cisplatin 48-57 BCL2 apoptosis regulator Homo sapiens 173-178 9484785-1 1998 To investigate the effects of the expression of Bcl-2 protein in bladder cancer on the apoptosis induced by cisplatin or adenoviral-mediated p53 gene (Ad5CMV-p53) transfer, we transfected the bcl-2 gene into KoTCC-1, a human bladder cancer cell line that does not express the Bcl-2 protein. Cisplatin 108-117 BCL2 apoptosis regulator Homo sapiens 48-53 9584207-1 1998 We investigated the roles of p53 and Bcl-2 homologues in the induction of apoptosis by cisplatin and paclitaxel in wild-type p53-expressing human ovarian carcinoma cells and cisplatin-resistant derivatives that have lost p53 function. Cisplatin 87-96 BCL2 apoptosis regulator Homo sapiens 37-42 9472640-7 1998 In the breast carcinoma MX-1, hypersensitive to cisplatin and to the lonidamine+cisplatin combination, the efficacy of drug treatment was associated with phosphorylation of bcl-2 followed by down-regulation of the protein. Cisplatin 80-89 BCL2 apoptosis regulator Homo sapiens 173-178 8205548-7 1994 Clones expressing high levels of Bcl-2 were resistant to cisplatin- and etoposide-induced cytotoxicity in a dose-dependent manner. Cisplatin 57-66 BCL2 apoptosis regulator Homo sapiens 33-38 9403032-0 1997 Modulation of NF-kappa B, and Bcl-2 in apoptosis induced by cisplatin in HeLa cells. Cisplatin 60-69 BCL2 apoptosis regulator Homo sapiens 30-35 9815594-7 1997 The expression of Bcl-2 relative to Bax decreased more after combined treatment with cisplatin and ATRA than after either drug alone. Cisplatin 85-94 BCL2 apoptosis regulator Homo sapiens 18-23 8616869-2 1996 We have found that Bcl-2 and p53, two proteins implicated in the control of apoptosis, are differently expressed in the ovarian cell line A2780 and its cisplatin-resistant variant 2780CP, with the resistant line overexpressing both proteins. Cisplatin 152-161 BCL2 apoptosis regulator Homo sapiens 19-24 8616869-3 1996 Transfection of the A2780 cells with a Bcl-2- or p53-expressing plasmid increases resistance to various drugs, including cisplatin, suggesting that Bcl-2 and p53 expression may influence the sensitivity of ovarian cancer cell lines to chemotherapy. Cisplatin 121-130 BCL2 apoptosis regulator Homo sapiens 39-44 8616869-3 1996 Transfection of the A2780 cells with a Bcl-2- or p53-expressing plasmid increases resistance to various drugs, including cisplatin, suggesting that Bcl-2 and p53 expression may influence the sensitivity of ovarian cancer cell lines to chemotherapy. Cisplatin 121-130 BCL2 apoptosis regulator Homo sapiens 148-153 7539458-5 1995 Forced expression of bcl-2 also attenuated TNF alpha-mediated cytotoxicity of glioma cell lines in the presence of actinomycin D and cycloheximide and conferred partial protection from irradiation and the cancer chemotherapy drugs, cisplatin and BCNU. Cisplatin 232-241 BCL2 apoptosis regulator Homo sapiens 21-26 9393748-2 1997 Here, we demonstrate that expression of galectin-3 in human breast carcinoma BT549 cells inhibits cis-diamminedichloroplatinum (cisplatin)-induced poly(ADP-ribose) polymerase degradation and apoptosis, without altering Bcl-2, Bcl-X(L), or Bax expressions. Cisplatin 128-137 BCL2 apoptosis regulator Homo sapiens 219-224 9494534-9 1997 Expression of bcl-2 family members (bax, bcl-x) was modulated by fotemustine, etoposide and cisplatin. Cisplatin 92-101 BCL2 apoptosis regulator Homo sapiens 14-19 9323493-0 1997 Changes in levels of expression of p53 and the product of the bcl-2 in lines of gastric cancer cells during cisplatin-induced apoptosis. Cisplatin 108-117 BCL2 apoptosis regulator Homo sapiens 62-67 9323493-2 1997 After incubation with cisplatin, apoptotic cells were detected more frequently among MKN-45 and MKN-74 cells with a wild-type gene for p53 and without expression of the bcl-2 protein than among HSC-39, MKN-28, and KATO-III cells with a mutation or complete deletion of the gene for p53 and with overexpression of the bcl-2 protein. Cisplatin 22-31 BCL2 apoptosis regulator Homo sapiens 169-174 9323493-2 1997 After incubation with cisplatin, apoptotic cells were detected more frequently among MKN-45 and MKN-74 cells with a wild-type gene for p53 and without expression of the bcl-2 protein than among HSC-39, MKN-28, and KATO-III cells with a mutation or complete deletion of the gene for p53 and with overexpression of the bcl-2 protein. Cisplatin 22-31 BCL2 apoptosis regulator Homo sapiens 317-322 9323493-4 1997 However, levels of bcl-2 protein were reduced in KATO-III after treatment with cisplatin. Cisplatin 79-88 BCL2 apoptosis regulator Homo sapiens 19-24 34876239-5 2021 However, the expression levels of other tumor-related factors, including Ki67, p27, p53, Bcl-2-associated X protein (Bax), B-cell lymphoma 2 (Bcl-2), caspase-3 (Cas-3), matrix metallopeptidase 2 (MMP2) and vascular endothelial growth factor (VEGF) proteins, were constantly maintained in the tumors of all three substrains after cisplatin treatment. Cisplatin 329-338 BCL2 apoptosis regulator Homo sapiens 123-140 21573386-5 1993 Further, the 19 kD and Bcl2 proteins also function similarly to suppress DNA fragmentation and cell death induced by the DNA damaging agents cisplatin and UV. Cisplatin 141-150 BCL2 apoptosis regulator Homo sapiens 23-27 33773191-11 2021 DS-1 treatment in combination with cisplatin could enhance activated p-p53 (Ser15) and p53 downstream signaling (Bax, Bcl-2, and Akt), leading to a higher level of apoptosis. Cisplatin 35-44 BCL2 apoptosis regulator Homo sapiens 118-123 34876239-5 2021 However, the expression levels of other tumor-related factors, including Ki67, p27, p53, Bcl-2-associated X protein (Bax), B-cell lymphoma 2 (Bcl-2), caspase-3 (Cas-3), matrix metallopeptidase 2 (MMP2) and vascular endothelial growth factor (VEGF) proteins, were constantly maintained in the tumors of all three substrains after cisplatin treatment. Cisplatin 329-338 BCL2 apoptosis regulator Homo sapiens 142-147 34476500-5 2021 In SKOV3/DDP cells, HAND2-AS1 overexpression inhibited cell viability and promoted cell apoptosis upon DDP treatment through the Bcl-2/caspase-3 apoptotic signaling. Cisplatin 103-106 BCL2 apoptosis regulator Homo sapiens 129-134 34634322-5 2021 We highlight that estrogen treatment or increased expression of ERs or ERRs are generally associated with higher cisplatin resistance in cancer in vitro, mostly due to decreased caspase activity, increased anti-apoptotic protein levels such as BCL-2, higher drug efflux and higher levels of antioxidant enzymes. Cisplatin 113-122 BCL2 apoptosis regulator Homo sapiens 244-249 34832966-12 2021 Bcl-2 levels were reduced only in SK-N-FI cells after treatment with cisplatin. Cisplatin 69-78 BCL2 apoptosis regulator Homo sapiens 0-5 34549307-8 2021 The results revealed that SPHK1 was positively correlated with cisplatin resistance in bladder cancer cells, exhibiting an antiapoptotic effect that was reflected by the downregulation of apoptosis-related proteins (Bax and cleaved caspase-3) and the upregulation of an antiapoptotic protein (Bcl-2) in SPHK1-overexpression cell lines. Cisplatin 63-72 BCL2 apoptosis regulator Homo sapiens 293-298 34216662-6 2021 Also, growing the cells in the scaffold sensitize the hepatocytes to the anti-tumor effect of cisplatin, by a mechanism involving the activation of ERK/p38alpha-MAPK and dysregulation of NF-kB/STAT3/Bcl-2 pathways. Cisplatin 94-103 BCL2 apoptosis regulator Homo sapiens 199-204 34837685-10 2021 In addition, HEnSCs resulted in upregulation of Bcl-2 and downregulation of Tnf-alpha in the cisplatin-induced AKI. Cisplatin 93-102 BCL2 apoptosis regulator Homo sapiens 48-53 34790046-4 2021 Here, we found that the expression of lncRNA CEBPA-DT/CEBPA/BCL2 was upregulated in cisplatin resistance OSCC cells (Cal27-CisR and HSC4-CisR) compared with their parental cells (Cal27 and HSC4). Cisplatin 84-93 BCL2 apoptosis regulator Homo sapiens 60-64 34790046-7 2021 In addition, we identified that CEBPA-DT regulates cisplatin chemosensitivity through CEBPA/BCL2-mediated cell apoptosis. Cisplatin 51-60 BCL2 apoptosis regulator Homo sapiens 92-96 34790046-8 2021 Knockdown of CEBPA and BCL2 could alleviate the increasement of cisplatin resistance induced by CEBPA-DT overexpression. Cisplatin 64-73 BCL2 apoptosis regulator Homo sapiens 23-27 34277781-11 2021 The experiment shows that ROPPIP can up-regulate the expression levels of MMP2, Ki67, and Bcl2 in HTR-8/Svneo cells, down-regulate the expression of caspase-3, promote the proliferation and migration of HTR-8/Svneo cells and inhibit the apoptosis induced by cisplatin, the activation of the phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway may be associated with the function of ROPPIP. Cisplatin 258-267 BCL2 apoptosis regulator Homo sapiens 90-94 34406846-7 2021 After silencing Bcl-2 with siRNA, the sensitivity of the cells to cisplatin (CDDP) increased. Cisplatin 66-75 BCL2 apoptosis regulator Homo sapiens 16-21 34406846-7 2021 After silencing Bcl-2 with siRNA, the sensitivity of the cells to cisplatin (CDDP) increased. Cisplatin 77-81 BCL2 apoptosis regulator Homo sapiens 16-21 34206951-6 2021 The combined action of both cisPt derivatives and anti-MUC1 was more effective than monotherapy in relation to Bad, Bcl-xL, Bcl-2, caspase-9, caspase-3, as well as pro- and cleaved caspase-3 protein, and T, sialyl Tn sugar antigens in cell lysates, and Tn, T, sialyl Tn, sialyl T antigens in culture medium. Cisplatin 28-33 BCL2 apoptosis regulator Homo sapiens 124-129 34204834-4 2021 In FaDu cells, combined CisPt + RSV treatment induced an increase in apoptosis, which was associated with an increase in c-MYC and TP53 and a decrease in BCL-2 expression. Cisplatin 24-29 BCL2 apoptosis regulator Homo sapiens 154-159 34080212-0 2021 Combination of cyanidin-3-O-glucoside and cisplatin induces oxidative stress and apoptosis in HeLa cells by reducing activity of endogenous antioxidants, increasing bax/bcl-2 mRNA expression ratio, and downregulating Nrf2 expression. Cisplatin 42-51 BCL2 apoptosis regulator Homo sapiens 169-174 34306367-0 2021 CHOP overexpression sensitizes human non-small cell lung cancer cells to cisplatin treatment by Bcl-2/JNK pathway. Cisplatin 73-82 BCL2 apoptosis regulator Homo sapiens 96-101 34306367-7 2021 CHOP increased the therapeutic effect of cisplatin on NSCLC cells through the Bcl-2/JNK pathway. Cisplatin 41-50 BCL2 apoptosis regulator Homo sapiens 78-83 34306367-8 2021 In summary, CHOP regulated cisplatin resistance in cells of NSCLC by promoting the expression of apoptotic proteins and inhibiting the Bcl-2/JNK signaling pathway, indicating the antitumor effects of CHOP. Cisplatin 27-36 BCL2 apoptosis regulator Homo sapiens 135-140 34204834-5 2021 While CisPt + RSV treatment induced apoptosis in PE/CA-PJ49 cells by inhibition of BCL-2 associated with high levels of MDM-2 and subsequently led to inhibition of TP53 gene expression. Cisplatin 6-11 BCL2 apoptosis regulator Homo sapiens 83-88 34149993-8 2021 The mAb against MOR also enhanced the cisplatin-induced apoptosis of HCC cells by downregulating p-ERK, Bcl-2 and upregulating Bax. Cisplatin 38-47 BCL2 apoptosis regulator Homo sapiens 104-109 34134962-11 2021 The nanoparticles significantly increased the intracellular expression level of miR-16 (P < 0.001) and decreased the expression of Bcl-2 and Chk-1 proteins in ovarian cancer cells, thus enabling miR-16 to promote apoptosis and enhance cisplatin sensitivity of the cells. Cisplatin 235-244 BCL2 apoptosis regulator Homo sapiens 131-136 34078815-9 2021 In human renal proximal tubular cells, cisplatin induced cell apoptosis by activating pro-apoptotic proteins (ERK1/2 and caspase 3), and reducing the anti-apoptotic protein (Bcl-2). Cisplatin 39-48 BCL2 apoptosis regulator Homo sapiens 174-179 34063628-5 2021 Interestingly, pretreatment with jorunnamycin A at 0.5 muM for 24 h considerably sensitized lung CSCs to cisplatin-induced apoptosis, as evidenced by upregulated p53 and decreased Bcl-2 in jorunnamycin A-pretreated CSC-enriched spheroids. Cisplatin 105-114 BCL2 apoptosis regulator Homo sapiens 180-185 34183962-10 2021 Piperine (20 muM) and cisplatin (5 muM) for 24 h induce apoptosis strongly through reduction of Bcl-2 and increase of caspase 3, p53, caspase 9, and Bax. Cisplatin 22-31 BCL2 apoptosis regulator Homo sapiens 96-101 34522245-11 2021 After cisplatin treatment, down-regulation of BANCR could consequently attenuate TU686-DDP-R and TU177-DDP-R cell proliferation, and the expression of MRP1, Bcl-2, and p-PKB was decreased and Bax was increased. Cisplatin 6-15 BCL2 apoptosis regulator Homo sapiens 157-162 35500680-9 2022 Low concentrations of 4 mug/ml cisplatin and 2.8 mug/ml sunitinib showed significant Bcl-2 down-regulation and Bax up-regulation. Cisplatin 31-40 BCL2 apoptosis regulator Homo sapiens 85-90 35636434-5 2022 In addition, qRT-PCR results showed that the expressions of miR-181 and P53, CYLD, CBX7 and BCL2 genes change in MG63 cells after treatment with the combination of cisplatin and melatonin, so that the expression of P53, CYLD and CBX7 increased and the expression of BCL2 and miR-181b decreases significantly. Cisplatin 164-173 BCL2 apoptosis regulator Homo sapiens 92-96 35636434-5 2022 In addition, qRT-PCR results showed that the expressions of miR-181 and P53, CYLD, CBX7 and BCL2 genes change in MG63 cells after treatment with the combination of cisplatin and melatonin, so that the expression of P53, CYLD and CBX7 increased and the expression of BCL2 and miR-181b decreases significantly. Cisplatin 164-173 BCL2 apoptosis regulator Homo sapiens 266-270 35398618-9 2022 Consistently, Nanog suppression combined with Cisplatin led to upregulation of Caspase-3 apoptotic gene and Bax/Bcl-2 ratio. Cisplatin 46-55 BCL2 apoptosis regulator Homo sapiens 112-117 35433741-12 2022 Moreover, ISL markedly increased the protein levels of Bcl-2 and SOD2, which were reduced by cisplatin stimulation. Cisplatin 93-102 BCL2 apoptosis regulator Homo sapiens 55-60 35099408-8 2022 The expression of cleaved caspase-3 and bcl-2 were, respectively, decreased and increased by the combination of norepinephrine and cisplatin in SCC-9 and Cal27 cells. Cisplatin 131-140 BCL2 apoptosis regulator Homo sapiens 40-45 35093886-4 2022 RESULTS: We observed an increase in O2 - production only in BCL2KO NB cells treated with cisplatin (three-fold) and CasIIIia (five-fold), whereas the production of H2O2 in BCL2KO NB cells treated with cisplatin and CasIIIia increased five-fold and three-fold, respectively. Cisplatin 89-98 BCL2 apoptosis regulator Homo sapiens 60-64 35093886-4 2022 RESULTS: We observed an increase in O2 - production only in BCL2KO NB cells treated with cisplatin (three-fold) and CasIIIia (five-fold), whereas the production of H2O2 in BCL2KO NB cells treated with cisplatin and CasIIIia increased five-fold and three-fold, respectively. Cisplatin 201-210 BCL2 apoptosis regulator Homo sapiens 60-64 35093886-4 2022 RESULTS: We observed an increase in O2 - production only in BCL2KO NB cells treated with cisplatin (three-fold) and CasIIIia (five-fold), whereas the production of H2O2 in BCL2KO NB cells treated with cisplatin and CasIIIia increased five-fold and three-fold, respectively. Cisplatin 201-210 BCL2 apoptosis regulator Homo sapiens 172-176 34994335-10 2022 These compounds combined with cisplatin caused upregulation in the pro-apoptotic Bax, Bid, caspase-3, caspase-8, caspase-9, Fas, and p53 gene expressions while downregulating anti-apoptotic DFFA, NFkB1, and Bcl2 gene expressions. Cisplatin 30-39 BCL2 apoptosis regulator Homo sapiens 207-211 33153817-16 2021 Further, we demonstrated in experimental models that the sensitivity to cisplatin is dependent on CXCR2 and BCL-2, and that targeting them sensitizes prostate cancer (PC) cells to cisplatin. Cisplatin 72-81 BCL2 apoptosis regulator Homo sapiens 108-113